



National and Kapodistrian  
UNIVERSITY OF ATHENS



ΟΡΓΑΝΩΤΗΣ ΕΛΛΗΝΙΚΗΣ ΙΑΤΡΙΚΗΣ

ΑΡΧΕΙΑ ΕΛΛΗΝΙΚΗΣ  
ΙΑΤΡΙΚΗΣ

ΠΕΡΙΟΔΙΚΟ ΤΗΣ ΙΑΤΡΙΚΗΣ ΕΤΑΙΡΕΙΑΣ ΑΘΗΝΩΝ

2015, Τόμος 32, Συμπληρωματικό Τεύχος 1



## 2nd AEGEAN HEMATOLOGY ONCOLOGY SYMPOSIUM

Chandris Hotel / Chios-Greece  
17-20 September 2015

[www.ahos2015.com](http://www.ahos2015.com)

2015, ΤΟΜΟΣ 32, ΣΥΜΠΛΗΡΩΜΑΤΙΚΟ ΤΕΥΧΟΣ 1, ΣΕΛ. 1-52

### 2<sup>nd</sup> AGEAN HEMATOLOGY ONCOLOGY SYMPOSIUM “AHOS 2015”

September 17-20, 2015, Hotel Chios Chandris, Chios, Greece

#### GUEST EDITORS

**Evangelos Terpos**

*Department of Clinical Therapeutics, School of Medicine,  
National and Kapodistrian University of Athens, Athens, Greece*

**Guray Saydam**

*Department of Hematology,  
Ege University Medical Faculty Hospital, Izmir, Turkey*


2015, Volume 32, Supplement 1

[www.mednet.gr/archives](http://www.mednet.gr/archives)

ISSN 1105-3992

Cited in EMBASE/Excerpta Medica  
INDEX COPERNICUS, SCOPUS, Google Scholar,  
DOAJ, SJR, CIRRIE, JournalSeek, Medword List,  
Biores, GFMER, J-Gate, HEAL-Link, Socolar,  
EBSCO Publications and in IATROTEK

OFFICIAL JOURNAL OF  
THE ATHENS MEDICAL SOCIETY



archives of  
HELLENIC MEDICINE



ΙΑΤΡΙΚΗ ΕΤΑΙΡΕΙΑ ΑΘΗΝΩΝ  
ΕΤΟΣ ΙΔΡΥΣΕΩΣ 1835



42°

ΕΤΗΣΙΟ  
ΠΑΝΕΛΛΗΝΙΟ  
ΙΑΤΡΙΚΟ  
ΣΥΝΕΔΡΙΟ

11-14 ΜΑΪΟΥ 2016  
ΑΘΗΝΑ



Θα χορηγηθούν μόρια  
Συνεχιζόμενης Ιατρικής Εκπαίδευσης  
(C.M.E.-C.P.D. CREDITS)

Διαγωνισμός Ιατρικών Γνώσεων  
Απονομή επάθλων

ΠΛΗΡΟΦΟΡΙΕΣ: ΙΑΤΡΙΚΗ ΕΤΑΙΡΕΙΑ ΑΘΗΝΩΝ, Μαιάνδρου 23, 115 28 ΑΘΗΝΑ  
Τηλ.: 210 7211845, 210 7243161, Fax: 210 7215082, E-mail: [iea@mednet.gr](mailto:iea@mednet.gr) - [mednet@mednet.gr](mailto:mednet@mednet.gr), <http://www.mednet.gr>



THE NEW GREEK MEDICAL NETWORK

## Διαδικτυακή πύλη της Ιατρικής Εταιρείας Αθηνών

[www.mednet.gr](http://www.mednet.gr)

Θεραπευτικά Πρωτόκολλα  
Συνταγογράφους με το  
συντονισμό της Ιατρικής  
Εταιρείας Αθηνών

Webinars από Διακεριμένους  
Έλληνες Επιστήμονες

Καθημερινή Ειδοσεογραφία  
για την τρέχουσα ιατρική  
επικαιρότητα

Βάση Δεδομένων με Έρευνες  
και Μελέτες για την Υγεία

Δυνατότητα Διαδραστικής  
Επικοινωνίας των Μελών και  
ανταπλαγής Επιστημονικών  
απόψεων μέσα από ιδιωτικά  
και δημόσια μπνύματα

Η ΙΣΤΟΣΕΛΙΔΑ ΑΠΕΥΘΥΝΕΤΑΙ  
ΑΠΟΚΛΕΙΣΤΙΚΑ ΣΕ ΕΠΑΓΓΕΛΜΑΤΙΕΣ ΥΓΕΙΑΣ

Η εγγραφή είναι ΔΩΡΕΑΝ

ΔΩΡΕΑΝ πρόσβαση στο  
Φαρμακευτικό Οδηγό  
και στη Βάση Αλληλεπιδράσεων  
της LEXICOMP

Επιλεγμένα Ιατρικά Άρθρα  
από Έγκεριμένους  
Επαγγελματίες Υγείας

Ομιλίες Ελληνικών  
Ιατρικών Συνεδρίων

Θέσεις Εργασίας • Υποτροφίες  
• Συνέδρια Εσωτερικού  
και Εξωτερικού

- Κατευθυντήριες Οδηγίες
- Περιοδικά άλλων  
ιατρικών Εταιρειών
- Ιατρικά Εγχειρίδια
- Βιβλιοπαρουσιάσεις
- Πρακτικά Συνεδρίων
- Ιατρική Νομοθεσία



ΓΡΑΦΟΥΜΕΝΑ ΠΟΡΤΑL ΙΑΤΡΙΚΗΣ ΕΤΑΙΡΕΙΑΣ ΑΘΗΝΩΝ

Διεύθυνση: Πλανόδιου 23, 145 28 Αθήνα  
Τηλ: 210 72 11 643, 210 72 43 161

E-mail: [ies@mednet.gr](mailto:ies@mednet.gr), [portal@mednet.gr](mailto:portal@mednet.gr)  
URL: [www.mednet.gr](http://www.mednet.gr)

Facebook: Ιατρική Εταιρεία Αθηνών – Athens Medical Society

# ΑΡΧΕΙΑ

## ΕΛΛΗΝΙΚΗΣ ΙΑΤΡΙΚΗΣ

### ΔΙΜΗΝΙΑΙΑ ΕΚΔΟΣΗ ΤΗΣ ΙΑΤΡΙΚΗΣ ΕΤΑΙΡΕΙΑΣ ΑΘΗΝΩΝ



Περιλαμβάνεται στο  
EMBASE/Excerpta Medica  
INDEX COPERNICUS, SCOPUS,  
Google Scholar, DOAJ, SJR,  
CIRRIE, JournalSeek,  
Medword List, Biores, GFMER,  
J-Gate, HEAL-Link, Socolar,  
EBSCO Publications και στο  
IATROTEK

Μαιάνδρου 23 - 115 28 Αθήνα

Τηλ.: +30 2107211845 - Fax: +30 2107215 082 - E-mail: [archives@mednet.gr](mailto:archives@mednet.gr)  
[www.mednet.gr/archives](http://www.mednet.gr/archives)

Εκδότης-Διευθυντής: Γιάννης Χρ. Μελέτης

#### ΙΑΤΡΙΚΗ ΕΤΑΙΡΕΙΑ ΑΘΗΝΩΝ

Γ. Κουράκης, Πρόεδρος  
Σ.Γ. Παπαγεωργίου, Αντιπρόεδρος  
Ε. Θεραίος, Γενικός Γραμματέας  
Θ.Γ. Βραχιλώτης, Ειδικός Γραμματέας  
Μ. Σαμάρκος, Ταμίας  
Μέλη  
Ε.Δ. Βογιατζάκης, Σ. Ηρακλειανού,  
Γ. Μάντζαρης, Δ.Τ. Μπούμπας

#### ΣΥΝΤΑΚΤΙΚΗ ΕΠΙΤΡΟΠΗ

Γιάννης Χρ. Μελέτης, Διευθυντής Σύνταξης  
Ν. Μαγκίνα, Αναπληρώτρια Διευθύντρια Σύνταξης  
Ειδικός Σύνταξτες  
Μ.Κ. Αγγελοπούλου (Αθήνα), Μεταμόχευση Μνελού  
Μ. Απειράκη (Αθήνα), Ενδοκρινολογία  
Ν. Ανάγου (Αθήνα), Αναγεννητική Ιατρική  
Γ.Ν. Αντωνακόπουλος (Λάρισα), Κυτταρολογία  
Κ. Βαγιανός (Αθήνα), Χειρουργική  
Γ. Βαζαρούλης (Αθήνα), Ρευματολογία  
Θ.Π. Βασιλακόπουλος (Αθήνα), Λευφράστα  
Π. Γαλάνης (Αθήνα), Εργασιομένη Ιατρική Έρευνα  
Ε. Γκόγκα (Αθήνα), Ογκολογία  
Γ.Λ. Δαΐκος (Αθήνα), Λοιμωξίες  
Λ. Θάνος (Αθήνα), Άξονος Τομογραφία  
Π. Καλοχαιρέτης (Αθήνα), Νεφρολογία  
Α. Καραφουτίδης (Αθήνα), Αιμοδοσία-Αιμάτωση  
Α. Κατσαρού-Κάτσαρη (Αθήνα), Δεματολογία  
Β. Καψιμάτη (Αθήνα), Ανοσολογία  
Χ. Κλωνάρης (Αθήνα), Αρρενολογία  
Κ. Κωνσταντοπούλος (Αθήνα), Σπάνια Νοσήματα  
Κ. Κώστικας (Λάρισα), Πλευρονολογία  
Γ.Α. Μαθιουδάκης (Αθήνα), Πνευμονολογία  
Ε. Μαλάμου-Λαδά (Αθήνα), Μικροφυλογία  
Μ. Μιχαλοδημάτρης (Ηράκλειο), Ιατροβιοστική/Τοξικολογία  
Θ. Μουντοκαλάκης (Αθήνα), Πλατολογία  
Α. Μπένος (Θεσσαλονίκη), Κονιονική Ιατρική  
Δ. Μπούνας (Αθήνα), Ονυχολογία  
Σ. Νανάς (Αθήνα), Εντατική Θεραπεία  
Σ.Π. Ντουράκης (Αθήνα), Ηπατολογία  
Α. Παπαβασιλείου (Αθήνα), Μοριακή Ιατρική  
Ε. Παπαβασιλείου (Αθήνα), Γαστρεντερολογία  
Π. Παπαγεωργίου (Αθήνα), Νεφρολογία  
Σ. Παπαδάκης (Αθήνα), Παιδιατρική  
Θ. Παπαδάς (Πάτρα), Φρονολαρυγγολογία  
Α. Παπαζαφειρούπολη (Αθήνα), Σαχαροδής Διαβήτης  
Ε. Πατσούρης (Αθήνα), Πλαθολογική Ανατομική  
Ε. Πετρίδης (Αθήνα), Επιδημιολογία  
Ε. Πουλάκου (Αθήνα), Ιστορική Ιατρικής  
Μ. Σαμάρκος (Αθήνα), Λοιμωξίες  
Π. Σκαπινάκης (Ιωάννινα), Ψυχιατρική  
Α. Σκλαβούνου (Αθήνα), Στοματολογία  
Α. Σολδά του (Αθήνα), Πλαντιτρική  
Κ. Σουλιώτης (Αθήνα), Πολυτική Υγείας  
Σ. Σπάρος (Αθήνα), Εργασιομένη Ιατρική Έρευνα  
Μ. Τεκτονίδης (Αθήνα), Ρευματολογία  
Ν. Τεντούλης (Αθήνα), Παθολογία, Σαχαροδής Διαβήτης  
Ε. Τέρπος (Αθήνα), Ανατολογία  
Δ. Τσεκούρα (Αθήνα), Καρδιολογία  
Γ. Υφαντόπουλος (Αθήνα), Οσκονομικά Υγείας  
Ν. Χαραλάκης (Αθήνα), Μεταμόχευση Μνελού  
Γ. Χατζής (Αθήνα), Ηπατολογία  
Προηγούμενοι Διευθυντές Σύνταξης  
Θ. Μουντοκαλάκης, Ι. Κοβιόπουλος, Ε. Βαλάσσον-Αδάμη,  
Γ. Ρηγάτος, Κ. Σολδάτος, Α.Ε. Γερμενής  
Γραμματέα  
Μ. Κατσαούνη, Ε. Γουρνά  
Επιμέλεια ελληνικών κειμένων  
Γ. Τσούφακης, Κ. Γλυκού  
Επιμέλεια αγγλικών κειμένων  
Σ. Νάκου  
Συντήρηση ηλεκτρονικών σελίδων  
Ε. Βασιλάκου

#### Επιμέλεια Έκδοσης - Διαφημίσεις Εγγραφές συνδρομητών - Επιταγές

#### ΙΑΤΡΙΚΗ ΕΤΑΙΡΕΙΑ ΑΘΗΝΩΝ ΜΑΙΑΝΔΡΟΥ 23 - 115 28 ΑΘΗΝΑ

#### ΣΥΝΕΞΙΖΟΜΕΝΗ ΙΑΤΡΙΚΗ ΕΚΠΑΙΔΕΥΣΗ

Μ.Κ. Αγγελοπούλου (Αθήνα), Αιματολογία  
Α. Ανδρουπάκη (Αθήνα), Παθολογική Ανατομική  
Γ.Ν. Αντωνακόπουλος (Λάρισα), Κυτταρολογία  
Θ.Π. Βασιλακόπουλος (Αθήνα), Αιματολογία  
Ν. Δαΐλιανης (Αθήνα), Υπερηχο-Στεφανωργαρία  
Ε. Διαμαντή-Κανθαράκη (Αθήνα), Ενδοχρονολογία  
Π. Διαμαντόπουλος (Αθήνα), Περιπτώσεις Παθολογίας  
Μ. Ελίσαφ (Ιωάννινα), Οξειδωτική Ιατροφυσική - Ηλεκτρολίτες  
Γ. Κουράκη (Αθήνα), Χειρουργική  
Γ.Ν. Κωνσταντίνου (Θεσσαλονίκη), Αλλεργολογία - Ανοσολογία  
Σ. Λιουδάκη (Αθήνα), Αγγειολογία  
Α.Γ. Μαθιουδάκης (Manchester, UK), Πνευμονολογία  
Π. Μπούρης (Αθήνα), Γαστρεντερολογία - Ενδοσκοπίσεις  
Σ. Μπούρος (Αθήνα), Περιπτώσεις Παθολογίας  
Ν. Νικτάκης (Αθήνα), Στοματολογία  
Ν. Πατέλης (Αθήνα), Αγγειοχειρουργική  
Ε. Πέτρου (Αθήνα), Ηλεκτροχαρδιογράφημα  
Μ.-Σ. Πομώνη-Γραμμένου (Αθήνα), Ιατρική Απεικόνιση  
Μ. Σαμάρκος (Αθήνα), Περιπτώσεις Παθολογίας  
Θ. Σπυριδόπουλος (Αθήνα), Παιδιατρική Απτινολογία  
Π. Τόμος (Αθήνα), Θωρακοχειρουργική  
Π. Χαραλαμπούδης (Αθήνα), Χειρουργική  
Λ. Χατζηκανάς (Αθήνα), Λοιμωξίες

#### ΕΚΤΥΠΩΣΗ

#### ΤΕΧΝΟΓΡΑΜΜΑmed


Λ. Μεσογείων 380, 153 41 Αγία Παρασκευή  
Τηλ.: 2106000643, Fax: 2106002295

e-mail: [techn@hol.gr](mailto:techn@hol.gr)

#### ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2015

Γιατροί	24 Ευρώ
Φοιτητές	12 Ευρώ
Εταιρείες	
Οργανισμοί - Βιβλιοθήκες	47 Ευρώ
Κύπρος	24 Ευρώ
Εξωτερικό	\$100
Μέλη Βαθκανικής Ιατρικής Ένωσης	\$50

Cited in  
EMBASE/Excerpta Medica  
INDEX COPERNICUS,  
SCOPUS, Google Scholar,  
DOAJ, SJR, CIRRIE,  
JournalSeek, Medword List,  
Biores, GFMER, J-Gate,  
HEAL-Link, Socolar, EBSCO  
Publications and in IATROTEK



# archives of HELLENIC MEDICINE

## BIMONTHLY JOURNAL OF THE ATHENS MEDICAL SOCIETY

23, Meandrou Street. GR-115 28 Athens-Greece  
Tel.: +30 210-72 11 845 - Fax: +30 210-72 15 082 - E-mail: archives@mednet.gr  
[www.mednet.gr/archives](http://www.mednet.gr/archives)  
Publisher-Director: J. Meletis

### EDITORIAL BOARD

John Meletis, *Editor-in-Chief*  
N. Maguina, *Associate Editor*  
**Section Editors**  
M. Alevizaki (Athens), *Endocrinology*  
N. Anagnou (Athens), *Regenerative Medicine*  
M.K. Angelopoulou (Athens), *Bone Marrow Transplantation*  
G.N. Antonakopoulos (Larisa), *Cytology*  
A. Benos (Thessaloniki), *Social Medicine*  
D. Bougas (Athens), *Urology*  
G.L. Daikos (Athens), *Infections*  
S.P. Dourakis (Athens), *Hepatology*  
P. Galanis (Athens), *Applied Medical Research*  
H. Gogas (Athens), *Oncology*  
N. Harnalakis (Athens), *Bone Marrow Transplantation*  
C. Hatzis (Athens), *Hepatology*  
P. Kalcheritis (Athens), *Nephrology*  
A. Karafoulidou (Athens), *Blood Banking-Hemostasis*  
V. Kapsimali (Athens), *Immunology*  
A. Katsarou-Katsari (Athens), *Dermatology*  
C. Klonaris (Athens), *Vascular Diseases*  
K. Konstantopoulos (Athens), *Rare Diseases*  
K. Kostikas (Larisa), *Pneumonology*  
G.A. Mathioudakis (Athens), *Pneumonology*  
H. Malamou-Lada (Athens), *Microbiology*  
M. Michalodimitrakis (Heraklion), *Forensic Medicine/Toxicology*  
T. Mountokalakis (Athens), *Internal Medicine*  
S. Nanas (Athens), *Intensive Care*  
V. Papadakis (Athens), *Pediatrics*  
T. Papadas (Patras), *Otorhinolaryngology*  
P. Papageorgopoulos (Athens), *Orthopedics*  
A. Papavassiliou (Athens), *Molecular Medicine*  
E. Papavassiliou (Athens), *Gastroenterology*  
S. Papageorgiou (Athens), *Neurology*  
A. Papazafiropolou (Athens), *Diabetes Mellitus*  
E. Patsouris (Athens), *Pathology*  
E. Petridou (Athens), *Epidemiology*  
E. Poulikou (Athens), *History of Medicine*  
M. Samarkos (Athens), *Infections*  
P. Skapinakis (Ioannina), *Psychiatry*  
A. Sklavounou (Athens), *Stomatology*  
A. Soldatos (Athens), *Pediatrics*  
K. Souliotis (Athens), *Health Policy*  
L. Sparos (Athens), *Applied Medical Research*  
M. Tektonidou (Athens), *Rheumatology*  
N. Tentolouris (Athens), *Internal Medicine, Diabetes Mellitus*  
E. Terpos (Athens), *Hematology*  
L. Thanos (Athens), *Computed Tomography*  
D. Tsekoura (Athens), *Cardiology*  
K. Vagianos (Athens), *Surgery*  
G. Vaïopoulos (Athens), *Rheumatology*  
T.P. Vassilakopoulos (Athens), *Lymphomas*  
J. Yfantopoulos (Athens), *Health Economics*  
**Pre-Editors**  
T. Mountokalakis, J. Koliopoulos, H. Valassi-Adam,  
G. Rigatos, K. Soldatos, A.E. Germenis  
**Secretariat**  
M. Kataouni, E. Gourna  
**Greek editing**  
G. Tsoufakis, K. Glykou  
**English editing**  
S. Nakou  
**Maintenance of E-pages**  
E. Vassilakou

### THE ATHENS MEDICAL SOCIETY

G. Kourakis, *President*  
S.G. Papageorgiou, *Vice President*  
E. Thireos, *Secretary General*  
T.G. Vrachliotis, *Secretary*  
M. Samarkos, *Treasurer*  
**Members**  
D.T. Boumbas, S. Irakleianou,  
G. Mantzaris, E.D. Vogiatzakis

### Editing, Subscription and Advertising Enquiries

ATHENS MEDICAL SOCIETY  
23 MEANDROU STR - 115 28 ATHENS, GR

### CONTINUING MEDICAL EDUCATION

A. Androulaki (Athens), *Histopathology*  
M.K. Angelopoulou (Athens), *Hematology*  
G.N. Antonakopoulos (Larisa), *Cytology*  
P. Bombotsi (Athens), *Gastroenterology - Endoscopy*  
S. Bouros (Athens), *Cases of Internal Medicine*  
P. Charalampoudis (Athens), *Surgery*  
N. Dalianis (Athens), *Echo-Coronary Angiography*  
E. Diamanti-Kandarakis (Athens), *Endocrinology*  
P. Diamantopoulos (Athens), *Cases of Internal Medicine*  
M. Elisaf (Ioannina), *Acid-base Balance-Electrolytes*  
L. Hadjihannas (Athens), *Infections*  
G.N. Konstantinou (Thessaloniki), *Allergy- Immunology*  
G. Kourakis (Athens), *Surgery*  
S. Lioudaki (Athens), *Vascular Diseases*  
A.G. Mathioudakis (Manchester, UK), *Pneumonology*  
N. Nikitakis (Athens), *Stomatology*  
N. Patelis (Athens), *Vascular Surgery*  
E. Petrou (Athens), *Electrocardiogram*  
M.-S. Pomoni-Gramenou (Athens), *Medical Imaging*  
M. Samarkos (Athens), *Cases of Internal Medicine*  
T.N. Spyridopoulos (Athens), *Pediatric Radiology*  
P. Tomos (Athens), *Thoracic Surgery*  
T.P. Vassilakopoulos (Athens), *Hematology*

The Archives of Hellenic Medicine accept for consideration reviews, research articles, case reports, general articles, brief communications, educational articles and letters to the Editor. A full copy is required to be sent to the Editor.

The submitted manuscripts should be accompanied with the "Submission form", accurately filled in. Submission forms can be found in every issue of the Journal.

The manuscripts should be written in accordance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (1997). Abstracts in English and in Greek should accompany the reviews and the research articles. Structured abstracts are required for research articles. In case the authors cannot provide a Greek abstract themselves, this will be done by the Editorial Board. Detailed information for authors can be found at the end of first issue of each volume.

Written permission from the Editor is required to reprint any kind of material published in the Journal. Material submitted to the Journal and accepted for publication will not be returned to the authors.

Galley proofs will be sent once to the authors for correction. No major changes are allowed at this stage.

Reprints should be ordered directly to the publisher. No reprints are furnished gratis.

Articles with no submission and acceptance dates have been invited.

### Printing

### TECHNOGRAMMA

380 Mesogeion Ave, 153 41 Ag. Paraskevi, GR  
Tel.: +30-2106000643, Fax: +30-2106002295  
e-mail: techn@hol.gr

### 2015 ANNUAL SUBSCRIPTION

Greece	
Personal edition	24 EURO
Student edition	12 EURO
Library edition	47 EURO
Cyprus	24 EURO
Rest of the world: Flat rate	\$100
Members of the Balkan Medical Union	\$50

Copyright © 2015

The Athens Medical Society



# CONTENTS

## *editorial*

The beliefs, myths and reality surrounding the word Haema (blood) from Homer to the present

J. Meletis

7

## **2nd Agean Hematology Oncology Symposium abstracts of posters**

ACUTE MYELOID LEUKEMIA (P01-P06)	17
MYELODYSPLASTIC SYNDROMES & PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (P07-P09)	20
CHRONIC LYMPHOCYTIC LEUKEMIA & HAIRY CELL LEUKEMIA (P10-P12)	21
HODGKIN'S LYMPHOMA (P13-P14)	23
NON-HODGKIN LYMPHOMAS (P15-P24)	24
MULTIPLE MYELOMA AND OTHER PLASMA CELL NEOPLASMS (P25-P43)	28
MYELOPROLIFERATIVE NEOPLASMS (P44-P48)	38
TRANSPLANTATION AND GENE THERAPY (P49-P62)	40
OTHER HEMATOLOGICAL MALIGNANCIES AND TREATMENT COMPLICATIONS (P63-P66)	47

## *index*

50

**Η υποβολή των εργασιών  
σε ηλεκτρονική μορφή επιταχύνει  
τη δημοσίευσή τους  
στο Περιοδικό και στο Internet**

- **Στείλτε σε δισκέτα μόνο  
την τελική διόρθωση του άρθρου σας**
- **Ακολουθείτε πιστά τις παρακάτω  
οδηγίες**



**Submitting of manuscripts  
on diskette can considerably  
shorten publication time in the  
Journal and the Internet**

- **Send us only the final updated  
version of your manuscript  
on diskette**
- **Follow carefully the following  
instructions**

- ◆ Τα ηλεκτρονικά αρχεία πρέπει να συνοδεύονται, απαραίτητα, από έντυπο αντίγραφο της εργασίας, γραμμένο σύμφωνα με τις οδηγίες του Περιοδικού για τους συγγραφείς.
- ◆ Το ηλεκτρονικό αρχείο πρέπει να ανταποκρίνεται ακριβώς στο κείμενο της εργασίας.
- ◆ Χρησιμοποιείτε, κατά προτίμηση, επεξεργαστή κειμένου MS Word for Windows.
- ◆ Αν δεν έχετε αυτή τη δυνατότητα, χρησιμοποιείτε οποιονδήποτε άλλον επεξεργαστή μπορεί να σώσει το κείμενό σας σε μορφή ASCII ή "text only".
- ◆ Σώζετε και στέλνετε το αρχείο της εργασίας σας σε δισκέτα 3,5" φορμαρισμένη σε DOS.
- ◆ Χρησιμοποιείτε το πλήκτρο tab και όχι το space στην αρχή των παραγράφων ή στη διαμόρφωση των πινάκων.
- ◆ Αφήνετε ένα κενό διάστημα μετά τα σημεία στίξης.
- ◆ Μην κάνετε αριθμηση των σελίδων με εμβόλιμους αριθμούς. Χρησιμοποιείτε γι' αυτό τη δυνατότητα του επεξεργαστή.
- ◆ Για σημάνσεις εντός του κειμένου χρησιμοποιείτε πλάγιους (italic) και όχι έντονους (bold) χαρακτήρες.
- ◆ Γράφετε πάνω στη δισκέτα τον αριθμό της εργασίας και το όνομα του αρχείου που περιέχει.
- ◆ Συσκευάζετε τη δισκέτα με τρόπο που να μην κινδυνεύει κατά τη μεταφορά.

- ◆ A printed copy of your manuscript written in accordance to the instructions of the Journal to the authors must accompany your diskette.
- ◆ The printed copy and the text file must correspond exactly.
- ◆ Preferably, write your manuscript in MS Word for Windows.
- ◆ In case MS Word is not available, use any other word processor able to save your file in ASCII or "text only" format.
- ◆ Save and send the file of your manuscript on a 3.5" diskette formatted for DOS.
- ◆ Do not use the space bar to make indents or to construct tables. A tabulator or an indent command should be used for this purpose.
- ◆ Put only one space after punctuation symbols.
- ◆ Do not insert page numbers manually. Use the automatic pagination incorporated in your word processor.
- ◆ To emphasize words or phrases in the text, use italic and not bold characters.
- ◆ On the label of the diskette, write the number of your manuscript and the name of your file.
- ◆ Pack your diskette safely.

---

**ΗΛΕΚΤΡΟΝΙΚΗ ΥΠΟΒΟΛΗ ΕΡΓΑΣΙΩΝ**

Για διευκόλυνση της διαδικασίας κρίσεως συνιστάται η ηλεκτρονική υποβολή των εργασιών. Για τη σύνταξη των εργασιών ακολουθούνται οι υποδείξεις του Περιοδικού. Οι εργασίες υποβάλλονται με e-mail στο Διευθυντή Σύνταξης κ. Γιάννη Μελέτη, e-mail: [imeletis@med.uoa.gr](mailto:imeletis@med.uoa.gr) ή στην Ιατρική Εταιρεία Αθηνών, e-mail: [archives@mednet.gr](mailto:archives@mednet.gr)

Το κείμενο και οι πίνακες της εργασίας θα πρέπει να στέλνονται υπό μορφή \*.doc (MS office for Windows) και οι εικόνες υπό μορφή: JPEG (\*.jpg, \*.jpeg, \*.jpe), CompuServe GIF (\*.gif), TIFF (\*.tif, \*.tiff), BMP (\*.bmp), Photoshop (\*.psd, \*.pdd)

---

**ONLINE MANUSCRIPT SUBMISSION PROCESS**

This facilitates the reviewing and Editorial process of manuscripts. Organization of the manuscript and instructions for authors are the same as described in Instructions. Manuscript can be submitted online via e-mail to: Prof. John Melletis, Editor-in-Chief, Journal Archives of Hellenic Medicine, e-mail: [imeletis@med.uoa.gr](mailto:imeletis@med.uoa.gr) or to Athens Medical Society, e-mail: [archives@mednet.gr](mailto:archives@mednet.gr)

Please send the whole document transforming this as a \*.doc file before submission. The supported extensions, fonts and other formats are the follows:

Supported formats: \*.doc (MS Office for Windows)

Supported fonts: Arial, Times, Helvetica, Times New Romans and Courier

Supported images: JPEG (\*.jpg, \*.jpeg, \*.jpe), CompuServe GIF (\*.gif), TIFF (\*.tif, \*.tiff), BMP (\*.bmp), Photoshop (\*.psd, \*.pdd).

## EDITORIAL

---

### The beliefs, myths and reality surrounding the word Haema (blood) from Homer to the present

---

“...Ιητρική, δε πάντα πάλαι υπάρχει, καί αρχή καὶ οδός ευρημένη, καθ' Ἰν καὶ τὰ ευρημένα πολλά τε καὶ καλώς ἔχοντα εύρηται εν πολλῷ, χρόνῳ, καὶ τὰ λοιπά ευρεθήσεται, ἣν τίς ικανός τε ὁν καὶ τὰ ευρημένα ειδώς εκ τούτων ορμώμενος ζητέῃ...”

“...all these requisites belong of old to Medicine, and an origin and way have been found out, by which many and elegant discoveries have been made, during a length of time, and others will yet be found out, if a person possessed of the proper ability, and knowing those discoveries which have been made, should proceed from them to prosecute his investigations...”

(Hippocrates, On Ancient Medicine)

According to many linguists, the Greek word ΑΙΜΑ (*haema*, *hema*, blood) is derived from the ancient Greek verb “*aíθω*” (*aetho*), which means “make red-hot, roast” “warm or heat”. In most ipsissima verba, according to this interpretation, the word stems from the passive present perfect of the verb “*aíθω*” (*aetho*) “*ήσμαι*” (*hesmae*). From this we get “*αίσμα*” (*haesma*) or “*αίμα*” (*haema*), which means literally “hot” or “incandescent” (as the body fluid is supposed to be).<sup>1</sup> There are some 1300 words in the English dictionary containing the Greek word “hema” and its derivatives. Many words are unedited or compound Greek words. Many words are Greek compounds with the prefixes hyper-, hypo-, auto- (“*auto*”=self, same), iso- (“*iso*”=equal, uniform), or adding the privative an- (“*a-*=without, not”). There are also compound Greek and Latin words (table 1).<sup>1,2</sup>

Its definition according to Claudius Galenos of Pergamon (in Latin Galen or Galenus) (200-130 BC)<sup>3-6</sup> was as follows:

“*αίμα εστί θερμό καὶ υγρόν εν ταις αρτηρίαις ολιγώτερον, εξ' ού το ζών τρέφεται*”, “*haema esti thermo kai hygron en tais arteriae, exou to zoon trephetai*” (hema is a warm and fluid material which is less in the arteries, from which the animal is fed).

The Greeks have always known haema as the well-known red fluid, which is seen as a bright red or crimson liquid

**Table 1.** Examples of words in the English dictionary containing the Greek word “hema” and its derivatives.

1. Unedited or compound Greek words

- Hematemesis (*H. +G. “emesis”=vomiting*),
- Hematocrit (“*hema*” +*G. “krites”=judge*),
- Hemapheresis (*H. +G. “apheresis”=removing*),
- Hemodialysis (*H. +G. “dialysis”=dissolution*),
- Hemochromatosis (*H. +G. “chroma”=color, “chrosis”=coloration*),
- Hemolysis (*H. +G. “lysis”=disintegration of cells*),
- Hemopoiesis (*H. +G. “poio”=to produce*),
- Hemorrhage (*H. +G. “rhegnymae”=to burst forth*), h
- Hemostasis (*H. +G. “stasis”=halt*),
- Oligemia (*G. “oligos”=few, little + H.*) etc.

2. Greek words compounds with

- a. The prefixes hyper- (*G. “hyper”=over, above, excessive, beyond*)
  - Hyperglycemia (*G. “hyper” +G. “glykys”=sweet +G. “hema”*)
  - Hyperuricemia (*G. “hyper” +G. “ourico”=uric +G. “hema”*)
- b. The prefixes hypo- (*G. “hypo”=below, beneath, under, less than normal*)
  - Hypoxemia (*G. “hypo” +G. “oxy”=oxygen +G. “hema”*)
  - Hypokalemia (*G. “hypo” +G. “kalio”=potassium +G. “hema”*)
- c. The prefixes auto- (*G. “auto”=self, same*)
  - Autohemolysis (*G. “auto” + H. +G. “lysis”=gradual decline*)
- d. The prefixes iso- (*G. “iso”=equal, uniform*)
  - Isohemolysis (*G. “iso” + G. H. +G. “lysis”=gradual decline*)
- e. Adding one privative a- (*G. “a-”=without, not*)
  - Anemia (“*a-* + G. “hema””).
- f. Compound Greek and Latin words
  - Hemoglobin (“*hema*” +L. “*globin*”= G. “*spherine*=*globus, globulin*”),
  - Immunohemolysis (*G. “anoso”= L. “immuno” + G. “hema” +G. “lysis”=gradual decline*) etc

Abbreviations: G.= Greek word, H. = Hema, L. = Latin word

gushing out of a wound in the human body or the body of a warm-blooded animal. The red cells are called erythrocytes (*ερυθρό=erythro=red, κύτταρα=cytes=cells*) while in French the term used is hématies (*αιμάτια=haemata=haema corpuscles*). The term “white blood cells” or leucocytes (*λευκός=leucos=white*) is not considered exact, but is used nonetheless because when they are examined fresh in the light of the microscope, they appear not as white, but as colourless cells (*άχρωμος=achromos*) and so the correct term would be “colourless blood corpuscles” or “achromocytes”.<sup>1,2</sup>

Most ancient people or nations of the East (Phoenicians, Persians, Egyptians, and Hebrews) hinged their beliefs about haema (blood) on their religious dogmas to such a degree that they could be seen as directly related to mythology or the origins of religion.

Scientific considerations about blood begin only with the Greeks. The knowledge about blood in Homeric times could be summarized in the four following concepts which are valid even today: (a) The blood is so essential for life that it is considered to be the centre of life itself.<sup>7-9</sup> (b) Death is considered to be definitive and irrevocable when it is caused by lack of blood. As a result, clashes in which murder and blood (“...φόνος τε καὶ αἷμα”, “...phinos te kai haema”) make their appearance are horrible.<sup>10-12</sup> (c) Besides red blood there is also dark blood in the body, not only in humans but also in animals. What we have here in fact is a distinction between arterial and venous blood. (d) From an anthropological, racial, ethnological, and social point of view, blood is regarded as a tribal, national and family bond. *“The Achaeans of different descent residing in an area extending from the north of Epirus to the southernmost island of Crete belong to one and the same nation because they have the same racial blood”*. Besides, the lineage blood connects the members of a family to each other, defined as “δόμαιμον”, “homaemon” (with the same blood) by Herodotus (c.484-c.425 BCE). Finally, he who is courageous, valiant, and virtuous is characterised as being of “αἵματος ἀγαθοίο”, “haematos agathoio” (of good and virtuous blood).<sup>8,9,13</sup>

Concerning scientific views about blood in historic Hellas, the ancient Greek savants or at least some of them, considered the blood to be the same as the soul (*ψυχή=psyche*), in the sense of the nonmaterial source of life otherwise called spirit (*πνεύμα=pneuma*). A similar fallacy is propounded by others, who maintain that this identification of haema (blood) with psyche (soul) is also to be found in the Holy Bible. The error is easy to refute as even in Homer, the Greek Gods and the monstrous daemons are “αναίμωνες=anhaemones», that is without blood,<sup>11,12,14</sup> which does not make them dead but, on the

contrary, immortal (because of the absence of blood) “... and out gushed the immortal blood of the goddess, ichor, such as flow in the veins of the serene gods, “...ρέε δ' ἀμβροτὸν αἷμα θείο, ίχώρ, οίος περ τε ρέει μακάρεσσι θεοίσι”, “...rhee d' amvroton haema theio, ichor, hoios per te rheei makaressi theoisi”.<sup>11,12,15</sup> It seems that the misunderstanding of later scholars can be traced to: (a) the misinterpretation of many extracts or phrases from ancient texts such as, for example, “αἷμα φασὶ τίνες εἶναι τηνψυχήν”, “haema fasi tines einai ten psychen” (the soul is said to be blood)—as Aristotle says—that in some people's opinion blood is life itself.<sup>5,6,15-17</sup> For the same reason are Galenos's words “...αἷμα εἶναι την ψυχήν”, “...haema einai ten psychen” (...blood is the soul).<sup>3,4,18</sup> (b) Finally, the most glaring of these errors is the misinterpretation of the theory of Empedocles (c.492-432 BC) “the soul, or the blood circulating around the heart, (“αἷμα γαρ ανθρώποις περικάρδιον εστί νόημα”, “haema gar anthropois pericardion esti noema”) as it identified the soul with the blood.<sup>19,20</sup> All the above would be true if we understood “psyche” as synonymous with “life” and more specifically “earthly life,” which explains why some identified blood with the material cause of physical life, in contrast with the majority of savants who considered blood to be the centre of physical life.

According to the most widespread ancient Greek scientific views, the blood was believed to be a necessary nutrient of the living body, as are juices for plants. Not all animals share the same type of blood and Aristotle (384-322 BC) notes that “...all animals are endowed with a fluid whose lack, either natural or symptomatic, causes their death. In some animals this liquid is their blood, while in others it is a colourless liquid which replaces blood” (“έναιμα”, “enhaema”, and “ἀναιμα”, “anhaema” i.e., with and without blood). He considers blood to be the essence of nutrition and the preservation of the body heat and calls it the ultimate food (“έσχατη τροφή”, “eschate trofe”), that is food in the most perfect form which creates and preserves the noblest parts of the body (the nature of man consists of the most pure substances that is, the blood, the flesh, and the other sensory organs, “η φύσις εκ μεν της καθαρώτατης ύλης (haema) σάρκας και των ἄλλων αισθητηρίων συνίστησιν...”, *physis ek men tes katharotates hyles sarcas kai ton allon haestheterion synistesin...*”).<sup>15-17</sup>

For the ancient world, the function of the heart and vessels was a great mystery. Many hundred years BC the Greeks Herophilus of Chalcedon (c.335-c.260 BC) and Alcamaeon of Croton (c.535-unknown BC) believed that arteries and veins are dissimilar in animals; arteries are thicker than veins and carry blood and made the first description of basic aspects of circulation.<sup>21,22</sup> They

suggested that sleep was caused by blood draining from the brain via the veins, and that death was the result of the brain becoming completely drained. Two hundred years later, Aristotle ascribed the power of thought to the heart, which he contended also contained the soul. Erasistratus (304-250 BC) understood that the heart served as a pump, thereby dilating the arteries, and he found and explained the role and function of the heart valves. He proposed that the arteries and veins both spread from the heart, dividing finally into extremely fine capillaries that were invisible to the eye. However, he believed that the liver formed blood and carried it to the right side of the heart, which pumped it into the lungs and from there to the rest of the body's organs. He also believed that pneuma, vital spirit, was drawn in through the lungs to the left side of the heart, which then pumped the pneuma through the arteries to the rest of the body. Galenos demonstrated the inaccuracies of many of these theories, demonstrating that the arteries carried blood rather than air, using animal dissections. Thus he proposed the theory that blood flowed back and forth within the arteries.<sup>23</sup>

Plato (427-347 BC) in Timaeus mentioned that the heart is the source of the blood which vigorously circulates through all parts of the body "...κατά πάντα τα μέλη του σώματος οφοδρώς περιφερομένου αίματος...," "...kata panta ta mele tou somatos sphodros peripheromenou haematos..."<sup>24</sup>, while Aristotle had already concluded that the blood must be uninterruptedly circulating within the blood vessels, periodically returning to its starting point the heart.<sup>15-17</sup> Long before Galenos, Hippocrates (c450-c.380 BC) already knew that the blood moves and performs a periodic or circular movement "εκτελεί περίοδον ἡ κύκλον", "periodon, cyclon".<sup>5,6,25,26</sup> Hippocrates also believed that blood is produced in the liver and spleen and travels to the heart and gets warmed or cooled in the lungs, in addition to the knowledge that the human body has four types of fluid (blood, phlegm, black, and yellow bile).<sup>27</sup> Galenos accurately describes the small blood circulation and suspects the previous while differentiating between venous and arterial blood. He used for the first time the word hematopoietic and also made the differentiation of venous blood (dark blood) originating from liver from the arterial blood (red blood) originating from the heart. He believed also that the blood is produced in the liver, travels through veins to body parts, and passes between ventricles through pores in the interventricular septum.<sup>21,22,28</sup> He also suspected the function of the breath during which the blood receives from the inhaled air not the air itself "...ουχί των ουσιών αυτού", "...ouchi ton ousion autou" but a familiar and friendly quality therein "...οικείαν και φίλην ποιότητα", "...oikeian

*kai philen poiota*"<sup>3,4,29</sup> which is a prerequisite for life, the breath of life "ζωτικόν πνεύμα", "zotikon pneuma" (*spiritus vitalis* or *life spirit*) as he called it, originating in the heart and flowing through the arteries.<sup>3,4,30</sup> This is what Lavoisier later called oxygen. However, Galenos also believed that life was sustained by food, which turned into blood in the liver, which nourished the heart, lungs, the brain, and other organs. Waste materials were also thought to be removed by the blood. Thus, the blood circulation and metabolism are significant elements of his philosophical theory and he was a pioneer in suggesting a relationship between food, blood, and air.<sup>3,4</sup>

The contribution of other Nations and scientists in the field of circulation, blood components, coagulation, and blood transfusion was very significant in the next centuries as well. The Syrian Ibn Nafis (1210-1288 AD) first described the pulmonary circulation,<sup>22,31</sup> the Iranian Rhazes (865-925 AD) made an accurate description of the heart valves,<sup>28,32</sup> the British William Harvey (1627) showed that the blood circulated within a closed system and described the mechanisms of both systemic and pulmonary circulation in humans,<sup>28</sup> and the Italian Marcello Malpighi (1658) made the first description of capillary circulation.<sup>28</sup> The first accurate descriptions of red blood cells were made by Dutch Jan Swammerdam (1630) and Antony van Leeuwenhoek (1674). The German Ernest Christian Neuman (1866) demonstrated that erythropoiesis and leukopoiesis formulate in the bone marrow and described the presence of nucleated red blood cells in bone marrow and proposed, in opposition to P. Ehrlich, in view of his one-stem-cell-theory for all blood cell lines even in extrauterine life. In this period, nobody noticed this idea (beside Pappenheim), which became such an importat fact today. On the basis of his observation, Ernst Neumann was the first to postulate the bone marrow as blood forming organ with a common stem cell for all hematopoietic cells.<sup>33</sup> The British William Osler (1870) made the first description of platelets, formation of blood clots, and hints of possible synthesis in bone marrow. The English William Hewson (1869) has been referred as the "father of hematatology" noted that the red cells were flat rather globular and also described the leukocytes for the first time and demonstrated that red blood cells were discoid rather than spherical as had been previously supposed by Anton van Leeuwenhoek, but incorrectly identified its dark center as its nucleus. In 1773 he produced evidence for the concept of a cell membrane in red blood cells, however, this last work was largely ignored.<sup>34</sup> The German Paul Ehrlich (1877) identified neutrophils, basophils, and eosinophils on the basis of staining of their granules. The first fully-documented blood transfusion to a human was

administered by the French Jean-Baptiste Denis (1667) when he transfused the blood of a sheep into a 15-year-old boy and the first human to human transfusion by British James Blundell (1818). The Austrian Karl Landsteiner (1901) documented the first three human blood groups (A, B, and O) and the American Reuben Ottenberg (1907) performed the first blood transfusion using blood typing and cross-matching.<sup>21-23,28,31,32</sup>

In the last century, the progresses are very impressive concerning the clinical as well as the experimental fields of haematology. The Americans Thomas Benton Cooley, Pearle Lee, and coworkers (1925) described thalassaemia as a particular entity, the Austrian-English Maxwell Myer Wintrobe (1929) describes the method of obtain the haematocrit by centrifusion of blood in a glass tube and defines MCV, MCH, and MCHC, and the American Wallace H. Coulter developed the electronic instrument for measuring the blood cell parameters of all blood cells. In the Mid-1960s the Canadians James Till and Ernest McCulloch (1961), the Australians Ray Bradley and Don Metcalf (1966), and the English Mike Dexter and coworkers (1977) developed the cultures of haematopoietic progenitor cells and the Canadians Bill Robinson and Beverley Pike and coworkers (1970s) made progresses for the recognition and use of colony stimulating factors in the stem cell research. At the end of 1960's the teams of the American E. Donnall Thomas and the French George Maté made the first attempts of bone marrow transplantation especially for leukemia after failure of all other treatments. The bone marrow transplantation technique was significantly assisted after HLA discovery by J. Dausset early in 1970's and at the ends of 1980s the team of French Eliane Gluckman made the first successful umbilical cord blood transplantation as an alternative source of stem cells. The research results of the last year have been ameliorated the pathophysiology, diagnosis, and management of all haematological disorders benign and malignant.<sup>35-41</sup>

Blood plays a significant role in Greek mythology, too, although the Greek Gods did not normally like blood sacrifices, which differentiates them from other ancient cultures. In mythology, the blood seems to have been something related to the psyche and the spirit, as one can easily conclude from primeval beliefs among savages and semisavages, who sprinkled the entrances to their caves or huts with it. This action is due to the belief that demons not only feed on blood but have an insatiable thirst for it and are attracted by its smell (hence their satisfaction by the blood sprinkled at entrances).<sup>42-44</sup> This belief was handed down to historical times and determined the role of blood in blood sacrifices.

Already in Homer's Iliad it is first mentioned that the type of blood is passed on to the descendants, "...ανδρών γενεής οίδ' αίματος εξ' εμού εισι", "...andron geneis oi d' haematos ex emou eisi" (...men of my lineage who have the same blood as mine)<sup>10-12,45</sup> and "...ανδρών οίτης εξ' αίματος εισί γενέθλης", "...andron oitis ex haematos eisi genethlis" (...men of your own blood lineage),<sup>10-12,46</sup> while the distinction between venous and arterial blood is also clearly drawn, "...ρέ εδ' αίμα κελαινεφές...", "...ree d' haema kelainephes..." (...dark blood was flowing),<sup>7-9,47</sup> "...σύτο δ' αίμα κελαινεφές...", "...syto d' haema keleinephes..." (...dark blood was gushing out),<sup>10-12,48</sup> and "...εκ θ' αίμα μέλαν ρέει...", "...ek th' haema reei" (...from the wound black blood was flowing).<sup>10-12,49</sup> In the Iliad we also read for first time about the coagulation of blood after being shed, "...άίμα παχύ πτύοντα...", "...haema pachy ptyonta..." (...shedding thick blood...)<sup>10-12,50</sup> and "...βρότον αιματόεντα", "...broton haematoenta" (...congealed blood).<sup>10-12,51</sup> Besides, the Odyssey mentions that blood is produced in the bone marrow which is also considered to be the regulator of human affect, "...της δ' επεί εκ μέλαν ρόη, λίπε δ' οστέα θυμός", "...tes d' epe i ek melan roe, lipe d' ostea thymos" (...as soon as black blood started flowing from the wound, vigour left the bones).<sup>7-9,52</sup> There is one point in Homeric mythology which is uncannily similar to modern haematology and more specifically with blood transfusions, namely, that the only one way for the "shadows" of the dead to recover their senses and be brought back to life is by being enriched with blood, even sheep's blood.<sup>8,9,53</sup> In this extract, Odysseus uses two sheep, sorceress Circe's gift, to bring the soothsayer Teiresias back to life, so that he can ask him about his companions and about the day of his return. Blood transfusions also seem to originate in the therapeutics of Galenos, who first raised the question of finding ways of "getting rid of the corrupt blood in a human body and infusing healthy blood in its place" ("εν ανθρώπου σώματι κενώσαι μεν το διεφθαρμένον αίμα, χρηστόν δε επεγχέειν", "en anthropou somatic kenosae men to diephtharmenon haema, christon de epencheein").<sup>3,4,54</sup> These views, however, happen to be shared by last century poetry. Thus, by bringing back to life, blood reactivates memory, being its prerequisite. In this context, a famous Greek poet, Lorentzos Mavilis, (1860-1912), wanting to safeguard peace and quiet for the dead, presents them as drinking "the water of oblivion" "ύδωρ λησμονιάς", "hydor lesmonias" from a crystal fountain, and not blood ("τέτοιαν ώραν οι ψυχές διψούν και πάνε στης λησμονιάς την κρουσταλλένια βρύση").<sup>55</sup>

Evidently, this connection between blood and the metaphysical dimension in human reality is evidently not Homer's monopoly. One finds it in later texts as well. Hippocrates, for example, relates the biological functions

of blood to human idiosyncrasy and mentions the four humours or bodily fluids [blood, phlegm, choler (yellow), and black bile “μέλαν χολή”, “melan chole” (melancholy)]—blood mutations which he considers responsible for man's health, sickness, or even behavioural patterns. According to Galenic medicine, in the case of “humor sanguinicus” (presumably an undesirably cheerful and lively temperament resulting from the dominance of the blood), doctors needed to bleed them to restore their patients' physiological balance. He also relates the humors to the seasons of the year.<sup>3,4,25,26</sup> This treatise is also the first attempt to categorize human character. Later on, in mythological texts which, having originated in Greece and spread eastwards with Alexander, were brought back to their birthplace by the Arabs and the Byzantines, one sees the same views about blood. The latter views bear such a striking resemblance to the former that the two cannot possibly be unrelated, thus opening the way to both medical and comparative literature historical research.

It is enjoyable to read about a Persian Zoroastrian doctor Perzhoe (Borzhoe in Persian) who was sent to India in the 6th century AD to learn the secrets of their philosophers and bring them to his king, Chosroes I, in order for the king to become wiser in his governance. The most important thing Perzhoe learns while copying and translating these texts is to be in constant discourse with his soul—the result of a smooth coordination between “his blood and his bile”.<sup>56</sup> This harmony between body and soul, the *krasis* (Greek for “mixture,” later “good health”), influences him to such a degree that he turns to introspection and philosophy, as he considers this to be the only way in which he can be a competent healer. Also during this internal discourse, he kept saying: “Oh soul, avoid the ephemeral, pursue the eternal and be self-sufficient; and be as virtuous as you can; and remember the constitution of your body, that it can be taken ill, that it can die, that the clay vessel of the body is filled with four fluids in delicate balance with each other and while these fluids coexist, it has life; if one of them is less or more than needed, the body collapses and dies. And just as a wooden effigy collapses when you take away the nails that hold its parts together, so does the human body if you disturb its *krasis*.”<sup>56</sup>

This extract alone would suffice to show the significance attached by savants (since Hippocrates's times to this day, as is evident in many later authored or folk texts, of the Byzantine period in particular) to the *krasis* of the blood and the other fluids in the function and constitution of the body and to the influence this awareness could have on a doctor of the period who would be keen on achieving true maturity and wisdom. Even today the boundaries

between the physician and the philosopher of medicine remain blurred.

**John Meletis, MD PhD**

Professor of Medicine and Haematology  
Emeritus Professor of National and Kapodistria,  
University of Athens, Greece

## References

1. MELETIS J. The derivatives of the Hellenic word “Haema”(hema, blood) in the English Language. *Haema* 2002, 5:140–163
2. DEPIERRE A. Les dérivés du grec HAEMA en anglais: étude de cas de variation. *Terminology* 2007, 13:155–176
3. GALENUS. Leipzig, Germany: Kühn; 1821–1833. (XIX 364)
4. CLAUDIOUS GALENUS, Selected Works. Oxford, UK: Oxford University Press; 1998
5. INTERNET ENCYCLOPEDIA OF PHILOSOPHY. <http://www.iep.utm.edu>
6. ENCYCLOPEDIA BRITANICA. <http://www.britannica.com>
7. AMEIS KF, HENZE C, CAUER P. *Odyssey*. Leipzig, Germany: Teubner; 1908–1911. (Rhapsody γ, rhume 455)
8. HOMER. *The Odyssey*. The Internet Classics Archive; Translated by S. Butler, <http://classics.mit.edu/Homer/iliad.html>
9. HOMER. *The Odyssey*. Noonday Press; 1998. translated by R. Fitzgerald
10. CAUER P. *Iliad*. Leipzig, Germany: Insel; 1921. (Rhapsody T, rhyme 214)
11. GIGUET P. L'Iliade et l'Odyssée d'Homère. Librairie de L'Hachette et Cie; 1866
12. BARESTE E. *Homère Iliade*. Paris, France: Lavigne, Librairie-Éditeur; 1843
13. AMEIS KF, HENZE C, CAUER P. *Odyssey*. Leipzig, Germany: Teubner; 1908–1911. (Rhapsody δ, rhume 611)
14. CAUER P. *Iliad*. Leipzig, Germany: Insel; 1921. (Rhapsody E, rhume 339, 340, 342)
15. ARISTOTLE. On the Parts of Animals, Movements of Animals, Progression of Animals. Loeb Classic Library; 1993. translated by A. C. Peck
16. ARISTOTLE. On the Parts of Animals. The Internet Classics Archive; translated by W. Ogle, [http://classics.mit.edu/Aristotle/parts\\_animals.mb.txt](http://classics.mit.edu/Aristotle/parts_animals.mb.txt)
17. BARNES J. The Complete Work of Aristotle: The Revised Oxford Translation. Princeton, NJ, USA: Princeton University Press; 1984
18. ROUSSEL P. Presence de Galien. Paris, France: Union Latine d'Editions; 1961
19. EMEDOCLES, About nature. extract 10, <http://plato.stanford.edu/entries/emedocles>
20. FAIRBANKS A, editor. The First Philosophers of Greece. London, UK: K. Paul, Trench, Trubner; 1898. Empedocles, fragment and commentary
21. DUCASSE E, SPEZIALE F, BASTE JC, MIDY D. Vascular knowledge in Medieval Times was the turning point for the humanistic

- trend. *European Journal of Vascular and Endovasc Surg* 2006, 31:600–608
22. KHAN IA, DAYA SK, GOWDA RM. Evolution of the theory of circulation. *Int J Cardiol* 2005, 98:519–521
23. ERASISTRATUS Biography. <http://www.faqs.org/health/bios/12/Erasistratus.html>
24. PLATO. Timaeus. The Internet Classic Archive; translated by B. Jowett, <http://classics.mit.edu/Plato/timaeus.html>
25. HIPPOCRATES. Corpus Hippocraticum. Lipsiae, Germany: Editionen Curavit, D. Carolus, Gottlab Kuhn; 1825. On human nature
26. JOUANNA J. Hippocrate. Paris, France: Fayard; 1992
27. SHOJA MM, TUBBS RS, LOUKAS M, ARDALAN MR. The Aristotelian account of «heart and veins». *Int J Cardiol* 2008, 125:304–310
28. AZIZI M-H, NAYERNOURI T, AZIZI F. A brief history of the discovery of the circulation of blood in the human body. *Arch Iran Med* 2008, 11:345–350
29. GALENUS. Leipzig, Germany: Kühn; 1821–1833. (XIY 714)
30. GALENUS. Leipzig, Germany: Kühn; 1821–1833. (Y281, X809)
31. MASIC I, DILIC M, SOLAKOVIC E, RUSTEMPASIC N, RIDJANOVIC Z. Why historians of medicine called Ibn al-Nafis second Avicenna? *Medicin Arhiv* 2008, 62:244–249
32. LOUKAS M, LAM R, TUBBS RS, SHOJA MAM, APAYDIN N. Ibn al-Nafis (1210–1288): the first description of the pulmonary circulation. *Am Surg* 2008, 74:440–442
33. ZECH NH, SHKUMATOV A, KOESTENBAUER S. Die magic behind stem cells. *J Ass Reprod Genet* 2007, 24:208–214
34. KLEINZELLER A. William Hewson's studies of red blood corpuscles and the evolving concept of a cell membrane. *Am J Physiol* 1996, 271:C1–C8
35. HEMATOLOGY. [http://www.ernst-neumann-koenigsberg.de/Ernst\\_Neumann/ernst\\_neumann.html](http://www.ernst-neumann-koenigsberg.de/Ernst_Neumann/ernst_neumann.html)
36. PEARSON HA. History of pediatric hematology oncology. *Pedc Res* 2002, 52:979–992
37. CHERNOFF AI. The distribution of the thalassemia gene: a historical review. *Blood* 1959, 14:899–912
38. METCALF D. Summon up the Blood. In Degged Pursuit of the Blood Cell Refulator. Miamisburg, Ohio, USA: AlphaMed Press; 2000
39. THOMAS ED. Landmarks in the development of hematopoietic cell transplantation. *World J Surg* 2000, 24:815–818
40. MATHÈ G. Hematopoietic cell grafts and their applications. *Presse Medicale* 1964, 72:2391–2394
41. GLUCKMAN E. Cord blood transplantation. *Biology of Blood and Marrow Transplantation* 2006, 12:808–812
42. GREEK MYTHOLOGY. <http://homepage.mac.com/cparada?GML>
43. ORPHEUS. <http://homepage.mac.com/cparada/GML/Orpheus.html>
44. CUTHRIE WKC. Orpheus and Greek Religion. A Study of the Oprhic Movements. Princeton, NJ, USA: Princeton University Press; 1993
45. CAUER P. Iliad. Leipzig, Germany: Insel; 1921. (Rhapsody T, rhyme 105)
46. CAUER P. Iliad. Leipzig, Germany: Insel; 1921. (Rhapsody T, rhyme 111)
47. AMEIS KF, HENZE C, CAUER P. Odyssey. Leipzig, Germany: Teubner; 1908–1911. (Rhapsody λ, rhume 37)
48. CAUER P. Iliad. Leipzig, Germany: Insel; 1921. (Rhapsody Φ, rhyme 167)
49. CAUER P. Iliad. Leipzig, Germany: Insel; 1921. (Rhapsody Φ, rhyme 119)
50. CAUER P. Iliad. Leipzig, Germany: Insel; 1921. (Rhapsody ψ, rhyme 697)
51. CAUER P. Iliad. Leipzig, Germany: Insel; 1921. (Rhapsody Η, rhyme 425)
52. AMEIS KF, HENZE C, CAUER P. Odyssey. Leipzig, Germany: Teubner; 1908–1911. (Rhapsody γ, rhume 455)
53. AMEIS KF, HENZE C, CAUER P. Odyssey. Leipzig, Germany: Teubner; 1908–1911. (Rhapsody λ, rhumes 50 and 96)
54. GALENUS. Leipzig, Germany: Kühn; 1821–1833. (XYIII β, 283)
55. LORENTZOS MAVILIS, Oblivion. Ta Sonetta. Athens, Greece: Pelila; 1935–1949
56. NIEHOFF-PANAGIOTIDIS J. Übersetzung und Rezeption. Die Byzantinischneugriechischen und Spanischen Adaptationen von Kalila-wa-Dimna. Wiesbaden, Germany: Reichert; 2003

*Corresponding author:*

John Meletis, MD PhD, Professor of Medicine and Haematology, Emeritus Professor of National and Kapodistria, University of Athens, Greece  
e-mail: [imeletis@med.uoa.gr](mailto:imeletis@med.uoa.gr)



---

National and Kapodistrian  
UNIVERSITY OF ATHENS

---




## **2<sup>nd</sup> AGEAN HEMATOLOGY ONCOLOGY SYMPOSIUM “AHOS 2015”**

**September 17-20, 2015, Hotel Chios Chandris, Chios, Greece**

GUEST EDITORS  
**Evangelos Terpos, Guray Saydam**

Under the auspice of Athens Medical Society



## **BOOK OF ABSTRACTS**

[www.ahos2015.com](http://www.ahos2015.com)

**2<sup>nd</sup> AEGEAN HEMATOLOGY ONCOLOGY SYMPOSIUM  
“AHOS 2015”**

**17-20 September 2015  
Hotel Chios Chandris, CHIOS, GREECE**

**ORGANIZING COMMITTEE**

Evangelos Terpos (*Co-chair*)

Guray Saydam (*Co-chair*)

Ridvan Ali

Seckin Cagirgan

John Meletis

Ilectra Papadimitriou

Fahri Sahin

Eleftherios Thiraios

Theodoros P. Vassilakopoulos

**SCIENTIFIC COMMITTEE**

Ridvan Ali

Seckin Cagirgan

Meletios A. Dimopoulos

Efstathios Kastritis

Kostas Konstantopoulos

Hayri Ozsan

Panagiotis Panagiotidis

Fahri Sahin

Guray Saydam

Evangelos Terpos

Eleftherios Thiraios

Mehmet Yilmaz

**ABSTRACT REVIEWERS**

Olga Meltem Akay

Stavroula Giannouli

Kostas Konstantopoulos

Mehmet Yilmaz

## WELCOME LETTER FROM THE CHAIRMEN

Dear Colleagues,

*It's a privilege to welcome you to the 2nd Aegean Hematology Oncology Symposium (AHOS), which is held on September 17–20, 2015, in Chios. The Symposium is co-organized by the University of Athens (School of Medicine) and the Athens Medical Society in collaboration with the Turkish Medical Association of EHOD (Aegean Hematology Oncology Society).*

*This meeting is planned to share country perspectives on hematology oncology topics between Greek and Turkish clinicians, to exchange experiences and to create the basis for multi-center, multi-national studies. During the last years, there was a significant progress in the biology of hematological malignancies that led to the development of several novel drugs in the field. The scientific program includes all these data presented by experienced hematologists and it is organized in well-balanced interactive sessions and teaching programs focusing on the needs of hematology/oncology clinicians.*

*We have also a very interesting poster program where all accepted abstracts will be displayed during the congress. Sixty-six abstracts from several centers of both Greece and Turkey depict the development of hematological oncology in our countries, they offer a unique opportunity for sharing ideas and they build bridges for collaborative studies. The abstracts are published in this supplement of the most historical Greek journal, the Archives of Hellenic Medicine, a bimonthly refereed journal of the Athens Medical Society. Before the published abstracts, the editor-in-chief of the journal, Professor John Meletis presents a historical review for the roots of the world "haema" (blood), the basis of the medical specialty of Hematology.*

*We hope that you enjoy both the scientific program and the beauties of Chios and we thank you for your contribution in the development of this congress. Our aim is to improve this meeting every year and to strengthen the bonds between the doctors of both countries.*

*Have a nice meeting and see you again next year in Thessaloniki (Greece) for the 3<sup>rd</sup> AHOS.*

*With warm regards,  
Evangelos Terpos & Guray Saydam  
Co-Chairmen of 2<sup>nd</sup> AHOS*

# **2<sup>nd</sup> AEGEAN HEMATOLOGY ONCOLOGY SYMPOSIUM (AHOS 2015)**

## **GENERAL INFORMATION**

### **VENUE LOCATION AND DATES**

The 2nd AHOS 2015 will be held from Thursday, September 17th to Sunday, September 20th 2015 in Chios, at Hotel Chios Chandris, [www.chandris.gr](http://www.chandris.gr)

### **REGISTRATION - CERTIFICATE OF ATTENDANCE - CREDITS**

All registered participants are entitled to receive a Certificate of Attendance.

The Certificate will be issued only upon display of participant badge, which will be issued by the Symposium secretariat and only upon satisfactory attendance.

### **OFFICIAL LANGUAGE**

The official language of the course is English.

### **EXHIBITION**

The Symposium will be accompanied by a major exhibition where pharmaceutical and/or equipment/device industries will display relevant products and therapeutic development.

### **ORGANIZING SECRETARIAT**



#### **Congress World, Event - Travel**

23 Meandrou str. 115 28 Athens,  
 +30 210 7222 518,  
 +30 210 7210 069  
 [www.congressworld.gr](http://www.congressworld.gr)  
 ap@congressworld.gr



#### **L.O.V.I., Tourism & Organization**

Ali Çetinkaya Bulvari No: 68 Doktorlar Sitesi  
D: 202 Alsancak - Konak / İzmir  
 0090 232 465 18 88  
 [www.loviturizm.com](http://www.loviturizm.com)  
 onur@loviturizm.com

## ABSTRACTS

### ACUTE MYELOID LEUKEMIA

#### P01

##### EFFECT OF THE CALCIUM CHANNEL BLOCKER VERAPAMIL ON CELL CYCLE AND APOPTOSIS IN AML CANCER CELL LINES (HL-60)

Gulper NACARKAHYA<sup>1</sup>, Mehmet YILMAZ<sup>2</sup>,  
Ibrahim Halil KILIC<sup>3</sup>, Isik Didem KARAGOZ<sup>3</sup>,  
Ebru TEMİZ<sup>1</sup>, Mehmet OZASLAN<sup>3</sup>

<sup>1</sup>Gaziantep University School of Medicine, Department of Medical Biology, Gaziantep, Turkey, <sup>2</sup>Gaziantep University School of Medicine, Department of Hematology, Gaziantep, Turkey, <sup>3</sup>Gaziantep University School of Medicine, Department of Molecular Biology, Gaziantep, Turkey

**Objective:** The drugs that are used in the chemotherapeutic treatment of cancer are quite toxic effects on target cells. To this end, giving specific doses of verapamil to the HL-60 AML cell line and apoptosis and cell cycle was evaluated.

**Methods:** HL-60 AML cell line was selected in this study. This cell line containing 10% FCS with 1% penicillin and streptomycin produced sub cultured in RPMI-1640. The effective dose (viability value) was determined by MTT method by 10, 30, 50, 80 µM of giving increasing doses verapamil to the HL-60 cell line 24 hours incubation. Determined the effective dose of verapamil, given to HL-60 cells, cycle and apoptosis were examined by flow cytometry. In Saline with HL-60 cells were used as control.

**Results:** Verapamil (50 µM) lead to increased programmed cell death ratio at the 24.hours compared to control and this result was statistically significant ( $p < 0.05$ ). Diploid cell cycle verapamil untreated group in G1 phase decreased according to verapamil treated group and a significant increase in S phase formed a significant difference ( $p < 0.05$ ), but formed no significant difference ( $p > 0.05$ ) in G2 phase. When the ratio of aneuploid cells in the G1 phase of verapamil untreated group compared to the group administered with verapamil creates increased a significant difference ( $p < 0.05$ ). Decrease in S phase does not constitute a significant difference ( $p > 0.05$ ).

**Conclusion:** The first main control point is DNA damage censor in the transition of G1/S phase. In the early to mid-G1 phase of damaged cells in the G1 phase are hanged back, damaged cells in late G1 phase, will continue in the S phase. Thus, cell G1/S transition of the cell phase ratios we have achieved with verapamil is arrested synchronization, which is consistent with this informa-

tion. Combining verapamil with other chemotherapeutic drugs may result in increasing effect in AML treatment.

#### P02

##### ACUTE MYELOID LEUKEMIA RELAPSING AS GRANULOCYTIC SARCOMA OF THE UTERINE CERVIX: A CASE REPORT

Muhammet MADEN<sup>1</sup>, Gulsum Emel PAMUK<sup>1</sup>, Demet TEKATAS<sup>2</sup>, Mehmet Sevki UYANIK<sup>1</sup>

<sup>1</sup>Department of Hematology, Trakya University, Edirne, Turkey, <sup>2</sup>Department of Internal Medicine, Edirne State Hospital, Edirne, Turkey

**Introduction:** Granulocytic sarcoma (GS) is defined as a tumor mass composed of immature myeloid cells localized in any extramedullary site. GS can be isolated or encountered during the course of acute myeloid leukemia (AML), myelodysplastic syndrome or chronic myeloproliferative neoplasms. It may be detected coexistent with the initial diagnosis of these diseases or may be seen in the relapse or as the first sign of the disease relapse. We present the case of a patient whose disease relapsed as GS of the uterine cervix.

**Case:** A 63-year-old female AML diagnosed patient who was given radiotherapy for 2 days after the cervix uteri cancer pre-diagnosis, followed for 1,5 years in remission, applied to hematology department with complain of dysuria. In the blood count leukocyte 61400/uL, hemoglobin 10.2 g/dL, platelets 24000/uL, in the biochemical analysis, urea 150 mg/dl, creatinine 2.5 mg/dL, LDH 1179 U/L, and in the peripheral blood smear, 60% myeloid and monostoid blasts were detected. In the all abdominal MRI, a rectum and bladder invasive mass which infiltrated the cervix uteri completely were detected. Endocervical curettage biopsy (MPO and CD117 positive, CD34, TDT, Ki67, HPV, p53 negative) was compatible with GS and in the bone marrow biopsy 95% blasts was detected and the patient was diagnosed with relapse AML accompanied by GS. Idarubicin+Ara-C induction chemotherapy was initiated and the patient died of sepsis on the 24th day of chemotherapy.

**Conclusion:** Clinically the incidence of GS in AML is 3–5%. The presence of GS is associated with a generally poor outcome and a shorter overall survival. GS can be found in almost any organ: the most common sites of involvement are bones, soft tissues, lymph nodes, skin, gastrointestinal tract. GS of the uterine cervix is very rare. MPO is the single most sensitive and specific antibody for detection of myeloid differentiation.

## P03

### A CASE REPORT: GRANULOCYTIC SARCOMA WHICH CAN BE CONFUSED WITH HISTIOCYTIC SARCOMA

**Ali GOKYER<sup>1</sup>, Mehmet Sevki UYANIK<sup>2</sup>,**

**Gulsum Emel PAMUK<sup>2</sup>**

<sup>1</sup>Trakya University, Department of Internal Medicine, Trakya, Turkey, <sup>2</sup>Trakya University, Department of Hematology, Trakya, Turkey

**Introduction:** Granulocytic sarcoma is a solid tumor formed by granulocyte precursors outside of bone marrow. Granulocytic sarcoma may manifest as a sign of acute myeloid leukemia (AML). In this case report, the patient we aimed to present was firstly diagnosed with histiocytic sarcoma after undergoing a biopsy, later he underwent a lymph node biopsy from the neck area to confirm this diagnosis, which resulted in granulocytic sarcoma.

**Case:** A 58-year-old male patient who was diagnosed of histiocytic sarcoma after tonsillectomy. The patient consulted us. Blood count results were as follows: leukocyte 7330/uL, hemoglobin 14.5 gr/dl, thrombocyte 314000/uL. Biochemical analysis resulted was normal. Peripheral blood smear test did not reveal any atypical cells, however during bone marrow biopsy 3-4% immature cells were detected. In the PET-CT, lymph node located in the left cervical section was considered. After excision, positive staining with myeloperoxidase (MPO), CD68, CD34 and CD56 markers confirmed the diagnosis of granulocytic sarcoma. The patient was administered idarubicin + cytosine arabinoside protocol. Upon detecting a progression in the following thoracic CT scan the patient was administered high dose cytosine arabinoside + idarubicin protocol. The mass regressed. However, after this therapy the patient died from opportunistic fungal infection.

**Conclusion:** Granulocytic sarcoma may occur in relation with AML. It is involved with central nervous system, skin and lymph nodes. It is a sign of poor prognosis for 2-14% of patients suffering from AML. Very occasionally it does not accompany AML, in our case bone marrow biopsy resulted with a myeloblast ratio of 4% and thus AML was not present. In our case, during cervical LAM biopsy MPO, CD68, CD34 and CD56 markers were confirmed and thus the patient was diagnosed with granulocytic sarcoma.

## P04

### BILATERAL SIXTH NERVE PALSY POSSIBLY ASSOCIATED WITH ARSENIC TRIOXIDE IN ACUTE PROMYELOCYTIC LEUKEMIA

**Pusem PATIR<sup>1</sup>, Merve Guner OYTUN<sup>2</sup>, Anil OZLUK<sup>2</sup>, Alide ALIYEVA<sup>2</sup>, Ayhan DONMEZ<sup>1</sup>, Murat TOMBULOGLU<sup>1</sup>**

<sup>1</sup>Ege University Faculty of Medicine, Department of Hematology, Izmir, Turkey, <sup>2</sup>Ege University Faculty of Medicine, Department of Internal Medicine, Izmir, Turkey

**Introduction:** Herein, we reported an 30-year-old patient with acute promyelocytic leukemia (APL) who was treated with low-

dose all trans retinoic acid (ATRA) and arsenic trioxide (ATO) because of bilateral sixth nerve palsies possibly associated with arsenic trioxide achieving molecular complete remission.

**Case:** A 30-year-old female patient was admitted to our department in November 2014. Pancytopenia was identified in this patient. Bone marrow aspiration biopsy was reported as acute myeloid leukemia. RT-PCR showed the proportion of fusion gene PML-RAR $\alpha$  was positive (53%). Diagnosis of APL was confirmed and treatment was started. She developed sudden blurred vision and diplopia. She developed an isolated bilateral 6th nerve palsies, more prominent on the left side, which were at onset suspected to be caused by isolated leukemic infiltration. The cerebrospinal fluid examination and brain MRI were performed in terms of nerve involvement and resulted normal. So 6th nerve palsies were considered to be caused by a drug reaction. ATRA and ATO treatment was stopped and she was followed. Her complaints improved. She was treated with ATRA at 40mg/day for 15 days and idarubicin at 5mg/m<sup>2</sup> for 4 days per week. Consolidation treatment with ATRA has been continued seamlessly therefore adverse ocular reaction was considered to be possibly associated with arsenic trioxide.

**Conclusion:** Treatment with ATO is alarming to patients and physicians alike due to the broad adverse effect profile. Unexplained strabismus and diplopia should be evaluated as a potential sign of CNS involvement and initially conventional imaging and cerebrospinal fluid examination should be performed. If CNS involvement of APL is not detected, abducens nerve palsy can be considered to be caused by a drug reaction. Herewith a thorough understanding of the safety and potential side effects of ATO as a therapeutic agent is necessary, in order to minimize its toxic complications.

## P05

### CLINICAL ANALYSIS OF 11 PATIENTS WITH MYELOID SARCOMA AS A SINGLE CENTER EXPERIENCE

**Mehmet YILMAZ, Hamit YILDIZ, Erdal GUNDOGAN, Mustafa PEHLIVAN, Vahap OKAN, Ibrahim SARI**

*Gaziantep University, Department of Hematology, Gaziantep, Turkey*

**Objective:** Myeloid sarcoma (MS) represents the proliferation and accumulation of myeloblasts at extramedullary sites. While extramedullary involvement in acute myeloblastic leukemia (AML) is uncommon in itself, MS without any bone marrow involvement are extremely rare and has a diagnostic and therapeutic challenge. Here, we presented the clinical features, diagnosis, treatment modality and results of MS patients as a single center experience.

**Methods:** This study included evaluation of 11 patients with MS from March 2010 to January 2014, retrospectively.

**Results:** Seven of 11 patients were male 4 were female. Median age was 41.0. The patients were presented with the involvement of L3-S1 vertebra (1), conjunctiva (1), eye lid (1), lower cervical region (1), skin (1), testis (1), inguinal region (2), and pharynx (3). Chronic

myeloid leukemia was developed after MS was diagnosed and 2 months later accelerated to blastic phase in 1 of 11 patients. He was treated with combined chemotherapy regimens, after achieving complete remission HLA identical unrelated bone marrow transplantation (BMT) was performed. But He was died related to chronic graft versus host disease and pulmonary aspergillosis 6 months later after BMT. Among 11 patients 6 were treated with chemotherapy, 2 chemotherapy plus radiotherapy, 5 patients were treated without chemotherapy, but treated with surgical resection. Of 3 of 11 patients were follow out after diagnosis of MS. Chemotherapy regimen was combined with idarubicine and cytarabine similar to AML. The average survival time of MS patients treated with or without chemotherapy were 19 and 11 months respectively, suggesting prolonging of survival time of patients treated with chemotherapy. The average survival time of MS patients treated with chemotherapy plus radiotherapy was 23 months, better than chemotherapy alone and without chemotherapy. Moreover one patient who was treated using chemotherapy combined with BMT is not alive now, living times was 26 months.

**Conclusion:** We found that chemotherapy similar as treatment of AML can decrease the probability of disease progressing into bone marrow abnormality, and if chemotherapy combines with radiotherapy and bone marrow transplantation, the survival time of MS patients can be longer. More research is necessary to elucidate the molecular pathogenesis of MS, its prognostic impact, and optimal treatment modalities.

## P06

### EXPRESSION PROFILING OF A PANEL OF APOPTOSIS-ASSOCIATED MICRORNAs IN ACUTE MYELOID LEUKEMIA IDENTIFIES DIFFERENTIALLY EXPRESSED MICRORNAs THAT TARGET EPIGENETIC MODIFIERS

Eleftheria HATZIMICHAEL<sup>1,2</sup>, Aggeliki DASOULA<sup>3</sup>, Maria IGGLEZOU<sup>3</sup>, Andreas KATSENOS<sup>3</sup>, Ioannis SAINIS<sup>3</sup>, Isidore RIGOUTSOS<sup>2</sup>, Evangelos BRIASOULIS<sup>1</sup>

<sup>1</sup>Department of Hematology, University of Ioannina, Ioannina, Greece, <sup>2</sup>Computational Medicine Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, U.S.A., <sup>3</sup>Cancer Biobank Center, University of Ioannina, Ioannina, Greece

**Objective:** Identifying molecular aberrations in Acute Myeloid Leukemia (AML) is still an unmet research target. We evaluated the expression of a panel of apoptosis-associated microRNAs (miRNAs) in leukemic blasts isolated from AML patients and investigated their predicted targets.

**Methods:** We used bone marrow or peripheral blood that were donated by eight AML patients (5 male, 3 female) at diagnosis. Mononuclear cells were isolated by Ficoll-Histopaque (Sigma Aldrich) density gradient centrifugation and were cryopreserved in liquid nitrogen at the Cancer Biobank Center of the University of Ioannina. MicroBeads technology was used for magnetic cell

sorting of CD34+ cells of patients' samples, while mononuclear blood cells from healthy individuals were used as controls. Small RNA (<200 b) was isolated using the NucleoSpin® miRNA kit (Macherey Nagel). Simultaneous quantification of 84 apoptosis-associated miRNAs was performed by using the miScript miRNA PCR Array Human Apoptosis (MIHS-114ZF, Qiagen) in a LightCycler® 480 instrument (Roche AG, Rotkreuz, Switzerland), and relative quantitation of expression was determined by the comparative CT method. For miRNA target prediction we used the RNA22 tool: <http://cm.jefferson.edu/rna22v2> and <http://cm.jefferson.edu/rna22v2.0>.

**Results:** We found 51 downregulated and 12 upregulated miRNAs compared to control. Among the downregulated miRNAs was the miR-29 family and among the upregulated was the miR-181 family, both of which have been previously implicated in AML. The top 10 downregulated miRNAs were miR-31-5p, miR-451a, miR-144-3p, miR-29b-3p, miR-204-5p, miR-9-5p, miR-409-3p, miR-542-3p, miR-29c-3p and miR-29a-3p, whereas the top 10 upregulated miRNAs were miR-186-3p, miR-149-3p, let-7c-5p, miR-222-3p, miR-214-3p, miR-181c-5p, miR-181a-5p, miR-181b-5p, miR-34a-5p and miR-181d-5p. Deepest downregulation (over -50fold) was seen for miR-144-3p, miR-451a and miR-31-5p. We used RNA22 to identify genes that are predicted to be simultaneously targeted by all of the 10 top downregulated miRNAs and also the genes that are predicted to be simultaneously targeted by all of the 10 top upregulated miRNAs. The predicted targets for all top 10 downregulated miRNAs include NSD1, KAT6B and SACS. NSD1 is an histone methyltransferase, whereas KAT6B is an histone acetyltransferase. The predicted targets of all top 10 upregulated miRNAs include 36 genes among which are DICER1, ZNF507, ZNF704 and MLLT6.

**Conclusion:** A variety of microRNAs are dysregulated in patients with AML. We confirm that the miR-29 family and the miR-181 family have altered expression in AML. Among predicted targets of the downregulated miRNAs are genes involved in chromatin remodelling, suggesting that altered function of epigenetic modifiers in AML may be due to dysregulation of miRNAs.

## MYELODYSPLASTIC SYNDROMES & PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

**P07**

### RETROSPECTIVE EVALUATION OF DEMOGRAPHIC AND CLINICAL FEATURES OF PATIENTS WITH MDS: SINGLE CENTER EXPERIENCE

**Gülay ALP<sup>1</sup>, Mahmut TÖBÜ<sup>2</sup>, Fahri ŞAHİN<sup>2</sup>, Murat TOMBULOĞLU<sup>2</sup>, Güray SAYDAM<sup>2</sup>**

<sup>1</sup>Ege University School of Medicine, Department of Internal Medicine, Izmir, Turkey, <sup>2</sup>Ege University School of Medicine, Department of Hematology, Izmir, Turkey

**Objective:** Myelodysplastic syndromes are heterogenous disease and have complex clinical presentation. Clinical and demographic data of 158 patients with Myelodysplastic Syndrome (MDS) followed in Ege University School of Medicine Department of Hematology, were analyzed retrospectively.

**Methods:** Those patients who were followed-up with the diagnosis of MDS, were evaluated in terms of their ages, genders, complaints and laboratory values based on their files.

**Results:** The average age at the time of diagnosis was 66 years old. While 79 of them were male, 79 cases were female. 27.2% (43) of the patients were in low risk MDS group, 48.7% (77) were intermediate-1, 9.5% (15) were intermediate-2 and 4.4% (7) were patients with high risk MDS according to IPSS. 50% (79) of patients had RA, 13.3% (21) had RAEB-2, 3.2% (5) had RARS, 8.9% (14) had RAEB-1, 19.7% (31) RCMD, 3.8% (6) had RT and 5q syndrome and 9.5% of patients had secondary MDS. Twenty-nine of the 114 patients that were checked for cytogenetic analysis, had abnormal cytogenetic. For the cytogenetic analysis; 12 patients had 5q deletion, 9 patients had trisomy 8, 3 patients had 20q deletion, 7 patients had 7q deletion and 3 patients had RB1gen (13q14) mutations were observed. Median survival was calculated as 24 months. During the follow up period, 10 patients progressed to AML. Twelve percent (19) of the 158 patients died during the follow-up period. Disease progression and infections were the major causes of the death. 4 patients had progression AML and 15 patients died because of the co-morbidities.

**Conclusion:** Myelodysplastic syndromes are complicated and heterogeneous disorders which are not well understood yet. Individualized approach is essential for these patients. Clinical and demographic characteristics of each patient should be determined before therapy.

**P08**

### HEREDITARY ICHTHYOSIS VULGARIS AND MYELODYSPLASTIC SYNDROME: A CASE REPORT

**Pelin AYTAN<sup>1</sup>, Kivilcim ERDOĞAN<sup>2</sup>, Emel GÜRKAN<sup>3</sup>**

<sup>1</sup>Mersin State Hospital, Department of Hematology,

<sup>2</sup>Çukurova University Balcalı Medical

Hospital, Department of Pathology, Adana, Turkey,

<sup>3</sup>Çukurova University Balcalı Medical Hospital, Department of Hematology, Adana, Turkey

**Introduction:** Hereditary ichthyosis (HI) vulgaris is an autosomal dominant disease first evident in early childhood. Unlike acquired ichthyosis HI is rarely associated with hematologic malignancies. In this case we present a girl with HI vulgaris with MDS-RAEB.

**Case:** G.A. is a twenty-one-year-old girl who has HI vulgaris. She has been consulted by her dermatologist because of her anemia. Otherwise she had no symptoms. She had hepatosplenomegaly and different types of scaling in different areas. There is moderate ectropion where the exposed conjunctiva was thickened and hyperaemic. The laboratory findings were: WBC:3.11 K/uL, HGB:11.2 g/dl, NE:1.54K u/L, MCV:814 fl, PLT:89 Ku/L, AST:70 U/L, ALT:60 U/L, LDH:199 U/L. In her peripheral blood smear there were anisocytosis, hyposegmentated and hypogranular neutrophils and low thrombocyte level. In her bone marrow aspiration there were hypolobulated neutrophils, erythroid serial dysplasia, dysmegakaryopoiesis and 6-8% elevated blasts. She is now using topical retinoids that her dermatologist suggested. She has been following by the haematology clinic for about seven months. Her family and she went for HLA matching testing for probable future allogeneic bone marrow transfusion. In her follow-ups there has been no need for blood transfusion and her neutrophil level has never been below 500 K/uL.

**Conclusion:** The myelodysplastic syndromes (MDS) compose a heterogeneous group of clonal stem cell disorders characterized by ineffective hematopoiesis in one or more cell lineages and have a propensity to progress to AML. MDS patients are often asymptomatic and the diagnosis is made at the time of routine laboratory screening tests that reveal cytopenias in one or more lines or dysplasia on the blood smear. There are not many cases in literature that report an association between HI and hematologic malignancies. In the present case the patient with HI also has MDS-RAEB which has a potential to progress acute myeloid leukemia.

**P09****THE AWARENESS OF PNH: A SINGLE CENTER EXPERIENCE FROM ANTALYA, TURKEY**

Hatice DUMAN<sup>1</sup>, Ozan SALIM<sup>1</sup>, Orhan Kemal YUCEL<sup>1</sup>, Melike ULUBAHSI<sup>1</sup>, Hediye SOLTEKIN<sup>1</sup>, Merve AYCICEK<sup>1</sup>, Erdal KURTOGLU<sup>2</sup>, Levent UNDAR<sup>1</sup>

<sup>1</sup>Department of Hematology, Akdeniz University, Antalya, Turkey, <sup>2</sup>Department of Hematology, Antalya Ataturk Research and Training Hospital, Antalya, Turkey

**Objective:** Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening but treatable disease characterized mainly by destruction of red blood cells by the complement system. The heterogeneity of the clinical manifestations and lack of awareness of PNH may cause delayed diagnosis. The fluorescein-labeled proaerolysin (FLAER) test by using flow cytometry is the gold standard methodology for screening of paroxysmal nocturnal hemoglobinuria.

**Methods:** We analyzed 388 cases screened for PNH with FLAER according to the main symptoms and laboratory findings from 2012 to 2015 in Akdeniz University Hospital, retrospectively.

**Results:** The median age was 47 years (range: 1-94 years) and the M/F ratio was 178/210. The commonest reason for screening for PNH at onset were PNH related symptoms (30.7%) (weakness, dyspnea, abdominal and chest pain, erectile dysfunction and dysphagia), bone marrow failure syndromes (28.3%) and thrombosis (29.6%). Screening was performed in hematology and internal medicine department, respectively. Positive FLAER results were detected nearly 10 percent of patients (38/388, 9.8%).

**Conclusion:** PNH should be considered as a differential diagnosis in patients with unexplained abdominal pain, dyspnea, renal failure, thrombosis and non-immune hemolytic anemia. Awareness of the possibility in a potential case is crucial for early diagnosis of PNH.

**CHRONIC LYMPHOCYTIC LEUKEMIA & HAIRY CELL LEUKEMIA****P10****ZAP-70 AND CD38 EXPRESSION AS A PROGNOSTIC MARKER FOR CHRONIC LYMPHOCYTIC LEUKEMIA**

Ahmet Kürşad GÜNEŞ, Mesude FALAY, Funda CERAN, Simten DAĞDAŞ, Gülsüm ÖZET

Ankara Numune Training and Research Hospital, Department of Hematology, Ankara, Turkey

**Objective:** Chronic Lymphocytic Leukemia (CLL) is one of the most common type of leukemias and lymphoid malignancies in adults. In the last decade several studies revealed some new prognostic markers like IgVH mutational status, iFISH, ZAP-70, CD 38. IgVH gene analysis is time consuming, expensive and difficult. ZAP-70 and CD38 expression is associated with IgVH mutation. The co-expression of these two molecules in neoplastic B cells is associated with high risk disease.

**Methods:** We aimed to assess the prognostic significance of correlation between ZAP-70 and CD38 expression by the different cut-off values of CD38. A total of 124 CLL patients referred to our clinic were retrospectively analyzed.

**Results:** The immunophenotype of all patient was CD5+CD19+CD20+CD23+Ig light chain κ/λ. The CD 38 were analysed in CD5+CD19+ cells. ZAP-70 was assessed in CD19+ B cells. The cut-off value of ZAP-70 were 20%. By CD38 there are two cut-off values, 7% and 20%. 124 patients, 85 male and 39 female ages between 31-87. By RAI staging; 50 patient stage 0 (40.3%), 21 stage I (16.9%), 11 stage II (8.9%), 24 stage III (19.4%), 18 stage IV (14.5%). Median follow up is 36 months (4-68 months). When the 20% cut-off applied for CD38, 62 patients were CD38(-)/ZAP70(-), 26 patients CD38(+)/ZAP70(+), 28 patients were in CD38/ZAP70 incompatible group. When the 7% cut-off value applied for CD38, 49 patients were CD38(-)/ZAP70(-), 48 patients CD38(+)/ZAP70(+) and 27 patients were in CD38/ZAP70 incompatible group. In the both cut off values for CD38, the double negative patients (CD38-/ZAP70-) have a higher remission time than double positive ones (CD38+/ZAP70+). 20% group: 58.8-3.3 months; 7% group: 66.4-5.8 months ( $p < 0.001$ ). When the incompatible groups compared for both cut-off values the CD38-/ZAP70+ group had a higher remission time than CD38+/ZAP70+ ones (20% group: 16.4-2.5 months, 7% group: 47.3-33.4 months).

**Conclusion:** Detection of CD38 and ZAP70 expression by flow cytometry is easier and cheaper than IgVH mutation analysis. In CLL patients co-expression of CD38/ZAP70 is associated with poor prognosis and double negative group is related with a better prognosis. When the incompatible group analyzed the CD38-/ZAP70+ patients have a better prognosis and higher treatment free survival.

**P11**

**PROGNOSTIC SIGNIFICANCE OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 5 AND 5B EXPRESSION IN EPSTEIN-BARR VIRUS POSITIVE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA**

Panagiotis DIAMANTOPOULOS<sup>1</sup>, Maria SOFOTASIOU<sup>1</sup>, Zafeiroula GEORGOUSSI<sup>2</sup>, Neefeli GIANNAKOPOULOU<sup>1</sup>, Vasiliki PAPADOPOLOU<sup>1</sup>, Athanasios GALANOPoulos<sup>3</sup>, Marie-Christine KYRTSONIS<sup>4</sup>, Aglaia DIMITRAKOPOLOU<sup>1</sup>, Nikolaos SPANAKIS<sup>1</sup>, Nora-Athina VINIOU<sup>1</sup>

<sup>1</sup>First Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, Athens, Greece, <sup>2</sup>Laboratory of Cellular Signaling and Molecular Pharmacology, Institute of Biosciences and Applications, National Center for Scientific Research "Demokritos", Athens, Greece, <sup>3</sup>Department of Clinical Hematology, G. Gennimatas District General Hospital, Athens, Greece, <sup>4</sup>First Department of Propedeutic Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

**Objective:** Signal Transducer and Activator of Transcription (STAT) proteins have been intensively studied in hematologic malignancies, and the efficacy of agents against STATs in lymphomas is already under research. The correlation of STATs with viral lymphomagenesis is being also actively studied. The objective of the present study was to investigate the expression of STAT5 and STAT5b in patients with Chronic Lymphocytic Leukemia (CLL) in correlation to the presence of Epstein-Barr virus (EBV) and its major oncoprotein (Latent Membrane Protein 1, LMP1).

**Methods:** We investigated the expression of total STAT5 and STAT5b (by Western-blotting) in peripheral blood samples of sixty three patients with CLL and fifteen healthy blood donors, in correlation to the presence of EBV (by RT-PCR for the BXLF1 gene) and LMP1 (by PCR and ELISA).

**Results:** STAT5b was only expressed in patients (but not in healthy blood donors) and total STAT5 but particularly STAT5b expression was correlated to the presence of the virus (77.3% versus 51.2%, p=0.006 for STAT5b) and to the expression of LMP1 (58.3% versus 21.6%, p=0.011 for STAT5b). Moreover, the expression of STAT5b and the presence of EBV and LMP1 were strongly negatively correlated to the overall survival of the patients (log rank test p=0.011, 0.015, 0.006 respectively).

**Conclusion:** This is, to our knowledge, the first report of a survival disadvantage of EBV-positive patients with CLL, and this is the first time that STAT5b expression is correlated to overall survival, a correlation that was found to be stronger than that of overall survival with the clinical stage of the disease in this group of patients. The correlation of STAT expression with EBV along with our survival correlations defines a subgroup of patients with CLL

that may benefit from anti-STAT agents and paves the way for a more intensive study of the role of EBV in CLL.

**P12**

**CLADRIBINE "RELATED" SEVERE AND FATAL BONE MARROW APLASIA IN A PATIENT WITH HAIRY CELL LEUKEMIA**

Ozlem KARPUZ<sup>1</sup>, Ramazan ERDEM<sup>1</sup>, Utku ILTAR<sup>1</sup>, Orhan Kemal YUCEL<sup>1</sup>, Ozan SALIM<sup>1</sup>, Ozge TURHAN<sup>2</sup>, Bahar AKKAYA<sup>3</sup>, Levent UNDAR<sup>1</sup>

<sup>1</sup>Department of Hematology, Akdeniz University, Antalya, Turkey, <sup>2</sup>Department of Infectious Diseases and Clinical Microbiology, Akdeniz University, Antalya, Turkey,

<sup>3</sup>Department of Pathology, Akdeniz University, Antalya, Turkey

**Introduction:** Hairy-cell leukemia (HCL) is a B-cell lymphoproliferative disorder which is characterized by pancytopenia, splenomegaly, characteristic cytoplasmic hairy projections and a typical flow cytometric profile. The disease course is usually indolent and the current standard of care is treatment with purine analogs. Cladribine is preferred initial therapy because of its ease of administration and favorable toxicity profile.

**Case:** A 73-year-old male patient was admitted with fever and cough to our emergency department. He was hospitalized because of community-acquired pneumonia and pancytopenia (hemoglobin: 10.4 g/dL, leukocyte: 850/ $\mu$ L, neutrophil: 580/ $\mu$ L, platelet: 125000/ $\mu$ L) and piperacillin tazobactam was started. Peripheral blood smear revealed cytoplasmic projections on medium size lymphocytes and CD19, CD20, CD25, CD11c and CD103 were positive with flow cytometric immunophenotyping. In the bone marrow biopsy, fat ratio was 70-80% and there was neoplastic infiltration of CD20, TRAP positive diffuse interstitial small lymphoid cells. Patient was diagnosed with hairy-cell leukemia. Single course of cladribine for 7 days with a dose of 0.1 mg/kg/day were started. After discharge he was readmitted to inpatient setting due to febrile neutropenia and he was unresponsive to granulocyte-colony stimulating factor (G-CSF) and he had prolonged severe cytopenias. Bone marrow aspiration and biopsy revealed aplastic bone marrow without any infiltration at second month of treatment. Other causes of acquired aplastic anaemia were excluded. He became totally dependent on erythrocyte and platelet transfusions, and due to prolonged severe neutropenia invasive pulmonary aspergillosis occurred. Unfortunately, he died due to sepsis with multiple organ failure 3 months after cladribine administration.

**Conclusion:** Treatment with purine analogues are well tolerated in the majority of patients with HCL. Common side effects of cladribine are immunosuppression and reversible myelosuppression. Recovery of peripheral blood counts may require weeks or even months. Cladribine associated irreversible bone marrow aplasia is extremely rare in the literature.

## HODGKIN'S LYMPHOMA

P13

### COMPARATIVE ASSESSMENT OF BONE MARROW INVOLVEMENT (BMI) BY BM BIOPSY (BMB) OR POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY (PET/CT) IN HODGKIN LYMPHOMA (HL)

**Theodoros VASSILAKOPOULOS<sup>1</sup>, Maria ANGELOPOULOU<sup>1</sup>, Vassilios PRASSOPOULOS<sup>2</sup>, Sofia CHATZIOANNOU<sup>3</sup>, Vassilios SOTIROPOULOS<sup>4</sup>, Georgios BOUTSIKAS<sup>1</sup>, Gerassimos PANGALIS<sup>5</sup>, Panayiotis PANAYIOTIDIS<sup>6</sup>, Konstantinos KONSTANTOPOULOS<sup>1</sup>, Phoebe RONDOGIANNI<sup>7</sup>**

<sup>1</sup>Department of Hematology, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece,

<sup>2</sup>Department of Radiology and Nuclear Medicine, Hygeia General Hospital, Athens, Greece, <sup>3</sup>Department of PET/

CT, Biomedical Research Foundation, Academy of Athens, Athens, Greece, <sup>4</sup>Department of PET/CT, Athens Medical Center, Athens, Greece, <sup>5</sup>Department of Hematology,

Athens Medical Center, Athens, Greece, <sup>6</sup>First Department of Propedeutic Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece,

<sup>7</sup>Department of Nuclear Medicine, Evangelismos General Hospital, Athens, Greece

**Objective:** Recent data suggest that few HL patients have positive BMB in the absence of PET/CT evidence for BMI. The aim of this study was to correlate BMB with BM-PET/CT findings and to assess the impact of our published clinical prediction rule (Vassilakopoulos et al, Blood. 2005) on the frequency of BMI detected by either method.

**Methods:** PET/CT data were visually graded as follows: (1) no increased BM FDG uptake; (2) increased BM FDG uptake  $\leq$ liver; (3) increased BM FDG uptake  $>$ liver; (4) solitary osseous/BM focus without CT correlate; (5) multiple osseous/BM foci. Patients were classified according to our clinical prediction rule for BMI in low-, standard- and high-risk groups.

**Results:** PET/CT and BMB data were available for 179 patients. PET/CT was negative for BMI in 148 and positive in 31 patients: 4 had a single focus and 27 multiple foci. Only 14 patients had BMI by BMB (7.8%). None of the patients of PET/CT categories 1, 2, 3 or 4 had a positive BMB; 14/27 patients graded as "5" had positive BMB (52%). The frequency of BMI by BMB and by PET/CT was 0%, 1.5%, 21.1% and 0%, 6.2% and 39.6% in low-, standard- and high-risk group respectively. The outcome of patients with BMI by PET/CT was inferior (3-year PFS 56% vs 85%, p=0.001). Patients with diffuse FDG uptake  $>$ liver tended to have increased "inflammatory" activity (leukocytosis, anemia, elevated ESR and CRP, thrombocytosis).

**Conclusion:** PET/CT is more efficient than BMB in detecting BMI. There was no case of positive BMB in the absence of BMI by PET/CT. Increased diffuse BM FDG uptake is not associated

with BMI. Our clinical prediction rule was adequately validated regarding the prediction of BMI by either BMB or PET/CT. These data suggest that BMB can be safely omitted in all patients with HL staged by PET/CT.

P14

### PET/CT FOR THE EARLY INTERIM EVALUATION OF RESPONSE IN ADVANCED HODGKIN LYMPHOMA (HL) AFTER ABVDX2: EFFECTIVE SALVAGE WITH BEACOPP BUT LOW NEGATIVE PREDICTIVE VALUE FOR STAGE IV

**Theodoros VASSILAKOPOULOS<sup>1</sup>, Phoebe RONTOGIANNI<sup>2</sup>, Georgios BOUTSIKAS<sup>1</sup>, Ioannis ASSIMAKOPOULOS<sup>1</sup>, Sofia CHATZIOANNOU<sup>3</sup>, Vassilios PRASSOPOULOS<sup>4</sup>, Gerassimos PANGALIS<sup>5</sup>, Panayiotis PANAYIOTIDIS<sup>6</sup>, Konstantinos KONSTANTOPOULOS<sup>1</sup>, Maria ANGELOPOULOU<sup>1</sup>**

<sup>1</sup>Department of Hematology, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece,

<sup>2</sup>Department of Nuclear Medicine, Evangelismos General Hospital, Athens, Greece, <sup>3</sup>Department of PET/CT, Biomedical Research Foundation, Academy of Athens, Athens, Greece, <sup>4</sup>Department of Radiology and Nuclear

Medicine, Hygeia General Hospital, Athens, Greece, <sup>5</sup>Department of Hematology, Athens Medical Center,

Athens, Greece, <sup>6</sup>First Department of Propedeutic Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

**Objective:** A positive PET/CT after ABVDx2 (PET-2) is a highly unfavorable prognostic factor in intermediate and advanced-stage HL. We report here our experience with PET-2 in patients with truly advanced HL and evaluate its prognostic accuracy.

**Methods:** 101 patients with advanced HL according to GHSG definition, who were treated with ABVD and underwent PET-2, were retrospectively evaluated. PET-2 was assessed according to Deauville criteria (scores 4-5 considered positive). Switch to BEACOPP-esc was at the discretion of the treating physician.

**Results:** The median age of patients was 31.5 years (100/101 <60 years), 57% were males, 84% had NS-cHL, 40% and 52% were classified as stage IV by conventional and PET-based staging respectively, and 67% had B-symptoms. The median IPS was 2; 46% had IPS 3-7. PET-2 was negative in 77 and positive in 24 patients (24%). Overall, 3-year PFS was 76%. The strong prognostic value of PET-2 was verified (3-year PFS 86% in PET-2(-) vs. 43% in PET-2(+) patients, p<0.0001), despite switch to BEACOPP-esc in 10/24 PET-2(+) patients (14 continued with ABVD). The 3-year PFS was 61% vs. 31% for PET-2(+) patients who received BEACOPP-esc and ABVD respectively (p=0.059). Based on conventional staging 3-year PFS did not differ between stage II-III and stage IV (89% vs. 82% respectively, p=0.36). When initial staging was based on PET/CT, the 3-year PFS was lower in stage IV compared to stage II-III patients (77% vs. 94%, p=0.057).

**Conclusion:** The results of our study confirm the strong prognostic value of PET-2, since the possibility of relapse was much higher in PET-2(+) patients, despite the more aggressive therapeutic approach adopted for 10/24 of them. Patients treated with BEACOPP-esc upon PET-2(+) tended to have superior outcomes. PET-2(-) patients with stage IV, as defined by baseline PET/CT, had inferior outcomes. This observation may have significant impact on treatment design.

## NON-HODGKIN LYMPHOMAS

### P15

#### COMPARISON OF IPI AND NCCN-IPI IN 324 DE-NOVO DLBCL PATIENTS: A MULTICENTER RETROSPECTIVE ANALYSIS

Erman ÖZTÜRK<sup>1</sup>, Murat ÖZBALAK<sup>2</sup>, Emin AVŞAR<sup>3</sup>, Anıl DOLGUN<sup>4</sup>, Ayşe SALİHOĞLU<sup>5</sup>, Şeniz ÖNGÖREN<sup>5</sup>, Cem AR<sup>5</sup>, Zafer BAŞLAR<sup>5</sup>, Teoman SOYSAL<sup>5</sup>, Burhan FERHANOĞLU<sup>6</sup>

<sup>1</sup>Koç University Hospital, Department of Hematology, Istanbul, Turkey, <sup>2</sup>Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, <sup>3</sup>Amerikan Hospital, Department of Oncology, Istanbul, Turkey, <sup>4</sup>Hacettepe University, Department of Biostatistics, Ankara, Turkey, <sup>5</sup>Cerrahpaşa Medical Faculty, Department of Hematology, Istanbul, Turkey, <sup>6</sup>Koç University Medical Faculty, Department of Hematology, Istanbul, Turkey

**Objective:** Until recently, IPI was almost the only widely used prognostic indicator in diffuse large B-cell lymphoma (DLBCL). IPI, being developed in pre-rituximab era, fails to predict the prognosis in a considerable portion of patients with DLBCL. NCCN-IPI was recently claimed to better predict the DLBCL outcomes. We aimed to compare the prognostic significances of IPI and NCCN-IPI in DLBCL patients treated with R-CHOP.

**Methods:** All patients (n=324) diagnosed with DLBCL and treated with R-CHOP regimen and analysed retrospectively.

**Results:** Median follow-up was 3.7 years. Progressive free survival and overall survival (OS) were compared between risk categories. 5-year OS was 91% for both IPI and NCCN-IPI low risk groups whereas 44% for IPI and 29% for NCCN-IPI high risk group. NCCN-IPI and IPI have similar discriminations with concordance probability estimates (CPE) (0,67 vs 0,68 respectively). There is a good correlation with these two risk classification model determined with the weighted  $\kappa$  statistics ( $\kappa_W=0.6817$ ,  $p<0.001$ ).

**Conclusion:** The authors indicated that NCCN-IPI provided increased capacity to discriminate both high-risk and low-risk de-novo DLBCL patients. Huang et al justifying the better discrimination capacity of NCCN-IPI compared to IPI. Our report is based on the analysis of 324 de-novo DLBCL patients. Our patients were treated in various hospitals, which reflect the "real-life" characteristic of our cohort. In our study, NCCN-IPI couldn't

better differentiate low risk group but it was able to discriminate OS more accurately in the high risk category compared to IPI. Recently published study showed that, even though gene-based predictors have good discriminating ability when used alone, IPI remains the most powerful predictor in DLBCL patients. DLBCL is a heterogeneous disease and we will probably explore more molecular, immunohistochemical and clinical (NCCN-IPI?) parameters in the future. These efforts will contribute to develop stronger risk classification process, maybe as a part of a never ending story.

### P16

#### HIGH BONE TURNOVER AND LOW BONE MINERAL DENSITY IS PRESENT IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA AFTER THE ADMINISTRATION OF FRONTLINE THERAPY

Konstantinos ANARGYROU<sup>1</sup>, Theodoros P. VASSILAKOPOULOS<sup>2</sup>, Dimitrios CHRISTOULAS<sup>1</sup>, Maria K. ANGELOPOULOU<sup>2</sup>, Maria DIMOU<sup>3</sup>, Athanasios PAPATHEODOROU<sup>4</sup>, Georgios BOUTSIKAS<sup>1</sup>, Panayiotis PANAYIOTIDIS<sup>3</sup>, Kostas KONSTANTOPOULOS<sup>2</sup>, Evangelos TERPOS<sup>5</sup>

<sup>1</sup>Department of Hematology, 251 General Air Force Hospital, Athens, Greece, <sup>2</sup>Department of Hematology, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, <sup>3</sup>First Department of Propedeutic Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, <sup>4</sup>Department of Medical Research, 251 General Air Force Hospital, Athens, Greece, <sup>5</sup>Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

**Objective:** The aim of the study was to evaluate the effects of chemotherapy on bone metabolism of patients with newly-diagnosed non-Hodgkin's lymphoma (NHL).

**Methods:** Bone mineral density (BMD) of the lumbar spine (L1-L4) and femoral neck (FN) of NHL patients was measured by DXA on day 1/cycle 1 (baseline) and on day 30 of the last chemotherapy cycle. The following bone metabolism markers were measured on the days of DXA: i) osteoclast stimulators [sRANKL and osteoprotegerin (OPG)], ii) osteoblast regulators [PTH, vitamin-D, and dickkopf-1 (Dkk-1)], iii) bone resorption markers [CTX and TRACP-5b], and iv) bone formation markers [bone alkaline phosphatase (bALP) and osteocalcin (OC)].

**Results:** Fifty-three patients have completed the study to-date: 36 (67.9%) had diffuse large B-cell lymphoma, 5 (9.4%) follicular (grade III), 4 (7.5%) mantle-cell, 6 (11.3%) marginal-zone and 2 (3.8%) T-cell NHL. Forty-seven patients (88.7%) received R-CHOP, 4 R-COP and 2 CHOP. At baseline, NHL patients had a median T-score of L1-L4 BMD of -0.63 (range: -4.27 to +3.68) and of FN BMD of -0.875 (-4.01 to +2.07). The administration of chemotherapy resulted in a dramatic reduction of BMD in L1-L4

(-1.12; -4.49 to +3.04;  $p<0.001$ ) and in FN (-1.115; -3.68 to +1.12;  $p<0.001$ ) compared to baseline. Patients who received 8 cycles of chemotherapy had a greater reduction of L1-L4 ( $p<0.001$ ) and FN ( $p=0.001$ ) BMD. Chemotherapy also resulted in elevations of CTX ( $p=0.017$ ), TRACP-5b ( $p<0.001$ ), bALP ( $p<0.001$ ), OC ( $p<0.001$ ) and Dkk-1 ( $p=0.022$ ) compared to baseline values. All studied markers (except of sRANKL/OPG) were increased in NHL patients post-chemotherapy compared to 30 healthy controls ( $p<0.01$ ). During study period, one male patient had a pathological fracture in his right FN.

**Conclusion:** Frontline treatment (chemotherapy and/or rituximab) results in high bone turnover, increased bone loss and reduced BMD in NHL patients. The prophylactic use of bisphosphonates or denosumab may be useful for preventing bone loss in these patients.

## P17

### PROGNOSTIC FACTORS IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL) UNDER STANDARD CHEMOTHERAPY WITH RITUXIMAB-CHOP (R-CHOP) WITH OR WITHOUT RADIOTHERAPY (RT)

Theodoros VASSILAKOPOULOS<sup>1</sup>,  
Maria ANGELOPOULOU<sup>1</sup>, Sotirios PAPAGEORGIOU<sup>2</sup>,  
Georgia KOURTIS<sup>3</sup>, Evangelos TERPOS<sup>4</sup>,  
Georgios BOUTSIKAS<sup>1</sup>, Konstantinos  
KONSTANTOPOULOS<sup>1</sup>, Panayiotis PANAYIOTIDIS<sup>5</sup>,  
Gerassimos PANGALIS<sup>6</sup>, Paraskevi ROUSSOU<sup>3</sup>

<sup>1</sup>Department of Hematology, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece,

<sup>2</sup>Second Department of Propedeutic Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, <sup>3</sup>Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, <sup>4</sup>Department of Clinical Therapeutics, National And Kapodistrian University of Athens, School of Medicine, Athens, Greece, <sup>5</sup>First Department of Propedeutic Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, <sup>6</sup>Department of Hematology, Athens Medical Center, Athens, Greece

**Objective:** Prognostic factors (PFs) in PMLBCL have not been extensively studied. Prior to the Rituximab era, the International Prognostic Index (IPI) appeared to retain its prognostic significance. R-CHOP provides very good results, but the applicability of various PFs needs to be evaluated in order to define high risk patient subgroups, since more intensive chemotherapy might provide better results. Aim of the study was the identification of PFs in PMLBCL patients treated with RCHOP±RT.

**Methods:** 213 patients with PMLBCL were treated with RCHOP±RT. The following potential prognostic factors were evaluated: Age, gender, B-symptoms, stage III/IV, infradiaphragmatic disease, extranodal involvement, pleuritis, pericarditis, performance status (PS)  $\geq 2$ , LDH levels, anemia, leukocytosis, ESR  $\geq 30$  mm/h,

albumin <4 g/dL, bulky disease, age-adjusted IPI (aaIPI).

**Results:** The median follow-up was 50 months. Among 52 failures, 51 occurred within 17 months from diagnosis. The 3-year FFP was 75% and the 5-year OS 88%. The aaIPI ( $\geq 2$ ) identified a minority of patients with a 5-year FFP of 64% vs. 79% for those with aaIPI 0-1 ( $p=0.04$ ) and 5-year OS of 76% vs. 92% ( $p=0.003$ ). Many of the examined variables had a significant or borderline association with both FFP and OS. In multivariate analysis of OS, extranodal involvement and bulky disease were independent PFs. OS at 5 years was effectively predicted, being 100%, 93% and 73% for patients with 0, 1 or 2 PFs respectively ( $p=0.0001$ ). The corresponding 5-year FFP rates were 88%, 79% and 59% ( $p=0.002$ ).

**Conclusion:** This is the largest series reported so far; RCHOP±RT provided satisfactory results in PMLBCL in terms of FFP and OS. The aaIPI was moderately predictive of the outcome. The combination of extranodal involvement and bulky disease defined a subgroup of patients with high risk of failure and death, who might be candidates for treatment intensification.

## P18

### PROGNOSTIC SIGNIFICANCE OF VON WILLEBRAND FACTOR ANTIGEN IN WALDENSTRÖM'S MACROGLOBULINEMIA

Evangelos TERPOS<sup>1</sup>, Efstatios KASTRITIS<sup>1</sup>,  
Ioannis PAPASSOTIRIOU<sup>2</sup>, Evangelos ELEUTHERAKIS-  
PAPAIKOVOU<sup>1</sup>, Nikolaos KANELIAS<sup>1</sup>,  
Michail MAZARAKIS<sup>2</sup>, Maria GAVRIATOPOLOU<sup>1</sup>,  
Magdalini MIGKOU<sup>1</sup>, Maria ROUSSOU<sup>1</sup>,  
Meletios A. DIMOPOULOS<sup>1</sup>

<sup>1</sup>Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, <sup>2</sup>Department of Clinical Biochemistry, "Aghia Sophia" Children's Hospital, Athens, Greece

**Objective:** Patients with Waldenstrom's Macroglobulinemia (WM) can manifest unique hemostatic disorders, including acquired von Willebrand syndrome (AVWS), paraprotein-induced platelet function defects, factor X deficiency, etc. Von Willebrand factor (vWF), a glycoprotein produced by the endothelial cells and megakaryocytes, plays a key role in primary hemostasis but is also a marker of endothelial "stimulation". The aim of this study was to evaluate vWF in WM and explore possible correlations with clinical data, including PFS and OS.

**Methods:** The analysis included 42 patients with symptomatic WM and 19 healthy controls of matched gender and age. According to IPSSWM, 22% had low, 43% intermediate and 35% high risk WM, respectively. The vWF antigen (vWF Ag) levels were measured in serum collected before initiation of therapy by means of a latex particle-enhanced immunoturbidimetric assay (HemosIL vWF antigen) with an automated coagulometer (ACL Top 3G, Instrumentation Laboratory, Lexington, MA, USA).

**Results:** Although the majority of WM patients had increased levels of vW antigen, 6/42 (14%) had vWF Ag levels <40 U/L;

which could be compatible with AVWS. There was an inverse correlation of platelet counts with levels of vWF Ag ( $R=-0.336$ ,  $p=0.032$ ) and vWF Ag  $\geq$  median was less frequent in patients with low (11%) vs. patients with intermediate (59%) or high (62%) risk IPSS ( $p=0.036$ ). Median follow up of symptomatic patients was 4 years. Patients with vWF Ag levels within the upper quartile (i.e. vWF Ag  $\geq 200$  U/dL) had a median progression free survival of 12 months vs. 63 months of patients with vWF Ag  $< 200$  U/L ( $p<0.001$ ). The median survival for patients with vWF Ag  $\geq 200$  U/dL was 37 months (4-year survival 29%) vs. 4-year survival of 97% for patients with vWF Ag  $< 200$  U/L ( $p<0.001$ ).

**Conclusion:** We conclude that serum vWF may become an important prognostic marker in WM and needs further investigation in larger cohort of patients.

## P19

### RETROSPECTIVE EVALUATION OF OUTCOMES OF DA-EPOCH-R REGIMEN IN PATIENTS WITH ADVANCED STAGE NON-HODGKIN LYMPHOMA AND WITH HIGH KI-67 EXPRESSION: SINGLE CENTER EXPERIENCE

Pusem PATIR<sup>1</sup>, Hatice Demet Kiper UNAL<sup>1</sup>, Mustafa DURAN<sup>1</sup>, Terane NAGIYEVA<sup>2</sup>, Ayhan DONMEZ<sup>1</sup>, Murat TOMBULOGLU<sup>1</sup>

<sup>1</sup>Ege University, Department of Hematology, Izmir, Turkey,  
<sup>2</sup>Ege University, Department of Internal Medicine, Izmir, Turkey

**Objective:** In most of CD 20(+) NHLs, rituximab-containing regimens mainly as R-CHOP have been defined as the standard therapy. Recently, molecular and biological features of the tumor including Ki-67 expression have been described that have potential impact on outcome and treatment decisions. The purpose of this study was to evaluate the efficiency and safety of the dose adjusted etoposide, prednisolone, vincristine, doxorubicin, and cyclophosphamide with rituximab (DA-EPOCH-R) regimen on patients with Non-Hodgkin Lymphoma (NHL) with advanced stage and high Ki-67 expression.

**Methods:** Ten patients (5 female and 5 male) with Non-Hodgkin Lymphoma were analyzed retrospectively who had received DA-EPOCH-R regimen. The characteristics of patients were illustrated in table 1. The median age of patients was 49,7(17-76) years old. All patients were stratified as in stage III/IV. Patients were treated with 3-6 cycles of DA-EPOCH-R.

**Results:** The results showed that the overall response rate of patients was 90%, including 9 patients (90%) in complete remission (CR) and 1 patient (10%) in stable disease (SD). At a median follow-up of 13,4 months. The major toxicity of DA-EPOCH-R regimen was hematologic toxicity. Other toxicities were mild, no treatment-related deaths occurred.

**Conclusion:** It is concluded that DA-EPOCH-R regimen is an effective and safe protocol for the patients with NHL with advanced stage and high Ki-67 expression. More and comparative studies are need to define the exact role of DA-EPOCH-R regimen in patients with poor molecular and biological features.

## P20

### A YOUNG MAN WITH A PALPABLE MASS IN THE LEFT AXILLA

Despoina BARBAROUSI, Nikolaos KANELLIAS, Enkeleida TRAIJE, Ioanna VARDOUNIOTI, Charis MATSOUKA, Konstantina PAPAIOANNOU

Hematology Laboratory, Alexandra General Hospital, Athens, Greece

**Introduction:** Anaplastic large cell lymphomas (ALCLs) are a frequent subcategory of Peripheral T-Lymphomas. A high fraction of ALCLs are associated with translocations involving ALK, the Anaplastic Lymphoma Kinase gene, located on chromosome 2p23. We will describe a case of ALK+ T-Lymphoma in a young adolescent.

**Case:** A 19-year-old adolescent was referred to our Department because of a painful enlargement in the right axilla. Patient's history as well as family history were unremarkable. Clinical examination revealed swelling in the left armpit (10 cm x 15 cm) accompanied with ulceration and cellulitis and palpable lymph nodes in the left cervical region. Laboratory examination revealed only an elevated ESR (85 mm) with no other abnormal findings. In PET scan there was abnormal 18-FDG uptake (SUV max: 18.5) in posterior cervical, left supraclavicular and subclavian Lymph nodes and a sizeable mass along the left lateral chest wall. Spleen also showed diffuse pathological uptake. Biopsy of the lymph nodes showed High grade Anaplastic large T-cell lymphoma ALK positive. According to cotswolds modification of Ann Arbor staging system, patient's stage was IISXBE with an IPI score II. (low intermediate) Patient received 6 cycles of CHOEP. After those 6 cycles, PET SCAN was negative and the patient received two more cycles of CHOP. After the completion of treatment, a left spontaneous pneumothorax was diagnosed, which required surgical intervention.

**Conclusion:** Our patient remains in complete response, three years after completion of treatment. Several studies have shown that ALCLs CD 30(+) ALK(+) represent a distinct clinicopathologic entity and have a distinctly better clinical outcome than ALK - systemic ALCLs. It is also known that normal serum LDH and an IPI score of  $\leq 3$  predicts a favorable clinical outcome.

## P21

### PRIMARY AND SECONDARY LYMPHOMA INVOLVEMENT OF THE BREAST; TWO CASES

Hatrice Demet KİPER ÜNAL<sup>1</sup>, Elvina DADASOVA<sup>1</sup>, Nazan ÖZSAN<sup>2</sup>, Özgür ÖMÜR<sup>3</sup>, Mahmut TÖBÜ<sup>1</sup>

<sup>1</sup>Ege University Medical Faculty, Hematology Department, Izmir, Turkey, <sup>2</sup>Ege University Medical Faculty, Pathology Department, Izmir, Turkey, <sup>3</sup>Ege University Medical Faculty, Nuclear Medicine Department, Izmir, Turkey

**Introduction:** Primary lymphoma of the breast is a rare form of NHL, representing approximately 0,5% of all breast malignan-

cies and 2,2% of all extranodal lymphomas. However, secondary involvement of the breast with lymphoma is not unusual. Diffuse Large B Cell Lymphoma (DLBCL) is the most common histopathological subtype. Here we report two cases of breast lymphoma one is primary and the other is secondary, who both achieved complete remission (CR) with standard chemotherapy.

**Cases:** Case 1: A 55-year-old woman presented with a painless left breast mass. Breast ultrasonography showed a non-homogeneous mass in the left breast and a pathological lymph node in left axilla. As the fine needle aspiration biopsy (FNAB) resulted negative, segmental mastectomy was performed. Histopathological diagnosis reported as DLBCL. In PET/CT; a few millimetric mild-metabolic jugular and axillary LAPs were found. There wasn't bone marrow infiltration. 2 cycles of R-EPOCH were performed and CR achieved as control US showed no residual mass. It has planned to complete chemotherapy six cycles.

Case 2: A 36-year-old woman presented with cervical mass and asymmetrical tonsil hypertrophy; diagnosed as DLBCL by the biopsy of left palatine tonsil. PET/CT showed multiple cervical and axillary LAPs and multiple hypermetabolic masses in right and left breasts. Since the defined lesions were bilateral and multifocal; lymphoma involvement was thought as the most probable diagnosis. FNAB was performed from her right breast but the results were non-diagnostic. There wasn't bone marrow infiltration. After two cycles of R-CHOP, control PET/CT showed anatomic and metabolic CR in breast lesions and LAPs. Chemotherapy was completed to eight cycles.

**Conclusion:** Lymphoma is the most common malignant disease metastasizing to the breast and rarely it presents as primary breast involvement. Considering lymphoma in the differential diagnosis of breast masses is important for developing an effective diagnostic and therapeutic approach.

## P22

### NODAL MARGINAL ZONE LYMPHOMA: OUR EXPERIENCE IN A PARTICULAR CASE

**Konstantina PAPAIOANNOU**, Nikolaos KANELLIAS,  
Despoina BARBAROUSI, Ioanna VARDOUNIOTI,  
Enkeleida TRAJCE, Charis MATSOUKA

Hematology Laboratory, Alexandra General Hospital,  
Athens, Greece

**Introduction:** Nodal Marginal Zone Lymphoma (NMZL) is a primary nodal B-cell neoplasm that morphologically resembles lymph nodes involved by MZL of extranodal or splenic types, but without evidence of extranodal or splenic disease. It's rare, approximately 1% of NHL cases. Nodal MZL usually progresses to a higher grade histologic subtype, such as diffuse large B-cell lymphoma. We present an unusual case of NMZL with transformation to Acute Leukemia.

**Case:** A 49-year-old man presented with a 3 week history of fever, cough and dyspnea. His physical examination revealed swollen lymph nodes in all anatomical sides, his chest computer

tomography (CT) showed mediastinal mass and pleural effusion and the bone marrow biopsy NMZL with bone marrow infiltration. He received four cycles of the combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP regimen), achieving partial response and then four more cycles. Soon after he relapsed. During his hospitalization lactate dehydrogenase (LDH) was elevated and he was diagnosed with bone marrow necrosis. He received salvage therapy with ESHAP regimen. Thirteen days later he presented with skin and eye damage. Skin biopsy revealed Hematodermic Lymphoma. After that he presented dyspnea and his chest computed tomography revealed excessive mediastinal enlargement. He was treated with radiotherapy but he quickly progressed to mixed phenotype acute leukemia and he died.

**Conclusion:** NMZL comprises a biologically and clinically heterogeneous spectrum of lymphoma cases. Transformation to a large B-lymphoma may occur. In our case the patient progressed to Hematodermic Lymphoma with mediastinal enlargement and then to acute leukemia which is extremely rare. Since there are not yet specific diagnostic hallmarks and treatment consensus guidelines for NMZL, we share our experience to this direction.

## P23

### PROGNOSTIC SIGNIFICANCE OF BODY MASS INDEX (BMI) IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) TREATED WITH RITUXIMAB-CHOP (R-CHOP) OR SIMILAR COMBINATIONS

Theodoros VASSILAKOPOULOS<sup>1</sup>,  
Sotirios PAPAGEORGIOU<sup>2</sup>, Maria ANGELOPOULOU<sup>1</sup>,  
Eugenia VERROU<sup>3</sup>, Maria MOSCHOGIANNIS<sup>4</sup>,  
Christina KALPADAKIS<sup>5</sup>, Georgios BOUTSIKAS<sup>1</sup>,  
Panayiotis PANAYIOTIDIS<sup>6</sup>, Gerassimos PANGALIS<sup>4</sup>,  
Konstantinos KONSTANTOPOULOS<sup>1</sup>

<sup>1</sup>Department of Hematology, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece,

<sup>2</sup>Second Department of Propedeutic Medicine, National and Kapodistrian University of Athens, School of

Medicine, Athens, Greece, <sup>3</sup>Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece,

<sup>4</sup>Department of Hematology, Athens Medical Center, Athens, Greece, <sup>5</sup>Department of Hematology, University

Hospital of Heraklion, Heraklion, Greece, <sup>6</sup>First Department of Propedeutic Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

**Objective:** Recent data suggested that increased BMI correlates with favorable outcome in white American males with DLBCL, while other studies provided controversial results. The aim of this study was the evaluation of the prognostic value of BMI in DLBCL.

**Methods:** 664 patients with DLBCL treated with R-CHOP or similar regimens were evaluated.

**Results:** The median BMI was 26.5 kg/m<sup>2</sup>, 156 (23%) patients were obese (BMI ≥30) and 273 (40%) overweight (BMI 25-29.9).

Increased BMI correlated with increased age, while decreased BMI with PS ≥2, ≥2 E-sites and B-symptoms. 7-year PFS of patients with BMI ≥30, 25-29.9 and <25 was 76%, 72% and 68% respectively (p=0.085 for BMI ≥30 vs. <30). BMI had not prognostic impact in patients <60 years. On the contrary, males >60 years with BMI≥30 and females >60 years with BMI ≥25 had more favorable outcomes than those with lower BMI. Similarly, BMI ≥30 was a favorable prognostic factor only for patients without B-symptoms. In multivariate analysis BMI had no independent prognostic impact in the whole patient population, while BMI ≥30 was an independent prognostic factor in males >60 years (p=0.03) along with LDH and PS, and BMI ≥25 was an independent prognostic factor along with LDH and stage III/IV in females >60 years (p=0.055). In a preliminary analysis of 277 patients, DI of chemotherapy did not differ between patients with BMI ≥30 or <30, while DI of Rituximab was slightly (but statistically significantly) lower in obese patients (p=0.01).

**Conclusion:** The effect of BMI on prognosis appears to be restricted to elderly DLBCL patients with different, possibly, cutoff (30 vs 25 kg/m<sup>2</sup>) for males and females. This could not be attributed either to the unfavorable prognosis of patients with weight loss, since the observation was restricted to patients without B-symptoms, or to differences in DI of immunochemotherapy according to BMI. A possible correlation with pharmacokinetic parameters needs verification.

## P24

### A CASE OF SPLENIC MARGINAL ZONE LYMPHOMA WITH CRYOGLOBULINEMIA

Yusuf DURMUS<sup>1</sup>, Mehmet Sevki UYANIK<sup>2</sup>, Muhammet MADEN<sup>2</sup>, Gulsum Emel PAMUK<sup>2</sup>

<sup>1</sup>Department of Internal Medicine, Edirne State Hospital, Edirne, Turkey, <sup>2</sup>Department of Hematology, Trakya University, Edirne, Turkey

**Introduction:** Splenic marginal zone lymphoma (SMZL) is B-cell neoplasia, manifested by small cells and it targets white pulp follicles, bone marrow and peripheral blood cells. Cryoglobulinemia is presence of cryoglobulins in the blood, which are abnormal immunoglobulins precipitating reversibly in low body temperature (<37°C). Autoimmune reactions may accompany SMZL. In this report we aimed to present SMZL case with immunologic and coagulation disorder.

**Case:** A 66-years-old male patient was diagnosed with SMZL after splenectomy performed 6 years ago. He applied with asthenia and weight loss. Physical examination revealed bilateral sub-knee purpuric eruption. Blood count resulted with hemoglobin 7.7 g/dl, MCV 106 fl, WBC 24700 u/L, platelet 78000u/L, LDH 1286 u/L, haptoglobin 32 mg/dl, reticulocyte 8.9%, also direct and indirect coombs were resulted positive. The prothrombin time was 34.6 seconds, INR 3.7, aPTT 51 seconds, and following values were found 1/1 dilution PT 22.3, INR 2.5, aPTT 51, the factor inhibitor test resulted positive. The patients factor II, VII, VIII,

IX, and X levels were low. Autoimmune hemolytic anemia and hemophilia manifested in the patient and 48 mg/day metilprednisolon was administered. During 6th day of therapy, hemolysis and coagulation parameters of the patient were not recovered; his cryoglobulin level was 0.147 OD. The HCV, HBV, HIV antibodies were negative. CHOP chemotherapy regime was used. However, in first week, he developed respiratory hemorrhage and died.

**Conclusion:** Autoimmune hemolytic anemia, immune thrombocytopenia, coagulation disorders, positive direct Coombs are confirmed 10-20% patients suffering from SMZL. There is a significant relation with SMZL and hepatitis-C virus. In our case, cryoglobulinemia was present even though HCV was negative. In SMZL patients with autoimmune hemolytic anemia and coagulation disorder, if steroid therapy does not benefit them, cryoglobulinemia should always come to mind. The real treatment of cryoglobulinemia is treatment of the underlying disease. For these patients chemotherapy must come to mind urgently.

## MULTIPLE MYELOMA AND OTHER PLASMA CELL NEOPLASMS

### P25

#### CIRCULATING LEVELS OF ADHESION MOLECULES IN 206 PATIENTS WITH MULTIPLE MYELOMA: A SINGLE CENTER PROSPECTIVE STUDY

Magdalini MIGKOU, Efstathios KASTRITIS, Dimitrios CHRISTOULAS, Maria GAVRIATOPOULOU, Nikolaos KANELIAS, Evangelos ELEUTHERAKIS-PAPAIKOVOU, Ioannis PANAGIOTIDIS, Maria ROUSSOU, Meletios A. DIMOPOULOS, Evangelos TERPOS

Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

**Objective:** Interactions between plasma cells and cells in the bone marrow microenvironment, through adhesion molecules, play a key role in the biology of multiple myeloma (MM) and regulate tumor growth, survival and migration in the bone marrow. The aim of our study was to evaluate the levels of soluble adhesion molecules in patients with different plasma cell dyscrasias and explore the correlations with disease characteristics, reported outcomes and how they are affected after treatment with novel agents.

**Methods:** Levels of circulating adhesion molecules VCAM-1, ICAM-1, P-, L- and E-selectin were measured with ELISA in serum of 47 patients with MGUS, 61 with AMM and 145 with symptomatic MM. Same adhesion molecules were measured in serum of 87 patients with symptomatic disease at first relapse that received second line therapy with novel agents, 47 received RD and 40 VD. Measurements have been conducted before initiation of therapy for newly diagnosed patients, or before the administration of the

first RD or VD, and after 4 cycles of therapy.

**Results:** Patients with MM had increased levels of VCAM-1 and ICAM-1 compared with MGUS, AMM patients and controls, while the levels of selectins did not differ. Patients with ISS-1 had lower circulating levels of VCAM-1 and higher circulating levels of P-selectin. For MM patients, there was a positive correlation between VCAM-1 and ICAM-1, and a negative correlation between VCAM-1 and P-selectin. Serum VCAM-1 showed strong correlation with  $\beta$ 2-microglobulin and creatinine. P- and L-selectin negatively correlated with  $\beta$ 2-microglobulin and creatinine. For patients with symptomatic disease median follow-up was 31 months, and median OS was 53 months. Median PFS was 23 months. Patients with VCAM-1 > median had median PFS 19 months vs 32 months of the others, and they also had median OS of 45 months vs 75 months. Patients with low P-selectin

**Conclusion:** Our study provides evidence about the role of microenvironment in the biology of myeloma patients. VCAM-1 had an independent prognostic value for both PFS and OS in patients with newly-diagnosed symptomatic disease. Also levels of ICAM-1 and VCAM-1 predicted for time to progression in patients with asymptomatic disease. Reduction of VCAM-1 and ICAM-1 after treatment with novel agents reveals an effect of these drugs on the microenvironment, while Rd altered also the levels of all studied selectins suggesting an effect of Rd on the vascular niche and the endothelium.

## P26

### THE ANTI-MYELOMA EFFECT OF BORTEZOMIB IS INDEPENDENT OF THE BCL-2 STATUS

**Dimitrios CHRISTOULAS, Efstathios KASTRITIS, Maria GAVRIATOPOLOU, Magdalini MIGKOU, Despoina KALAPANIDA, Eftychia KAFANTARI, Maria ROUSSOU, Flora ZAGOURI, Meletios A. DIMOPOULOS, Evangelos TERPOS**

*Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece*

**Objective:** The transcription nuclear factor-kappa B (NF-kappaB) offers a significant survival potential in multiple myeloma (MM) cells. Bortezomib inhibits the degradation of IkappaB and hence sequesters cellular NF-kappaB, blocking NF-kappaB transcriptional activity, and thus it leads to reduced levels of growth factors and cell adhesion molecules. Bortezomib also enhances apoptosis in MM cells by bypassing anti-apoptotic mechanisms. Bcl-2 is an anti-apoptotic protein that confers unregulated growth and resistance to conventional chemotherapy in MM cells. The aim of this study was to evaluate the effect of bortezomib on patients with relapsed/refractory MM regarding their bcl-2 status.

**Methods:** We evaluated the immunophenotypic findings of myeloma cells in the bone marrow biopsies of 24 patients (14M/10F; median age: 59 years, range: 35-71 years) who had received >4 lines of treatment previously, including autologous stem cell transplantation. Twelve patients had IgG MM, while 6 had IgA,

one non-secretory and 5 light-chain MM. Bortezomib was given at the dose of 1.3mg/m<sup>2</sup>, iv or sc, in 3-week cycles, on days 1, 4, 8, and 11 of each cycle along with standard dose of dexamethasone. The patients were assessed before treatment and after 4 cycles of treatment.

**Results:** Fourteen (58%) patients had achieved a partial response, while 2 (8%) patients had stable disease after 4 cycles of therapy. Cellularity was reduced in all patients after 4 cycles of treatment. Plasma cell infiltration was reduced in 19 (79%) patients. Bcl-2 was strongly positive in all pre-treatment biopsy specimens. This strong positivity persisted even after the 4 cycles of bortezomib administration. Other immunophenotypic characteristics, including epithelial membrane antigen (EMA), CD79-alpha, and cyclin D1, have not altered following bortezomib treatment.

**Conclusion:** Previous studies with MM cell lines have suggested that agents that reduce NF-kappaB also lower bcl-2 levels and promote apoptosis. These results suggest that the anti-myeloma effect of bortezomib is independent of bcl-2.

## P27

### THE RAPID RESOLUTION OF PSEUDOHYPERPHOSPHATEMIA IN AN IgAk MULTIPLE MYELOMA PATIENT AFTER THERAPY WITH A BORTEZOMIB-CONTAINING REGIMEN: A CASE REPORT

Muhammet MADEN<sup>1</sup>, Gulsum Emel PAMUK<sup>1</sup>, Veysi Asoglu ASOGLU<sup>2</sup>, Omer Nuri PAMUK<sup>3</sup>

<sup>1</sup>Department of Hematology, Trakya University, Edirne, Turkey, <sup>2</sup>Department of Internal Medicine, Edirne State Hospital, Edirne, Turkey, <sup>3</sup>Department of Rheumatology, Trakya University, Edirne, Turkey

**Introduction:** Hyperphosphatemia might be encountered in renal failure, tumour lysis syndrome, hypoparathyroidism, pseudohypoparathyroidism, lactic acidosis, and ingestion of exogenous phosphate-containing sources. Hyperphosphatemia in multiple myeloma (MM) is rare; and is expected when glomerular filtration rate (GFR) is <30 ml/min. We present a MM patient with pseudohyperphosphatemia.

**Case:** A 54-year-old male patient was admitted with weakness. The laboratory analyses revealed anemia, hypoalbumenia, hyperglobulinemia, hypercalcemia (10.1 mg/dL), hyperphosphatemia (20 mg/dL), GFR was 61 ml/min. Serum parathormone, vitamin D levels, the 24-hour calcium and phosphorus excretions were normal. There was a monoclonal spike in the  $\beta$ -region of serum protein electrophoresis. Serum IgA and kappa were, respectively, 6060 mg/dL and 5860 mg/dL. Serum immunoelectrophoresis showed monoclonal bands in IgA and  $\kappa$  regions. Bone marrow aspiration revealed 22% plasma cells. He was diagnosed as stage III IgAk MM according to International Staging System. He was given calcium acetate 500 mg three times a day for two days with no significant change in phosphorus level. He was administered VCD (bortezomib, cyclophosphamide, dexamethasone) protocol.

On the fifth day of VCD, phosphorus became 3.2 mg/dL, total protein/albumin were 8.4/2.9 mg/dL.

**Conclusion:** Hyperphosphatemia in MM might be explained by the binding of paraprotein to phosphate or the interference of globulin fraction with colorimetric assays, resulting in falsely elevated phosphorus levels. Two ml of serum should be deproteinized with 200 µl of sulfosalicylic acid to remove the paraprotein. Our patient had no hypocalcemia, advanced renal failure or any sign of hyperphosphatemia; so, considering pseudohyperphosphatemia we discontinued calcium acetate, and instituted chemotherapy. He is the first reported MM patient whose phosphorus normalized shortly after a bortezomib-containing regimen. In case of suspicion of pseudohyperphosphatemia in MM; serum should be deproteinized and effective chemotherapy should be started to lower the paraprotein level. Bortezomib-containing VCD protocol was observed to correct pseudohyperphosphatemia rapidly.

## P28

### THE PROGNOSTIC VALUE OF C-TERMINAL CROSS-LINKING TELopeptide OF COLLAGEN TYPE-I (CTX) IN PATIENTS WITH MULTIPLE MYELOMA

**Dimitrios CHRISTOULAS, Efstatios KASTRITIS, Nikolaos KANELLIAS, Magdalini MIGKOU, Maria GAVRIATOPOLOU, Maria GKOTZAMANIDOU, Evangelos ELEUTHERAKIS-PAPAIKOVOU, Dimitrios ZIOGAS, Meletios A. DIMOPOULOS, Evangelos TERPOS**

*Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece*

**Objective:** The aim of this study was to evaluate the impact of bone markers on the survival of multiple myeloma (MM) patients who are treated upfront with novel agents.

**Methods:** We studied 122 consecutive, unselected, newly diagnosed patients with symptomatic MM who received upfront treatment with novel agents: 75 with IMiDs-based and 47 with bortezomib-based regimens. The circulating levels of the following bone remodeling markers were evaluated at diagnosis: i) osteoclast regulators: sRANKL and osteoprotegerin (OPG); ii) osteoblast inhibitor dickkopf-1 (Dkk-1); iii) bone resorption markers: CTX and TRACP-5b; and iv) bone formation markers: bone-specific alkaline phosphatase (bALP) and osteocalcin.

**Results:** At diagnosis, MM patients had increased serum concentrations of sRANKL, OPG, CTX, TRACP-5b, Dkk-1 and sRANKL/OPG ratio and decreased levels of bALP compared to 30 controls ( $p<0.01$ ), while their levels correlated with the extend of bone disease. The median survival of all patients was 59 months. In the univariate analysis, among the studied bone markers, only CTX, as a continuous variable, was predictive of survival (HR: 1.292,  $p=0.024$ ). Patients with low CTX concentrations ( $<0.28$  ng/ml; lower quartile; N=29) had superior survival compared

to patients with higher CTX concentrations (not reached vs. 54 months respectively;  $p=0.034$ ). This was more profound in patients treated with IMiDs-based regimens: the median survival of those with low CTX levels ( $<0.28$  ng/ml) has not been reached yet vs. 39 months of all others ( $p=0.02$ ). On the contrary, in patients who were treated with bortezomib-based therapies, high CTX could not define such a poor prognosis group.

**Conclusion:** Our study suggests that in the era of novel agents, only CTX, among 7 serum bone remodeling markers, correlated with survival and could distinguish a subset of patients who receive frontline IMiDs-based therapies and have poor prognosis. This was not observed with bortezomib-based therapies, possibly due to the beneficial effect of bortezomib on bone metabolism.

## P29

### BONE MARROW BIOPSY SHOULD BE CONSIDERED FOR THE INITIAL EVALUATION OF INDIVIDUALS WITH ASYMPTOMATIC MONOCLONAL GAMMOPATHY AND IMMUNOPARESIS OR MONOCLONAL COMPONENT $\geq 1\text{g/dL}$

**Efstathios KASTRITIS, Evangelos TERPOS, Maria GAVRIATOPOLOU, Dimitrios CHRISTOULAS, Evangelos ELEUTHERAKIS-PAPAIKOVOU, Magdalini MIGKOU, Despoina KALAPANIDA, Eftychia KAFANTARI, Maria ROUSSOU, Meletios A. DIMOPOULOS**

*Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece*

**Objective:** The aim of the study was to identify factors that could aid in the evaluation of individuals presenting with asymptomatic monoclonal gammopathy.

**Methods:** We analyzed the database of patients who were referred to our department for evaluation of asymptomatic monoclonal gammopathy. A bone marrow (BM) trephine biopsy, serum and urine protein electrophoresis with immunofixation and quantitative immunoglobulins are routinely performed in all patients with monoclonal gammopathy.

**Results:** Our analysis included 162 patients: 53% had a monoclonal IgG, 15.5% IgA, and 24% IgM, while 4% had a biclonal paraprotein; 63% had a kappa light chain. The median serum M-protein was 0.95 g/dl (range 0.1-2.99 g/dl) and was higher in those with IgG or IgA vs. those with IgM ( $p=0.009$ ). Immunoparesis of at least one of the uninvolved immunoglobulins was present in 38% and of both of the uninvolved immunoglobulins in 6% of patients. Median infiltration by monoclonal cells in BM biopsy was 7% for those with an IgM-gammopathy and 15% for those with monoclonal IgG or IgA ( $p=0.047$ ). There was a significant correlation of the size of M-protein and of the BM infiltration ( $R=0.592$ ,  $p<0.001$ ). Among those with M-protein  $<0.5$  g/dl, 11% had  $\geq 10\%$  clonal cells in their BM biopsies while the respective rates were 88% for those with M-protein  $\geq 1$  g/dl and 97% for M-protein  $\geq 2$  g/dl. Immunoparesis of at least one of the uninvolved

immunoglobulins was associated with  $\geq 10\%$  BM clonal cells in 90% of patients. In regression analysis, immunoparesis of at least one of the uninvolved immunoglobulins (OR:6.45, 95%CI:2.32-18,  $p<0.001$ ), an IgG or IgA monoclonal protein (OR:2.67, 95%CI:1.1-6.4,  $p=0.028$ ) and an M-protein  $\geq 1$  g/dl (OR:5.4, 95%CI:2.23-13) were independently associated with  $\geq 10\%$  clonal infiltration in BM biopsy.

**Conclusion:** BM biopsy can reveal asymptomatic myeloma or Waldenstrom's Macroglobulinemia that may escape identification with standard criteria and should be included in the initial workup of individuals with asymptomatic monoclonal gammopathy.

## P30

### T-REGULATORY CELLS ARE SIGNIFICANTLY REDUCED AFTER TREATMENT WITH LENALIDOMIDE, BUT NOT WITH BORTEZOMIB, AND CORRELATE WITH THE ACHIEVEMENT OF AT LEAST VGPR IN PATIENTS WITH MULTIPLE MYELOMA

Christina HADJIAGGELIDOU<sup>1</sup>, Evangelos TERPOS<sup>2</sup>, Evdokia MANDALA<sup>3</sup>, Dimitra MARKALA<sup>1</sup>, Eythimia GIANNAKI<sup>1</sup>, Athanasios PAPATHEODOROU<sup>4</sup>, Sofia VAKALOPOULOU<sup>5</sup>, Pavlina KONSTANTINIDOU<sup>1</sup>, Meletios A. DIMOPOULOS<sup>2</sup>, Eirini KATODRITOU<sup>1</sup>

<sup>1</sup>Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece, <sup>2</sup>Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, <sup>3</sup>Fourth Department of Internal Medicine, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece, <sup>4</sup>Department of Medical Research, 251 General Air Force Hospital, Athens, Greece, <sup>5</sup>Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece

**Objective:** Immune dysfunction is an important feature of multiple myeloma (MM) and has been associated with reduced survival. Studies have shown that regulatory T cells (Tregs) are implicated in the immune surveillance of different tumors, including MM. Data regarding alterations of Tregs during therapy with novel agents (NA), i.e. bortezomib and lenalidomide, are limited. Our aim was to explore the alterations of Tregs and T subpopulations (i.e. T4, T8, NK, NK-like), as well as changes in the levels of cytokines related to Tregs function and MM biology (IL-6, IL-2, IL-17, TGF- $\beta$ ), during treatment with NA and to explore possible correlations with disease characteristics and response parameters.

**Methods:** We evaluated 29 patients with symptomatic MM, at diagnosis or relapse (M/F: 15/14, median age: 61 years, range: 39-77 years). Eleven patients received bortezomib-dexamethasone (BD) (group A) and 18 patients received lenalidomide-dexamethasone (Rd) (group B). The median number of previous treatment lines was 1 (0-3).

**Results:** In group A, no significant alterations of Tregs %, T subpopulations or cytokines was observed. In group B, there was a significant reduction of Tregs % ( $p<0.001$ ) and this was more

profound in those who achieved  $\geq$  very good partial response (vgPR;  $p=0.04$ ). No alterations regarding T subpopulations or cytokines was observed. Significant correlations between disease characteristics and Tregs were not observed in either group of patients. In the cox regression analysis, Tregs % did not correlate with progression-free survival (PFS).

**Conclusion:** We have demonstrated that Tregs % are significantly reduced after treatment with Rd especially in patients with  $\geq$  vgPR, suggesting a possible relation of immune surveillance with quality of response. However, PFS was not affected in the current study. Bortezomib-based treatment has no impact on Tregs number or function. No relation between Tregs % and relative cytokines was proved in the current study, indicating the unexplored immune mechanisms underlying MM.

## P31

### LACK OF SURVIVAL IMPROVEMENT WITH NOVEL ANTI-MYELOMA AGENTS FOR PATIENTS WITH MULTIPLE MYELOMA AND CENTRAL NERVOUS SYSTEM INVOLVEMENT: THE GREEK MYELOMA STUDY GROUP EXPERIENCE

Eirini KATODRITOU<sup>1</sup>, Evangelos TERPOS<sup>2</sup>, Sossana DELIMPASI<sup>3</sup>, Argiris S. SYMEONIDIS<sup>4</sup>, Marie-Christine KYRTSONIS<sup>5</sup>, Chrysa VADIKOLIA<sup>6</sup>, Michael MICHAEL<sup>7</sup>, Maria KOTSOPOULOU<sup>8</sup>, Pavlina KONSTANTINIDOU<sup>1</sup>, Meletios A. DIMOPOULOS<sup>2</sup>

<sup>1</sup>Department of Hematology, Theagenio Cancer Hospital, Thessaloniki, Greece, <sup>2</sup>Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, <sup>3</sup>Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos Hospital, Athens, Greece, <sup>4</sup>Hematology Division, Department of Internal Medicine, University of Patras Medical School, Patras, Greece, <sup>5</sup>First Department of Propedeutic Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, <sup>6</sup>Department of Hematology, 424 General Military Hospital, Thessaloniki, Greece, <sup>7</sup>Department of Hematology, General Hospital of Nicosia, Nicosia, Cyprus, <sup>8</sup>Department of Hematology, Metaxa Cancer Hospital, Piraeus, Greece

**Objective:** Multiple myeloma of the central nervous system (CNS-MM) is a rare extramedullary manifestation of MM. It occurs in less than 1% of MM cases and exhibits a dismal prognosis with overall survival (OS) of less than 6 months. The purpose of the current study was to describe the incidence, the clinical and laboratory characteristics, the response to treatment, the outcome and the possible prognostic factors of CNS-MM survival, in the era of novel agent-based combinations (NAC). To our knowledge this is one of the largest studies including CNS-MM patients treated in the vast majority with NAC and mostly with bortezomib-based combinations.

**Methods:** We retrospectively reviewed the medical records of

30 consecutive patients with CNS-MM, diagnosed and treated in 12 Centers of the Greek Myeloma Study Group.

**Results:** Between January 2000 and December 2013, 31 (0.9%) out of 3408 newly diagnosed symptomatic MM patients, consecutively diagnosed and treated during the same period developed CNS-MM (M/F: 15/16, median age: 59 years, range: 20-96 years; newly diagnosed/relapsed-refractory: 2/29; median time to CNS-MM diagnosis: 29 months). Twenty-six percent of patients had circulating plasma cells (PCs) or plasma cell leukemia (PCL) at the time of CNS-MM diagnosis and 39% had skull-derived plasmacytomas, suggesting hematological and contiguous spread. Treatment for CNS-MM was offered in 29/31 patients and 11/29 responded (NAC: 18/29, additional radiotherapy: 9/28, intrathecal chemotherapy: 13/29). The median post CNS-MM survival was 3 months (95% CI: 1.9-4.1) and did not differ between patients treated with NAC and/or radiotherapy vs. others. In the multivariate analysis, prior treatment of MM with NAC, extramedullary disease (EMD) during MM course (i.e. plasmacytomas, circulating PCs or documented PCL) and abnormally high LDH at MM diagnosis were independent prognostic factors, whereas treatment of CNS-MM with NAC did not predict for post CNS-MM survival.

**Conclusion:** Despite the relatively limited number of patients due to the rarity of CNS-MM, our results suggest that NAC do not seem to improve post CNS-MM survival. Patients with EMD display shortened post CNS-MM survival and should be followed thoroughly.

## P32

### PROGRESSION-FREE SURVIVAL 2 (PFS-2) IS THE MOST SIGNIFICANT PROGNOSTIC FACTOR OF LONG-TERM SURVIVAL IN THE ERA OF NOVEL AGENTS: A SINGLE MYELOMA CENTER EXPERIENCE

Eirini KATODRITOU<sup>1</sup>, Nikos SPYRIDIS<sup>1</sup>, Sofia PAPADAKI<sup>1</sup>, Evlambia GIANNOPOULOU<sup>1</sup>, Vassiliki PALASKA<sup>1</sup>, Dimitra MARKALA<sup>1</sup>, Evgenia VERROU<sup>1</sup>, Christina HADJIAGGELIDOU<sup>1</sup>, Pavlina KONSTANTINIDOU<sup>1</sup>, Evangelos TERPOS<sup>2</sup>

<sup>1</sup>Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece, <sup>2</sup>Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

**Objective:** Before the era of novel agents (NA), 3-4% of Multiple myeloma (MM) patients were considered as long-term survivors (LTS) (i.e. patients remaining alive for >10 years). Herein, we describe the incidence, characteristics and prognostic factors of LTS MM patients of a Greek hematology center.

**Methods:** We checked the database of our center for the presence of LTS. In addition to Progression Free Survival (PFS) and overall survival (OS), we evaluated PFS2, defined as the time from MM diagnosis to second objective disease progression, or death from any cause.

**Results:** We identified 50 LTS (7.7%; M/F: 23/27, median age: 65 years, range: 47-72 years) out of 648 consecutive MM patients

who were diagnosed between 1989 and 2013. LTS were younger and most of them presented with ISS stage I/II compared to all others ( $p<0.001$ ). LTS had higher hemoglobin, lower creatinine and lower beta2-microglobulin at diagnosis compared to controls ( $p<0.05$ ). Bence-Jones proteinuria and immunoparesis at diagnosis presented less frequently in LTS; recovery of immunoparesis after 1st line treatment was more common in LTS ( $p<0.05$ ). 72% of LTS received novel agents (NA) during the course of MM. The number of patients treated with NA and the response rate after 1st line therapy did not differ between LTS and the other patients; LTS received more frequently autologous transplantation at 1st line and NA at 2nd line treatment compared to all other patients ( $p<0.05$ ). After a 12-year median follow-up (range: 2-180 months), 28/50 LTS vs. 84/598 of other MM patients were alive ( $p<0.001$ ); 22 LTS patients died (due to MM: 13 patients, irrelevant causes: 9 patients); 12/28 alive LTS were in CR during evaluation. The median PFS and OS for LTS vs. other patients was 81 months (95% CI: 56-105) vs. 17 months (95% CI: 15-19) and 200 months (95% CI: 180-219) vs. 33 months (95% CI: 30-36), respectively ( $p<0.05$ ). In the multivariate analysis, PFS-2 was the only positive predictor for long-term survival ( $p<0.001$ ; HzR: 0.98, 95% CI: 0.96-0.99); 28% of patients with  $PFS_2 \geq 4$  years were alive after 10 years compared to 0.4% of those with  $PFS_2 < 4$  years.

**Conclusion:** In conclusion, the percentage of LTS has increased in the era of NA. LTS present with more favorable disease characteristics compared to other MM patients. PFS-2 was the most significant prognostic factor of long-term survival, suggesting that disease control during the initial phase of MM, where sensitive clones still prevail and when there is no drug resistance, should be the main goal of the treatment strategy. Finally, about 1/3 of patients who displayed disease control of  $\geq 4$  years after 2 treatment lines, enjoyed a long-term survival and most importantly, 1/3 of them remained in CR and could be considered as "cured" from MM, challenging the dogma of incurable disease.

## P33

### CHANGES IN CHROMATIN STRUCTURE AND KEY-MOLECULES OF THE DNA DAMAGE RESPONSE PATHWAYS AFFECT THE TRANSFORMATION PROCESS OF MYELOMAGENESIS AND THE OUTCOME OF ANTI-MYELOMA THERAPY

Maria GKOTZAMANIDOU<sup>1</sup>, Evangelos TERPOS<sup>1</sup>, Meletios A. DIMOPOULOS<sup>1</sup>, Vassilis L. SOULIOTIS<sup>2</sup>

<sup>1</sup>Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, <sup>2</sup>Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, Athens, Greece

**Objective:** Important anticancer drugs exert their antitumor effects through the production of DNA interstrand cross-links (ICLs). However, the precise mechanisms contributing to differential response of patients to chemotherapy with these drugs

are poorly understood.

**Methods:** DNA damage response (DDR) signals, chromatin structure and transcriptional activity were examined following ex vivo melphalan treatment of peripheral blood mononuclear cells (PBMCs) from 25 healthy controls (HC) and 15 newly-diagnosed multiple myeloma (MM) patients, responders ( $\geq PR$ , n=9) and non-responders

**Results:** The accumulation of monoadducts was inversely correlated with the first-phase repair capacity of PBMCs, being significantly higher in HC than in responders and lowest in non-responders ( $P<0.001$ ). Also, although ICL “unhooking” rates were similar in all individuals, accumulation of ICLs was significantly higher in HC compared to responders ( $P<0.01$ ), due to higher levels of monoadducts (precursors of ICLs) left unrepaired in PBMCs. Minimal amounts of ICLs were observed in non-responders. Moreover, DSBs burden was significantly higher in HC than in responders’ PBMCs, due to higher accumulation of ICLs (precursors of DSBs) and lower rates of DSBs repair in these cells ( $P<0.01$ ). Minimal amounts of DSBs were observed in non-responders. Interestingly, apoptosis rates were inversely correlated with the DSBs repair efficiency of PBMCs, being significantly higher in HC compared to responders and lowest in non-responders ( $P<0.05$ ). An inverse correlation was found between the chromatin condensation and the repair capacity of PBMCs, with the looseness of the chromatin structure being significantly higher in non-responders compared to responders and lowest in HC ( $P<0.05$ ). Finally, an altered expression of several DNA damage response-related genes was found between HC and MM patients as well as between responders and non-responders.

**Conclusion:** Changes in chromatin structure and key-molecules of the DDR pathways affect the repair capacity of MM patients, thus contributing to both myelomagenesis and the outcome of anti-myeloma therapy.

## P34

### EARLY DEVELOPMENT OF OSTEONECROSIS OF THE JAW IN PATIENTS WITH MULTIPLE MYELOMA WHO RECEIVE ZOLEDRONIC ACID THERAPY: THE ROLE OF GENETIC FACTORS

Pelagia MELEA<sup>1</sup>, Evangelos TERPOS<sup>2</sup>, Tina BAGRATUNI<sup>2</sup>, Evangelos ELEFTHERAKIS-PAPAIKOVOU<sup>2</sup>, Maria GAVRIATOPOULOU<sup>2</sup>, Ioannis PANAGIOTIDIS<sup>2</sup>, Ioannis MELAKOPOULOS<sup>1</sup>, Christina TESSEROMATIS<sup>3</sup>, Efstathios KASTRITIS<sup>2</sup>, Meletios A. DIMOPOULOS<sup>2</sup>

<sup>1</sup>Department of Maxillofacial Surgery, Henry Dunant Hospital, Athens, Greece, <sup>2</sup>Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, <sup>3</sup>Department of Pharmacology, National and Kapodistrian University of Athens, Faculty of Medicine, Athens, Greece

**Objective:** One of the complications of bisphosphonates is osteonecrosis of the jaw (ONJ). The aim of this study was to

investigate a possible association between SNPs in CYP2C8 and PPAR- $\gamma$  and the risk of developing ONJ in a large number of multiple myeloma (MM) patients who received zoledronic acid (ZA) for their bone disease.

**Methods:** We screened 36 patients who developed ONJ and 104 patients who did not develop ONJ for the SNPs of interest in PPAR- $\gamma$  (rs1152003) and CYP2C8 (rs193495) genes by direct sequencing of peripheral blood derived DNA.

**Results:** The median follow up of the patients was 72 months and the median time to ONJ development was 47 months (range: 7-182 months). Patients who developed ONJ had a median of 31 ZA infusions versus 25 infusions for the others. However, 31% of patients who developed ONJ had received <24 ZA infusions. An extraction preceded the development of ONJ in 60% of patients, it was unprovoked in 20% and it was associated with trauma/inflammation in 20% of patients. In patients with <24 infusions of ZA, the presence of SNPs in both PPAR- $\gamma$  and CYP2C8 was associated with a significantly higher probability of ONJ development (55% versus 16%,  $p=0.011$  and 29% versus 7%,  $p=0.07$ , respectively) and a shorter time to development of ONJ (19 versus 69 months,  $p<0.001$  for PPAR- $\gamma$ ). Combining the genotype risk, those with high risk of SNPs in both genes had a 70% cumulative incidence of ONJ within 24 months from initiation of ZA versus 17% for those carrying one of the two SNPs and 0% for those without any high risk of SNPs ( $p<0.001$ ).

**Conclusion:** We conclude that SNPs in the CYP2C8 and PPAR- $\gamma$  genes are associated with a risk of early development of ONJ. However, increasing cumulative dose of ZA increases substantially the risk of ONJ in all patients, independently of genotype-defined risk.

## P35

### CENTRAL NERVOUS SYSTEM RELAPSE AFTER CHEMOTHERAPY IN A PATIENT WITH MULTIPLE MYELOMA

Serife Solmaz MEDENİ<sup>1</sup>, Ferda BİLGİR<sup>2</sup>, Can ÖZLÜ<sup>1</sup>, Sinem NAMDAROĞLU<sup>1</sup>, Tugba ÇETİNTEPE<sup>1</sup>, Oktay BİLGİR<sup>1</sup>

<sup>1</sup>Department of Hematology, Bozyaka Training and Research Hospital, Izmir, Turkey, <sup>2</sup>Department of Internal Medicine and Immunology, Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey

**Introduction:** We report a case of central nervous system relapse with intraparacanial, dural and leptomeningeal involvement after high dose chemotherapy.

**Case:** A 72-year-old man received two cycles of bortezomib and dexamethasone as an induction treatment for stage IIIA IgA kappa multipl myeloma. Partial response achieved after two cycles of bortezomib and dexamethazone and continued to treat. Biphosphonate treatment was given because of lytic bone lesions. Four months after bortezomib and dexamethasone therapy increased plasma cells in the bone marrow was observed. Patients were considered refractory multiple myeloma and began

therapy with lenalidomide and dexamethasone. Two months after lenalidomide -dexamethasone therapy the patient admitted with sudden transient loss of vision, headache. Cranial computer tomography imaging revealed mass lesion occupying bilateral frontal lobes, was determined mega cisterna magna, both cerebral hemispheric cortical sulci were detected especially in the parietooccipital expanded to be more specific. Heterogenous dural and leptomeningeal infiltration was detected. After lenalidomide therapy symptoms related with central nervous system involvement and cytopenias related bone marrow infiltration got worse. The patient was lost from sepsis and renal failure.

**Conclusion:** Central nervous system involvement of multiple myeloma is rare. It may manifest as dural myeloma or intraparenchymal infiltration or with diffuse leptomeningeal involvement. In the literature there is no standard therapeutic approach regarding the central nervous system relapse after high dose therapy and median survival of patients with CNS relapse is 2 to 3 months. There are no treatment guidelines for central nervous system myelomatosis in the literature. Systemic chemotherapy regimes, radiotherapy and intrathecal chemotherapy were tried, but they have not prolonged survival. The central involvement of myeloma patient is presented for contributions to the literature.

## P36

### PATIENTS WITH CONCURRENT CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MULTIPLE MYELOMA (MM)

Eftychia NIKOLAOU<sup>1</sup>, Paraskevi PAPAIOANNOU<sup>1</sup>, Tatiana TZENOU<sup>1</sup>, Anastasia POULI<sup>2</sup>, Sotiria KOTSANTI<sup>1</sup>, Panayiota PETSA<sup>1</sup>, Maria DIMOU<sup>1</sup>, Theodoros ILIAKIS<sup>1</sup>, Panayiotis PANAYIOTIDIS<sup>1</sup>, Marie-Christine KYRTSONIS<sup>1</sup>

<sup>1</sup>National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, Athens, Greece,

<sup>2</sup>Department of Hematology, Agios Savvas Anticancer Hospital, Athens, Greece

**Objective:** MM and B-cell CLL are two distinct lymphoproliferative disorders that arise at different stages of the B-cell maturation pathway. Their coexistence has sporadically been reported, with their clonal relationship being controversial.

**Methods:** We report a series of 5 patients with simultaneous CLL/MM.

**Results:** 5 patients (60% females) were diagnosed as symptomatic MM 7 years (4-10) after the initial diagnosis of CLL. Mean age at CLL and MM diagnosis was 68 (63-73) and 75 (67-79) years respectively. Adverse prognostic factors at the time of CLL diagnosis were unmutated CLL (60%), CD38+ (40%) and complex karyotype (20%). 60% of patients had received at least one CLL therapy-line, while all the patients were stable, with a long follow up period before developing MM. MM type was IgG (60%), LC (20%) and IgD (20%), while patients' DS stage was III (100%) and ISS stage was II (40%) and III (60%). Most common symptoms were: bone disease with multiple fractures (80%), anaemia (60%), severe renal failure (60%) requiring hemodialysis (40%). 60% of

patients had bone marrow infiltration >60%. Hypercalcemia, immunoparesis and thrombocytopenia presented more rarely (20%). Two patients presented the same clonality at CLL and at MM diagnosis. One patient had kappa-restricted CLL cells and lambda-restricted myeloma cells, while in the two last ones the CLL light chain restriction was unclear. At the time of MM diagnosis, bone marrow biopsy revealed 2 distinct populations (60%) or total infiltration by CLL (20%) or MM (20%) cells.

**Conclusion:** MM can occur late at the course of CLL, with severe manifestations. One case presented clearly 2 different clones, while for the others, IgH rearrangement studies need to be done in order to understand the biology of this coexistence.

## P37

### SKELETAL-RELATED EVENTS REMAIN A SIGNIFICANT COMPLICATION OF MULTIPLE MYELOMA EVEN IN THE ERA OF NOVEL AGENTS

Evangelos TERPOS, Nikolaos KANELIAS, Dimitrios CHRISTOULAS, Maria GAVRIATOPOLOU, Despoina FOTIOU, Dimitrios ZIGAS, Evangelos ELEUTHERAKIS-PAPAIKOVOU, Eftychia KAFANTARI, Efstatios KASTRITIS, Meletios A. DIMOPOULOS

*Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece*

**Objective:** The aim of this study was to evaluate the SREs incidence in the era of novel agents.

**Methods:** We retrospectively evaluated 400 consecutive patients with symptomatic MM (207M/193F, median age: 63 years). All patients had a whole-body skeletal survey using conventional radiography at diagnosis and then at the time of relapse or whenever clinically indicated.

**Results:** At diagnosis, the skeletal survey detected osteolytic disease in 284 (71%) patients. SREs were observed in 167 (41.7%) patients at diagnosis: 104 (26%) patients presented with pathological fractures, while 22 (5.5%) patients required surgery to bone, 21 (5.2%) radiotherapy and 20 (5%) patients presented with SCC. The incidence of SREs was higher in patients with osteolytic lesions (49.5% vs. 24%, p<0.001). However, approximately 25% of patients without lytic lesions presented with a SRE at diagnosis. During first line treatment, 7 (1.75%) patients developed a SRE: 2 on bortezomib- and 5 on IMiD-based regimens. The median follow-up was 39 months. At the time of first relapse (n=176), 3 patients presented with fractures and 35 patients required local radiotherapy to bone (SRE incidence: 21.6%). Patients who had received only bortezomib-based regimens (VD or VCD, n=20) had lower SRE rate (2/20, 10%) vs. all others (36/156, 22%). In total, during the course of their disease, 52.8% of the patients presented with at least one SRE. Presentation with SREs at diagnosis did not predispose for SREs during the disease course, regardless of anti-myeloma treatment, possibly due to the low

number of fractures and the higher number of radiation needed after frontline therapy.

**Conclusion:** SREs remain a significant complication of MM. Despite high response rates after frontline therapy >20% of patients required radiotherapy at the time of relapse. The fracture rate was low during first line therapy and at first relapse probably due to the extensive use of BPs and bortezomib, which has bone anabolic effects.

## P38

### CIRCULATING TISSUE INHIBITOR OF METALLOPROTEINASE-1 CORRELATE WITH ADVANCED STAGE AND ABNORMAL BONE REMODELING IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSE WHO RECEIVE THE COMBINATION OF LENALIDOMIDE AND DEXAMETHASONE

Evangelos TERPOS, Magdalini MIGKOU, Dimitrios CHRISTOULAS, Maria GAVRIATOPOLOU, Despoina FOTIOU, Ioannis PANAGIOTIDIS, Dimitrios ZIOGAS, Maria ROUSSOU, Efstathios KASTRITIS, Meletios A. DIMOPOULOS

Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

**Objective:** Tissue inhibitors of metalloproteinases (TIMPs) are endogenous inhibitors of metalloproteinase activities and thus they modulate matrix metalloproteinase function and suppress extracellular matrix turnover. Pre-treatment serum TIMP-1 is associated with advanced myeloma but there is no information for the role of TIMP-1 at the time of relapse.

**Methods:** Circulating TIMP-1 levels were evaluated in 36 myeloma patients at first relapse who received the combination of lenalidomide plus dexamethasone (RD) at the standard dose, according to their renal function. Patients were also given zoledronic acid, 4 mg iv, monthly, both pre- and post-RD. Serum TIMP-1 was determined on day 1/cycle 1 and on day 28/cycle 3 of RD, using an ELISA methodology (Oncogene Science, Cambridge, MA, USA) along with serum markers of bone remodeling (CTX, TRACP-5b, bALP and osteocalcin) and osteoblast/osteoclast regulators (Dkk-1, sRANKL and OPG).

**Results:** The mean serum TIMP-1 level of all patients was 251.1 ng/ml (SD 95.4 ng/ml). Only two patients (1M/1F; 5%) had elevated values of TIMP-1 (UNL 459 ng/ml for males and 374 ng/ml for women). Patients had increased levels of Dkk-1, sRANKL, sRANKL/OPG ratio and bone resorption markers (CTX, and TRACP-5b) ( $p<0.01$  compared with 25 healthy controls). Serum TIMP-1 correlated with OPG ( $r=0.644$ ,  $p<0.001$ ), creatinine ( $r=0.572$ ,  $p<0.001$ ), beta2-microglobulin ( $r=0.481$ ,  $p=0.003$ ), TRACP-5b ( $r=0.449$ ,  $p=0.006$ ) and Dkk-1 ( $r=0.444$ ,  $p=0.007$ ). Patients with ISS-3 disease at diagnosis continued to have higher levels of TIMP-1 at first relapse compared with those with ISS-1 or ISS-2. No significant alterations of TIMP-1 were observed after 3 cycles of RD. TIMP-1 did not predict for survival, both as continuous

variable and as dichotomous variable, in this cohort of patients.

**Conclusion:** We conclude that serum TIMP-1 is not elevated in myeloma patients at first relapse although its levels correlate with abnormal bone remodeling and ISS. This may be due to the continuous use of zoledronic acid in our patients.

## P39

### VEGFR-1 CORRELATES WITH INCREASED MICROVESSEL DENSITY AND INFERIOR SURVIVAL IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA

Gerasimos-Petros PAPASSOTIRIOU<sup>1</sup>, Efstathios KASTRITIS<sup>2</sup>, Evangelos ELEFTHERAKIS-PAPAIKOVOU<sup>2</sup>, Filia APOSTOLAKOU<sup>1</sup>, Maria GKOTZAMANIDOU<sup>2</sup>, Despoina FOTIOU<sup>2</sup>, Ioannis PANAGIOTIDIS<sup>2</sup>, Ioannis PAPASSOTIRIOU<sup>1</sup>, Meletios A. DIMOPOULOS<sup>2</sup>, Evangelos TERPOS<sup>2</sup>

<sup>1</sup>Department of Clinical Biochemistry, Aghia Sophia Children's Hospital, Athens, Greece, <sup>2</sup>Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

**Objective:** The aim of the study was to evaluate placental growth factor (PIGF) and vascular endothelial growth factor receptor-1 (VEGFR-1) in symptomatic multiple myeloma (MM), compare the results with asymptomatic MM and MGUS and explore possible correlations with marrow angiogenesis (microvessel density, MVD) and survival.

**Methods:** Circulating levels of PIGF and VEGFR-1 were measured in 64 patients with newly diagnosed MM (16 with asymptomatic MM and 48 with symptomatic MM), 8 with MGUS and 20 healthy controls, using an electrochemiluminescence immunoassay. MVD was evaluated in trephine biopsies according to standard procedures.

**Results:** Symptomatic MM patients had elevated PIGF (median 19.5 pg/ml, range 6.7-91.3 pg/ml vs. 16.1 pg/ml, 10.9-25.0 pg/ml of control group;  $p<0.01$ ) and elevated VEGFR-1 levels (88.6 pg/ml, 51.5-320 pg/ml vs. 73.3 pg/ml, 62.9-100.8 pg/ml;  $p<0.001$ ). In MM patients there was a positive correlation between PIGF and VEGFR-1 ( $r=0.62$ ,  $p=0.009$  for asymptomatic and  $r=0.36$ ,  $p=0.01$  for symptomatic MM). Eighteen (37%) patients with symptomatic MM had low grade, while 20 (41%) had intermediate and 10 (20%) high grade angiogenesis. The median values and ranges of VEGFR-1 for low, intermediate and high grade angiogenesis were: 75.1 pg/ml (51.5-109.1 pg/ml), 94.2 pg/ml (61.2-143.8 pg/ml) and 151.8 pg/ml (103.7-320.0 pg/ml), respectively ( $p$ -ANOVA<0.0001). These patients received frontline therapy with novel agent-based regimens: 25 with lenalidomide-, 16 with thalidomide- and 7 with bortezomib-based regimens. The median follow-up period was 18.8 months and 8/47 patients have died. The probability of survival was 86% at 1 year and 78% at 2 years. In the univariate analysis the VEGFR-1 as a continuous variable correlated with higher risk of death (HR: 1.011, 95% CI: 1.004-1.018,  $p=0.003$ )

**Conclusion:** Our study suggests that myeloma patients have

increased circulating PIGF and VEGFR-1. High VEGFR-1 correlated with increased angiogenesis and inferior survival, supporting a significant role of VEGFR-1 in the biology of angiogenesis in MM.

## P40

### OSTEOPROTEGERIN IS A SIGNIFICANT PROGNOSTIC FACTOR FOR OVERALL SURVIVAL IN PATIENTS WITH PRIMARY SYSTEMIC AMYLOIDOSIS INDEPENDENT OF THE MAYO STAGING

**Maria GAVRIATOPOULOU, Efstrathios KASTRITIS, Meletios A. DIMOPOULOS, Evangelos ELEUTHERAKIS-PAPAIKOVOU, Nikolaos KANELLIAS, Magdalini MIGKOU, Maria ROUSSOU, Constantinos PAMBOUCAS, Savvas Th. TOUMANIDIS, Evangelos TERPOS**

*Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece*

**Objective:** Deregulation of bone metabolism is common in plasma cell dyscrasias, including multiple myeloma (MM) and MGUS, but very little is known for bone remodeling in patients with primary systemic (AL) amyloidosis. The aim of our prospective study was to evaluate bone metabolism in newly diagnosed patients with AL amyloidosis, to compare the results with those of patients with other plasma cell neoplasms and explore possible correlations with disease characteristics, including survival.

**Methods:** We evaluated bone remodeling indices in 102 patients with newly diagnosed AL amyloidosis, 35 healthy controls, 35 newly diagnosed, symptomatic MM patients and 40 MGUS patients. An enzyme-linked immunosorbent assay (ELISA) was used for the detection of the following serum indices: i) osteoclast regulators: soluble RANKL and osteoprotegerin (OPG); ii) bone resorption markers: CTX, NTX and TRACP-5b and iii) bone formation markers: bone-alkaline phosphatase and osteocalcin.

**Results:** Bone resorption markers (CTX, NTX) and osteoclast regulators (sRANKL, OPG) were increased in AL patients compared to controls ( $p<0.01$ ) but bone formation was unaffected. Myeloma patients had increased bone resorption and decreased bone formation compared to AL patients, while sRANKL/osteoprotegerin ratio was markedly decreased in AL, due to elevated osteoprotegerin in AL ( $p<0.001$ ). Osteoprotegerin correlated with NT-proBNP ( $p<0.001$ ) and was higher in patients with cardiac involvement ( $p=0.028$ ) and advanced Mayo stage ( $p=0.001$ ). OPG levels above the upper value of healthy controls was associated with shorter survival (34 vs. 91 months;  $p=0.026$ ), while AL patients with OPG levels in the top quartile had very short survival (12 vs. 58 months;  $p=0.024$ ). In Mayo stage-1 disease, OPG identified patients with poor survival (12 vs. >60 months;  $p=0.012$ ).

**Conclusion:** We conclude that increased OPG in AL is not only a compensation to osteoclast activation, but may also reflect early cardiac damage and may identify patients at increased risk of death within those with earlier Mayo stage.

## P41

### DEVELOPMENT OF DOUBLE EXPRESSING DIFFUSE LARGE B-CELL LYMPHOMAS IN THE COURSE OF MULTIPLE MYELOMA, SUCCESSFULLY TREATED WITH RITUXIMAB AND LENALIDOMIDE

**Paraskevi PAPAIOANNOU, Tatiana TZENOU, Eftychia NIKOLAOU, Sotiria KOTSANTI, Anastasia POULI, Panayiota PETSA, Maria DIMOU, Theodoros ILIAKIS, Panayiotis PANAYIOTIDIS, Marie-Christine KYRTSONIS**

*National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, Athens, Greece*

**Introduction:** The coexistence of two distinct lymphoproliferative disorders is quite rare. We herein present a 63-year-old patient with multiple myeloma who developed diffuse large B-cell lymphoma (DLBCL) 16 years after the diagnosis of multiple myeloma (MM).

**Case:** In 1997 our patient presented with gradually worsening sciatica and a monoclonal serum spike. Further tests revealed multiple osteolytic lesions, a pelvic left plasmacytoma, 15% plasma cells infiltration in the bone marrow biopsy, an IgAk paraprotein while the other tests were normal. He was diagnosed with IgAk multiple myeloma, stage II A according to Durie-Salmon and ISS 2; treatment was initiated with radiotherapy followed by chemotherapy. He relapsed 10 years after, with a tongue plasmacytoma and minimal bone marrow plasma cell infiltration (12%); he received bortezomib-dexamethazone, achieved complete remission and subsequently underwent autologous stem cells transplantation. Three years later, he complained of continuous and worsening epigastric pain and discomfort. Ultrasound followed by MRI revealed an abdominal mass and thickening of the terminal ileum, biopsy of which established the diagnosis of DLBCL of the "double expressing" (bcl-6, bcl-2) subtype. Staging examination tests revealed no other lesions, while the bone marrow had 65% plasma cell infiltration. R-EPOCH combination was started resulting in partial response. Because of coexisting myeloma, treatment continued with the combination of rituximab, lenalidomide and dexamethazone. After completion of 6 cycles of the above mentioned regimen, he achieved complete remission for both diseases and was submitted to a second autologous stem cell transplantation.

**Conclusion:** The interest of the present case lies on both the development of double expressing DLBCL in the course of MM and the very good response of this especially aggressive lymphoma to rituximab, lenalidomide and dexamethazone treatment.

**P42****POEMS SYNDROME PRESENTING WITH INSIDIOUS DISTAL PARAPLEGIA**

**Fatos Dilan KOSEOGLU**, Hatice Demet KİPER UNAL,  
**Pusem PATIR**, Fahri SAHIN, Guray SAYDAM

Ege University Faculty of Medicine, Izmir, Turkey

**Introduction:** We describe a patient with POEMS on the purpose of emphasising the insidious symptoms of this rare syndrome. POEMS syndrome is a rare multisystemic disorder characterized by a combination of polyneuropathy, hemangioma, hyperpigmentation and hypertrichosis of the skin, variable endocrine disturbances, generalized edema, organomegaly and a plasma cell dyscrasia with an M-protein often associated with myeloma. Patients are often misdiagnosed with myeloma or monoclonal gammopathy of undetermined significance (MGUS).

**Case:** A 40-year-old woman presented to the clinic of neurology with numbness in her feet which has been occurred for months. On detailed history she has no chronic illness and drug utilization. Peripheral neuropathy had been diagnosed with electromyography. Muscle power was grade three in bilateral legs. Lower limb reflexes were abnormal. No other finding was found with detailed physical examination. In a couple days, patient developed bilateral foot drop, paraesthesia of her feet. Thoracolumbar MRI was performed due to her back pain. MRI showed a destructive sclerotic lesion on the level of T11. An enlarged spleen (17 cm) and hemangioma (8 mm) in the liver was also evident on abdominal ultrasonography. Primarily, metastatic lesions secondary to a solid tumour was considered. After detailed body scanning with radiologic and physical examination, no suspicious focus was found. Endocrinologic examination revealed hypothyroidism and three hypoechoic thyroid nodules. Urine was negative for Bence-Jones protein. Serum immunofixation was consistent with immunoglobulin G $\lambda$  monoclonal gammopathy. The lesion was biopsied under CT guidance and found to be a plasmacytoma,  $\lambda$  chain restricted. The presence of lytic lesions, splenomegaly, hypothyroidism, hemangioma and peripheral neuropathy the patient diagnosed with POEMS syndrome.

**Conclusion:** POEMS syndrome is a rare multisystem syndrome associated with plasma cell dyscrasia and can reliably be distinguished from other diseases if a thorough history is taken and examination performed.

**P43****THE DNA REPAIR CAPACITIES OF THE INTERSTRAND CROSS-LINKS AND DOUBLE-STRAND BREAKS IN THE OUTCOME OF ANTI-MYELOMA THERAPY - THE SYNERGISTIC EFFECT OF DNA REPAIR INHIBITORS**

**Maria GKOTZAMANIDOU**<sup>1,2</sup>, Evangelos TERPOS<sup>1</sup>,  
**Nikhil MUNSHI**<sup>2</sup>, Meletios A. DIMOPOULOS<sup>1</sup>,  
**Vassilis SOULIOTIS**<sup>3</sup>

<sup>1</sup>Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, <sup>2</sup>Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA, <sup>3</sup>Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, Athens, Greece

**Objective:** Many important anticancer agents exert their antitumor effect through the production of DNA interstrand cross-links (ICLs). Herein, using the ICL-inducing drug melphalan, we investigated the underlying mechanisms in processing and repair of drug-induced DNA damage and their contribution to response of Multiple Myeloma (MM) patients to anti-myeloma therapy.

**Methods:** We examined the melphalan-induced DNA damage formation/repair in MM cell lines [melphalan-sensitive (RPMI8226) and melphalan-resistant (LR5)] and CD138+ bone marrow plasma cells (BMPCs) from MM patients (8M/7F; median age 61 years), responders (n=9) or non-responders (n=6) to subsequent melphalan therapy.

**Results:** Following *ex vivo* melphalan treatment of BMPCs, higher accumulation of monoadducts was observed in responders, due to the slower first-phase repair capacity of these cells ( $P<0.01$ ). Although the ICL repair efficiencies were similar in all patients, accumulation of ICLs was significantly higher in responders' BMPCs ( $P<0.01$ ), due to higher levels of monoadducts (precursors of ICLs) left unrepaired in these cells. Moreover, double strand breaks (DSBs) burden was significantly higher in responders, due to higher accumulation of ICLs (precursors of DSBs) and lower rates of DSB repair in these cells ( $P<0.05$ ). An inverse correlation was found between the apoptotic rate and the DSBs repair efficiency of BMPCs, with the apoptotic rate being significantly higher in responders compared to non-responders ( $P<0.01$ ). In line with BMPCs data, significantly higher accumulation of monoadducts, ICLs and DSBs were found in RPMI8226 compared to LR5 cells ( $P<0.001$ ). Interestingly, in all cell types analyzed, co-treatment with DSB repair inhibitors (NU7026, IR-1) significantly increased the accumulation of DSBs and the melphalan sensitivity of the cells ( $P<0.01$ ).

**Conclusion:** BMPCs from responders to melphalan treatment are characterized by the simultaneous accumulation of the extremely cytotoxic ICL and DSBs lesions. Moreover, our results suggest that DSB repair inhibitors offer a strategy toward the improvement of existing regimens in MM.

## MYELOPROLIFERATIVE NEOPLASMS

### P44

#### A RAPID AND SENSITIVE METHOD TO DETECT COMBINATIONAL MUTATIONS IN EPIGENETIC MODIFIER GENES IN PATIENTS WITH MYELOFIBROSIS

**Andreas GIANNOPoulos<sup>1</sup>, Christine ZOI<sup>1</sup>, Theodoros LOUPIS<sup>1</sup>, Marina MANTZOURANI<sup>2</sup>, Nora-Athina VYNIOU<sup>2</sup>, Panagiotis TSIRIGOTIS<sup>3</sup>, Dimitris LOUKOPOULOS<sup>1</sup>, Marianna POLITOU<sup>4</sup>, Kostas KONSTANTOPOULOS<sup>5</sup>, Katerina ZOI<sup>1</sup>**

<sup>1</sup>Hematology Research Laboratory, Biomedical Research Foundation, Academy of Athens, Athens, Greece,

<sup>2</sup>First Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, Athens, Greece, <sup>3</sup>Hematology Unit, Second Department of Propedeutic Medicine, National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital, Athens, Greece,

<sup>4</sup>Laboratory of Hematology and Blood Transfusion Unit, National and Kapodistrian University of Athens, School of Medicine, Aretaieion Hospital, Athens, Greece,

<sup>5</sup>Department of Hematology, National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, Athens, Greece

**Objective:** The mutational spectrum in myelofibrosis includes driver mutations in genes such as JAK2, CALR, and MPL with approximate frequencies 60%, 23%, and 5% respectively. Recurrent mutations in epigenetic modifiers such as ASXL1, IDH1/2 and DNMT3a have also been described. Recent studies indicate that the number and type of mutations have important clinical consequences. In this report we describe a rapid and sensitive HRM analysis PCR method using the LightCycler4800 for the detection of ASXL1, IDH1/2 and DNMT3a mutations.

**Methods:** 119 patients with myelofibrosis were studied. DNA was extracted from peripheral blood samples by standard procedures. JAK2V617F and MPLW515L/K mutations were detected using standard PCR assays (sensitivity>1%). CALR exon 9 mutations were detected using an HRMA-PCR assay (sensitivity>2.5%). Mutations in ASXL1, IDH1/2 and DNMT3a genes were detected using HRMA-PCR methods for the respective amplicons according to the COSMIC database. Results were confirmed by Sanger sequencing.

**Results:** 65 of the 119 patients carried the JAK2V617F mutation (54.62%), 6 presented MPL mutations (5.04%), and 24 CALR mutations (20.16%). ASXL1 mutations detected in 45 patients (37.81%). In 25 cases ASXL1 mutations coexisted with JAK2V617F, in 6 with CALR mutations, in 3 with MPL, while in 10 cases ASXL1 mutations was the only molecular lesion. IDH2 mutations detected in 2 cases; in one patient coexisted with JAK2V617F and ASXL1 mutation, while in the other only with ASXL1. The IDH1 mutation

was observed in one patient along with CALR mutation. DNMT3a mutations detected in 5 cases; in three along with JAK2V617F, in one with CALR and one alone.

**Conclusion:** Our findings indicate that HRMA-PCR represent a rapid and sensitive method for the detection of mutations in epigenetic modifiers genes. Our results suggest that routine screening for these mutations may be useful to determine a patient's risk for thrombosis, leukaemic transformation, and survival according to the bibliography.

### P45

#### HEMATOLOGICAL COMPLETE REMISSION BY PONATINIB IN A CHRONIC MYELOID LEUKEMIA PATIENT WITHOUT T315I MUTATION

**Çiğdem DİNÇKAL<sup>1</sup>, Püsem PATIR<sup>2</sup>, Nur AKAD SOYER<sup>2</sup>, Güray SAYDAM<sup>2</sup>**

<sup>1</sup>Ege University, Department of Internal Medicine, Izmir, Turkey, <sup>2</sup>Ege University, Department of Hematology, Izmir, Turkey

**Introduction:** Imatinib was the first TKI developed to target the bcr-abl protein for the treatment of chronic myeloid leukemia (CML), and it was followed subsequently by nilotinib, bosutinib, dasatinib, and most recently, ponatinib. Ponatinib is a third-generation TKI that is uniquely effective in inhibiting the gatekeeper T315I mutation that confers resistance to all other kinase inhibitors.

**Case:** A 53-year-old male presented to hematology outpatient clinic with complaints of leukocytosis, in August 2009. Cytogenetic and PCR analyses showed the presence of Philadelphia chromosome. Imatinib mesylate 400 mg/day was started. In June 2013, BCR/ABL level was found 22.55% IS. Imatinib mesylate was discontinued due to loss of molecular response. Treatment was continued with dasatinib. In April 2014, BCR/ABL level was found 304,598% IS. In this time Dasatinib was interrupted and Nilotinib was started. In November 2014, again on the fact that loss of hematologic response, patient was evaluated refractory against second-line tyrosine-kinase inhibitors. A molecular study did not reveal a T315I mutation of the BCR-ABL gene. It was decided to start and continue ponatinib 45mg daily until an unrelated donor was found for stem cell transplantation. In follow-up, ponatinib related toxicity was not observed except constipation. Four months later, he re-achieved hematologic response.

**Conclusion:** Conclusion Ponatinib is a potent TKI that can overcome several resistance mechanisms in previously treated patients with CML. Unlike other BCR-ABL TKIs, ponatinib was designed to overcome the T315I mutation. This case report showing the effectiveness of ponatinib therapy for refractory against first and second-line CML patients not bearing the T315I BCR-ABL mutation. Further studies are necessary to confirm the efficacy and applicability of ponatinib therapy.

**P46**

**INCREASED PLATELET COUNTS AT DISEASE DIAGNOSIS ARE RELATED WITH EARLY INTRODUCTION OF CYTOREDUCTIVE TREATMENT AND REDUCED EVENT-FREE SURVIVAL IN YOUNG ADULT PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA; A FOLLOW UP STUDY OF 33 PATIENTS**

**Emmanouil SPANOUDAKIS**, Costas ZAGORIDIS,  
Stamatia GULIAMTZI, Dimitrios MARGARITIS,  
Ioannis KOTSIANIDIS

*Department of Hematology, Democritus University of Thrace, Medical School, Alexandroupolis, Greece*

**Objective:** Essential thrombocythemia (ET) is not such an innocent disease in young adults. Most thrombotic events occur during diagnosis and almost half of the initially asymptomatic patients will have an event during the course of their disease.

**Methods:** Herein, we analyzed retrospectively the medical records of 33 ET patients diagnosed below the age of 45 years and followed in a single institution from 1992 to 2014. Management was left at the discretion of the treating physician but antithrombotic agents were used from disease diagnosis in all patients. Among 33 young adult patients, 11 were males and 22 females. Eighteen patients were followed for a median period of 94.5 (range 45-178) months and left untreated and they were included in group A. While cytoreductive treatment was introduced in 15 patients included in group B. Among 15 treated patients cytoreduction was introduced from disease diagnosis in seven patients and in eight during the course of their disease after a median period on observation of 36 months (range: 6-168).

**Results:** We separated our patients into two groups according to the need to start any cytoreductive treatment and try to discover patient's characteristics at diagnosis that can predict the early use of cytoreductive treatment. Splenomegaly of any grade was palpated in 3/18 (16.5%) patients in group A and in 2/15 (13%) in group B; p=0.796. Although hematocrit levels were equal between the two groups [42.7% (34.7-47.6) in group A and 40.7% (37.3-46) in group B; p=0.84] as were also and the leucocyte counts [7.85 (5.6-13.2)  $\times 10^3$  pcm in group A and 9.73 (4.7-11.7)  $\times 10^3$  in group B; p=0.6], the median values of platelet counts at diagnosis was significantly higher in group B compared to group A [805(490-2300)  $\times 10^9$  pcm versus 604.5 (490-921)  $\times 10^9$  pcm; p=0.012]. Fibrosis (grade I) at the initially performed bone marrow biopsy was met at higher percentages in patients allocated in group B 40% (6/15) in group B and 11% (2/18) at group A; p=0.03. JAK2V617F was detected in 40% (6/15) in group B and 50% (9/18) in group A; p=1. According to the IPSET-thrombosis scoring system in group A most patients had low thrombotic risk 10/18, 7/18 had intermediate thrombotic risk and 1/18 had high thrombotic risk. In group B 7/15 had low thrombotic risk, 3/15 intermediate and 5/15 had high thrombotic risk. In the total cohort of 33 young ET patients platelet counts at disease diagnosis can predict reduced event free survival (EFS). As an event were considered thrombohemorrhagic complications, development

of myelofibrosis and the need to start cytoreductive treatment. 10-year EFS was for patients with platelet counts < 600  $\times 10^9$  pcm 89%, for platelet counts between 600-800  $\times 10^9$  pcm 66% and for platelet counts > 800  $\times 10^9$  pcm was 22% (p=0.003, Kaplan-Mayer, LogRANK test). On the contrary the presence of grade-fibrosis was not associated with reduced EFS.

**Conclusion:** In young ET patients increased platelet counts at disease diagnosis can predict an eventful disease journey with early need for the use of cytoreductive treatment and reduced EFS.

**P47**

**MULTICENTER-RETROSPECTIVE ANALYSIS OF TURKISH PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS**

**Nur SOYER<sup>1</sup>, Ibrahim C. HAZNEDAROGLU<sup>2</sup>, Demet CEKDEMIR<sup>3</sup>, Mehmet YILMAZ<sup>4</sup>, Ali UNAL<sup>5</sup>, Oktay BILGIR<sup>6</sup>, Osman ILHAN<sup>7</sup>, Fusun OZDEMIRKIRAN<sup>8</sup>, Fahri ŞAHİN<sup>1</sup>, Guray SAYDAM<sup>1</sup>**

*<sup>1</sup>Ege University Medical Faculty Hospital, Department of Hematology, Izmir, Turkey, <sup>2</sup>Hacettepe University Medical Faculty Hospital, Department of Hematology, Ankara, Turkey, <sup>3</sup>Sakarya Research and Training Hospital, Department of Hematology, Sakarya, Turkey, <sup>4</sup>Gaziantep University Medical Faculty Hospital, Department of Hematology, Gaziantep, Turkey, <sup>5</sup>Erciyes University Medical Faculty Hospital, Department of Hematology, Kayseri, Turkey, <sup>6</sup>Bozyaka Research and Training Hospital, Department of Hematology, Izmir, Turkey, <sup>7</sup>Ankara University Medical Faculty Hospital, Department of Hematology, Ankara, Turkey, <sup>8</sup>Izmir Ataturk Research and Training Hospital, Department of Hematology, Izmir, Turkey*

**Objective:** Chronic Myeloproliferative neoplasms (CMPN) that are Philadelphia-negative malignancies include Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF), according to WHO classification. The aim of this report was to determine the demographic features, disease characteristics, JAK mutational status, treatment strategies, and survival rates of 708 patients with CMPN from 8 centers in Turkey.

**Methods:** Across all of Turkey, 8 centers were enrolled in the study. We retrospectively evaluated 708 patients' results with CMPN.

**Results:** The JAK2V617F mutation was found positive in 75.11% of patients with PV, in 51.5% of patients with ET and in 50.4% of patients with PMF. Thrombosis occurred in 20.65% of patients with PV, in 15.12% of patients with ET and in 9.6% of patients with PMF. Bleeding at diagnosis occurred in 7.5% of PV patients, in 9% of ET patients and in 10.4% of PMF patients. Six hundred and eight patients (85.9%) had a cytoreductive therapy. The most common used drug was hydroxyurea (75.1%). Cytoreductive therapy was changed in 198 (28% of all) patients. In the second-line treatment, the most common used drug was anagrelide (147 of 198 patients). Anti-platelet therapy was used in 553 (78.1%) patients. Splenectomy was performed in 10 (1.4%) patients.

Eight PMF patients (1.1% of all CMPN patients) were treated with allogeneic stem cell transplantation. Progression to acute leukemia and secondary myelofibrosis were observed in 0.6 % and 11.3% of all patients, respectively. The median follow- up was 38 months (0-322) and overall survival (OS) was 86.7% at 10 years in all patients.

**Conclusion:** Our patients results is compatible the literature except the frequency of JAK2V617F mutation in PV patients. Hydroxyurea was the most common used cytoreductive therapy in our patient cohort.

## P48

### A CASE OF COLON ADENOCARCINOMA IN A PATIENT WITH CHRONIC MYELOID LEUKEMIA TREATED WITH DASATINIB

Püsem PATIR<sup>1</sup>, Damla GÜNERÇ<sup>2</sup>, Damla AKDAĞ<sup>3</sup>, Fahri SAHİN<sup>1</sup>, Güray SAYDAM<sup>1</sup>

<sup>1</sup>Ege University, Department of Hematology, Izmir, Turkey,

<sup>2</sup>Ege University, Department of Internal Medicine, Izmir,

Turkey, <sup>3</sup>Ege University, Department of Infectious Diseases and Microbiology, Izmir, Turkey

**Introduction:** Chronic myeloid leukemia (CML) is a chronic myeloproliferative disorder, caused by the unregulated proliferation of granulocytes at different stages of development and maturation. Solid tumors may occur in 3% of the patients with CML. Especially, in older ages, a second malignancy is much more common.

**Case:** We report the case of a 54-year-old woman carrier Ph+ CML who developed colon adenocarcinoma under the therapy of dasatinib that was started after five years of imatinib therapy that was discontinued due to loss of molecular response. During treatment with oxaliplatin-capecitabine and dasatinib, CML relapse and serious myelosuppression were not observed.

**Conclusion:** Our report suggests that the clinician should carefully check the CML patients, especially elder, in terms of secondary malignancy on routine follow-up and dasatinib is an important treatment option for colon adenocarcinoma cancer in patients with CML.

## TRANSPLANTATION AND GENE THERAPY

### P49

#### LOW CIRCULATING MANNAN-BINDING LEPTIN LEVELS CORRELATE WITH INCREASED NUMBER OF FEBRILE EPISODES IN MYELOMA PATIENTS WHO UNDERGO AUTOLOGOUS STEM CELL TRANSPLANTATION AND DO NOT RECEIVE ANTIBIOTIC PROPHYLAXIS

Evangelos ELEFTHERAKIS-PAPAIKOVOU,  
Evangelos TERPOS, Dimitrios CHRISTOULAS,  
Magdalini MIGKOU, Maria GAVRIATOPOLOU,  
Maria GKOTZAMANIDOU, Ioannis PANAGIOTIDIS,  
Efstathios KASTRITIS, Meletios A. DIMOPOULOS,  
Christos PAPADIMITRIOU

*Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece*

**Objective:** Patients with multiple myeloma (MM) are at a higher risk of infections. The mannan binding leptin (MBL) pathway of the complement system is part of the innate immune system and seems to influence the risk of infections in cancer patients during treatment. The aim of this study was to evaluate the impact of MBL levels on the risk of infections and of febrile episodes in MM patients who undergo autologous transplantation (ASCT).

**Methods:** We studied 100 MM patients who underwent an ASCT between 1996-2011. Sixty-seven patients participated in a randomized study, where in the A arm patients received prophylactic antibiotics during ASCT, while in the arm B there was no antibiotic prophylaxis. MBL serum levels were measured in all patients on the day of mobilization, using an ELISA methodology (R&D Systems, Minneapolis, MN, USA).

**Results:** Seventeen patients had MBL levels <500 mg/L (the lower normal limit). Of those, 11 received antibiotics prophylaxis and 6 did not. In general, there was no statistical difference regarding the development of fever or neutropenic fever between patients with MBL serum levels of <500 mg/L or >500 mg/L. However, among 17 patients with MBL levels of <500 mg/L, 6/11 patients who received antibiotics prophylaxis developed a febrile episode compared to 6/6 patients who did not receive antibiotics prophylaxis and developed a febrile episode ( $p=0.049$ ). Nevertheless, patients with MBL levels <500 mg/L attained a lower response rate to first line therapy with antibiotics, requiring administration of a second line regimen, compared to patients with MBL levels of >500 mg/L (66.7% versus 88.9%, respectively;  $p=0.05$ ).

**Conclusion:** MM patients who undergo ASCT and have low MBL levels have a lower response rate in first line antibiotic regimens, requiring more often administration of a second, more advanced, line of antibiotics. The administration of prophylactic antibiotics to these patients seems to reduce the number of febrile episodes.

**P50**

**EFFICACY AND SAFETY OF BORTEZOMIB AND LENALIDOMIDE CONSOLIDATION POST-AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA: FINAL RESULTS OF A PROSPECTIVE STUDY**

Evangelos TERPOS, Efstathios KASTRITIS,  
Dimitrios CHRISTOULAS, Evangelos ELEUTHERAKIS-  
PAPAIKOVOU, Maria GAVRIATOPPOULOU,  
Magdalini MIGKOU, Despoina KALAPANIDA,  
Maria ROUSSOU, Flora ZAGOURI,  
Meletios A. DIMOPOULOS

*Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece*

**Objective:** The primary endpoint of the study was to explore the efficacy of VR (bortezomib and lenalidomide) consolidation, without dexamethasone, in newly-diagnosed patients with multiple myeloma (MM), who received bortezomib-based induction treatment and then underwent autologous transplantation (ASCT). Secondary endpoints included: safety, time to progression (TTP), time to next treatment (TtNT), overall survival (OS) and VR effects on bone metabolism in the absence of bisphosphonates administration.

**Methods:** Between January 2010 and November 2013, 59 patients (30M/29F, median age 54 year) who achieved at least stable disease post-ASCT were entered into this study. Consolidation consisted of 4 VR cycles, which started on day 100 post-ASCT. Bortezomib was given at a dose of 1.3 mg/m<sup>2</sup>, on days 1, 4, 8 and 11 of a 21-day cycle, while lenalidomide was given at a dose of 25 mg, p.o., daily on days 1-14. Patients did not receive any bisphosphonate during the study. We measured the following bone remodeling molecules on the day of stem cell collection and then before and after VR consolidation: sRANKL, osteoprotegerin, dickkopf-1, sclerostin, CTX, TRACP-5b, bone-specific ALP and osteocalcin.

**Results:** Before HDM, one (1.7%) patient had achieved a sCR, one (1.7%) CR, 30 (50.8%) vgPR, 22 (37.3%) PR, while 5 (8.5%) patients had stable disease. After ASCT, 34 (57.6%) patients improved their status of response, while after VR consolidation, 23/59 (39%) patients further improved their response status. Overall, 30 (50.8%) patients achieved a sCR, one (1.7%) CR, 26 (44.1%) vgPR and two (3.4%) PR. The most important adverse events included neutropenia (68%, grade 3/4 23%), thrombocytopenia (59%, 7%), peripheral neuropathy (56%, 2%), anemia (50%, 4.5%), skin rash (34%, 9%), infections (34%, 0%), fatigue (20%, 0%), diarrhea (16%, 0%) and constipation (14%, 2%). No patient developed deep vein thrombosis. Post-VR consolidation there was a reduction of sRANKL/OPG ratio and of sclerostin ( $p<0.001$ ), while no skeletal-related events (SREs) were observed during the study period. The median follow-up after the ASCT was 35 months (range: 7-60) and 24 patients have progressed. The median TTP after the ASCT was 42 months. There was a trend

for longer TTP in patients achieving sCR compared to others (48 vs. 35 months,  $p=0.145$ ).

**Conclusion:** Four cycles of VR consolidation without dexamethasone is an effective regimen which improves the quality of response in approximately 40% of patients and produces long TTP. In the absence of bisphosphonates, VR consolidation has beneficial effects on bone metabolism and is related with no SREs.

**P51**

**SUCCESSFUL MOBILIZATION WITH PLERIXAFOR, USED AS SALVAGE REGIMEN AFTER CHEMO-MOBILIZATION, FOR PATIENTS WITH MULTIPLE MYELOMA WHO RECEIVED RADIOTHERAPY PRIOR TO AUTOLOGOUS TRANSPLANTATION**

Evangelos ELEUTHERAKIS-PAPAIKOVOU,  
Dimitrios ZIOGAS, Ioannis PANAGIOTIDIS,  
Magdalini MIGKOU, Despoina FOTIOU,  
Christine LIACOS, Efstathios MANIOS,  
Efstathios KASTRITIS, Meletios A. DIMOPOULOS,  
Evangelos TERPOS

*Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece*

**Objective:** High dose melphalan (HDM) and autologous stem cell transplantation (ASCT) remains the treatment of choice for eligible patients with multiple myeloma (MM). Prior administration of radiotherapy before ASCT has been associated with poor stem cell mobilization. We report two MM patients who underwent extensive radiotherapy prior to ASCT and required plerixafor administration as salvage mobilization agent, after chemo-mobilization with cyclophosphamide and G-CSF.

**Methods:** The first patient (a 42-year-old male) received radiotherapy (30Gy) in right costal arch for plasmacytoma and additional radiotherapy (30Gy) in T6-T9 vertebrae for T8 plasmacytoma. Patient's therapeutic regimen also included 3 cycles of PAD. Due to residual disease he received 3 additional PAD cycles. The second patient (a 52-year-old man) received radiotherapy (30Gy) on thoracic vertebrae due to plasmacytoma evolving from T2 vertebra. He also received 4 cycles of anti-myeloma therapy with VCD.

**Results:** The first patient received chemo-mobilization with 2.5 g/m<sup>2</sup> cyclophosphamide and G-CSF. Initial stem cell harvested  $0.8 \times 10^6$  CD34+/kg. Salvage administration of plerixafor on the night of first collection date resulted in a subsequent harvest of  $6.2 \times 10^6$  CD34/kg. The latter collection allowed HDM administration and stem cell re-infusion. The second patient received stem cell mobilization with 2.5 g/m<sup>2</sup> cyclophosphamide and G-CSF. Initial harvest resulted in collection of  $1.2 \times 10^6$  CD34+ cells/kg. Plerixafor was administered and led to a second collection of  $8.6 \times 10^6$  CD34+/kg that allowed administration of HDM.

**Conclusion:** Plerixafor has been reported to increase 4-5 times the number of collected stem cells when it is used as initial mobiliza-

tion regimen with G-CSF or 2-3 times when it is used as salvage regimen after chemo-mobilization with cyclophosphamide and G-CSF. Our cases support that plerixafor facilitates stem cell mobilization (>7 fold compared to chemo-mobilization) in MM poor mobilizers after radiotherapy. Further data are needed to clarify this issue and to determine the best mobilization regimen for this subgroup of patients.

## P52

### THERAPEUTIC CANCER VACCINE: PRODUCING DENDRITIC CELL FROM ALLOGENEIC DONOR STEM CELLS

**Ayşe BİREKUL, Ali ÜNAL, Esen KARAKUŞ,  
Mehmet Çağrı ÜNAL, Yusuf ÖZKUL, Yavuz KÖKER**

*Erciyes University, Department of Hematology, Kayseri, Turkey*

**Objective:** Tumor immunotherapy is a treatment modality that has been long attempted to use as a supportive treatment along with standard therapies. Cellular therapy, a method of tumor immunotherapy, is introduced in cancer therapy as allogeneic and autologous stem cell transplantation. Donor leukocyte infusion is a salvage method to regain remission in patients with recurrent or minimal residual disease after stem cell transplantation. T lymphocytes and antigen-presenting cells (dendritic cells) are two cell lineages that play crucial role in the battle of organism against cancer. Close similarity between cancer cells and normal cell structure is the most important reason of escape from defense cells, namely T lymphocytes. Stimulation and enhancement of T lymphocytes against cancer cells comprise principal part of therapy. Tumor immunotherapy involves active immunotherapy, passive vaccination and immunomodulatory therapies. Active immunotherapy provides better recognition of tumor-related antigens by immune system of patient, enhanced immune system and elimination of malignant cells. This modality employs therapeutic potential of donor specific and tumor specific immune responses. Active immunotherapy targets immunosuppressive and tolerogenic mechanisms suppressed by tumor. Active immunotherapy has emerged in clinical practice since 1990 following years of experimental studies.

**Methods:** To generate allogeneic dendritic cells, leukemic stem cells were isolated from blood samples drawn from patients with acute leukemia. Lysate was prepared from leukemic stem cells identified by flow cytometry. For allogeneic stem cell transplantation, stem cells and mononuclear cells ( $1 \times 10^6 > 6/\text{kg}$ ) obtained from sibling donors by apheresis were separated to produce tumor vaccine. For dendritic cell transformation, GM-CSF and IL-4 were added to media where leukemic stem cell lysate from patient and mononuclear cells from sibling donor were treated. Surface markers for dendritic cells including CD80, CD83 and CD86 were evaluated in samples obtained from cultured cell on the hours 48, 72 and 96 by using flow cytometry.

**Results:** Mononuclear cells were detected by 27% among allogeneic hematopoietic cell groups harvested by apheresis.

After culture under GMP conditions, mononuclear cell rate was found to be 24% on hours 96 and 120. It was seen that 88% of mononuclear cells transformed to mature dendritic cells after 96-hours culture.

**Conclusion:** In cancer patients, tumor vaccine obtained from allogeneic sibling donor can be used in lieu of autologous tumor vaccine and it is thought to be more effective. In cancer patients, minimal residual disease can be eliminated by active tumor vaccine after reducing tumor burden by standard methods. Allogeneic dendritic cells produced at 37°C in CO<sub>2</sub> media under GMP conditions can be used in tumor immunotherapy. More effective method would have been used by employing dendritic cells against cancer stem cells rather than cancer cells itself.

## P53

### SAFETY AND EFFICACY OF CHEMO-MOBILIZATION AND LARGE VOLUME LEUKAPHERESIS IN HEMATOLOGY/ONCOLOGY PATIENTS: A SINGLE CENTER EXPERIENCE IN 327 PATIENTS

**Evangelos ELEFTHERAKIS-PAPAIAKOVOU,  
Magdalini MIGKOU, Ioannis PANAGIOTIDIS,  
Christine LIACOS, Maria ROUSSOU, Efstatios  
MANIOS, Efstatios KASTRITIS, Evangelos TERPOS,  
Christos PAPADIMITRIOU, Meletios A. DIMOPOULOS**

*Department of Clinical Therapeutics, National and  
Kapodistrian University of Athens, School of Medicine,  
Athens, Greece*

**Objective:** Autologous stem cell transplantation (ASCT) is widely used for the management of lymphomas and myeloma. To improve stem cell (SC) collection efficiency, chemo-mobilization combined with large volume leukapheresis has been evaluated as a more efficient apheresis procedure. Here we report our experience regarding the safety and efficacy of large volume leukapheresis.

**Methods:** Between 1996-2010, 327 patients with hematological malignancies or solid tumors have been recruited in our study. The vast majority of patients received intravenous cyclophosphamide (4 mg/m<sup>2</sup> or 2.5 mg/m<sup>2</sup>) with G-CSF for mobilization of peripheral blood SC (PBSC). PBSC collection was performed with a COBE Spectra Blood Cell Separator (COBE Laboratories, Lakewood, CO). Large volume leukapheresis was defined either by processing a minimum of 15L of peripheral blood or by processing more than three times the total peripheral blood volume, as previously reported.

**Results:** 327 patients underwent a cumulative total of 407 SC collections. Large volume leukapheresis was generally well tolerated with hypocalcaemia, decrease in platelets counts (median decrease 46.7%) and hypokalemia being the most common side effects. 90% of patients managed to collect sufficient number of SC for transplantation (defined as  $>3 \times 10^6 \text{ CD34}/\text{kg}$ ) whereas most of these patients (67%) managed to collect sufficient SC with one harvest and 46 (16%) patients yielded enough cells to

allow a second transplantation. The median product volume per collection was 350 ml (range 50-838 ml). The median total CD34+ cell yield/kg was  $6.46 \times 10^6$  CD34+ cells/kg (0-64.7). Factors that negatively affected SC yield were >2 lines of chemotherapy or radiotherapy before HDT, while patients with >65kg needed more often at least two days for sufficient SC collection.

**Conclusion:** Large volume leukapheresis in combination with stem cell chemo-mobilization is a relatively safe and highly efficient procedure, leading in a successful collection in the vast majority of patients, minimizing the use of more advanced and more expensive mobilization regimens.

## P54

### EFFICIENCY OF PLERIXAFOR FOR AUTOLOGOUS STEM CELL MOBILIZATION; A SINGLE CENTER EXPERIENCE FROM TURKEY

Ali ÜNAL<sup>1</sup>, Ayşe BİREKUL<sup>1</sup>, Mehmet Çağrı ÜNAL<sup>1</sup>,  
Gülşah AKYOL<sup>1</sup>, Leylagül KAYNAR<sup>1</sup>, Esra YILDIZHAN<sup>1</sup>,  
Serdar ŞIVGIN<sup>2</sup>, Esen KARAKUŞ<sup>1</sup>, Bülent ESER<sup>1</sup>,  
Mustafa ÇETİN<sup>1</sup>

<sup>1</sup>Erciyes University, Department of Hematology, Kayseri, Turkey, <sup>2</sup>Erciyes University, Department of Internal Medicine, Kayseri, Turkey

**Objective:** In this study, plerixafor stem cell mobilizing activity was assessed in patients with autologous stem cell transplantation and the adequate number of stem cell could not have been collected with chemotherapy and G-CSF (granulocyte colony stimulating factor) before.

**Methods:** This study was participated by 25 patients, from whom adequate stem cell numbers could not have been collected with chemotherapy and filgrastim (10 mcg/kg) at Erciyes University Department of Hematology Apheresis Unit between 27.01.11 and 06.09.14. In the second-line treatment for 15 patients, subcutaneous plerixafor 0.24 mg/kg was applied, and the remaining 10 patients a couple of weeks later. The collected CD34+ cell numbers and percentage ratios were analyzed.

**Results:** Donors of 8 (32%), Multiple Myeloma, donors of 4 (16%) Hodgkin's lymphoma, and donors of 8 (32%) Non-Hodgkin's lymphoma (follicular, B and T cell lymphomas) and donors of 5 of (20%) is the diagnosis of testicular tumors. Sixteen patients were male(64%) and 9 were female (36%). Mobilization process for 10 patients using peripheral and central venous catheter was used in 15 patients. The median age of donors 46 (min: 17, max: 71), the median weight of 67 kg (min: 50, max: 96kg). Mean dose of G-CSF was  $10.5 \pm 2.0$  (min: 6 max: 13). Before the procedure, peripheral CD34 (+) cell count was median 21.85/ microliter (min: 2.20, max: 103.80)and median collected CD34 (+) cell count was  $4 \times 10^6$  / kg (min: 2.35, max: 13.58). Five of our patients could not be gathered enough stem cells. Autologous stem cell transplantation was performed to 17 of all patients that adequate number of stem cells has been collected. Average neutrophil engraftment period of these patients was  $10.6 \pm 0.89$

(min: 10, max: 13) days, and mean platelet engraftment period was  $13.2 \pm 3.02$  (min: 10, max: 23)days. Five of the patients are still waiting for transplantation.

**Conclusion:** Plerixafor addition to G-CSF is effective on mobilization as well as the collection of adequate number of stem cells with drug combination in cases who have been scheduled with autologous stem cell transplantation and from whom adequate number of stem cells could not have been collected with chemotherapy followed by G-CSF.

## P55

### EBMT 2015 - PHYSICIANS ABSTRACT (INCLUDING DATA AND QUALITY MANAGEMENT)

Mehmet Çağrı ÜNAL<sup>1</sup>, Ayşe BİREKUL<sup>1</sup>, Ali ÜNAL<sup>1</sup>,  
Leylagül KAYNAR<sup>1</sup>, Esra ERMIŞ TURAK<sup>1</sup>, Serdar ŞIVGIN<sup>1</sup>,  
Neslihan MANDACI<sup>2</sup>, Bülent ESER<sup>1</sup>, Mustafa ÇETİN<sup>1</sup>

<sup>1</sup>Erciyes University, Department of Internal Medicine, Kayseri, Turkey, <sup>2</sup>Erciyes University, Department of Internal Medicine, Kayseri, Turkey

**Objective:** Adequate hematopoietic stem cell mobilization and collection is essential for patients who are candidate for autologous stem cell transplantation. In this study we compared mobilization success rates, amount of collected stem cells and the factors that could affect the procedure for patients younger and older than 60 years old.

**Methods:** For this study, 112 patients who admitted to Erciyes University BMT Center for autologous stem cell transplantation were enrolled. Thirty-three of them (36%) were under 60 years called young group and 76 of them (%64) over 60 years called elderly group. Among the participants, 73 of them were multiple myeloma, 23 of them Non-Hodgkin's lymphoma, 17 of them Hodgkin's lymphoma. Between the groups we compared the amount of pre-apheresis white blood cell (WBC), platelets, peripheral CD34+ cells, value of collected CD34+ cells and mononuclear cells, mobilization failure and success rates and number of apheresis sessions.

**Results:** The median values of pre-apheresis peripheral CD34+ cells were  $8.72 \times 10^6$ /kg and platelets were  $86 \times 10^9$ /L in young group; CD34+ cells were  $8.95 \times 10^6$ /kg and platelets were  $86.5 \times 10^9$ /L in elderly group ( $p=0.918$  and  $p=0.899$ , resectively). The median values of collected CD34+ cells were  $7.61 \times 10^6$ /kg (range: 2.52-46.62) and  $7.60 \times 10^6$ /kg (2.87-25.50) in under and over 60 years, respectively ( $p=0.800$ ). Also the median values of total collected mononuclear cells (MNC) were  $1.41 \times 10^7$ /kg and  $1.4 \times 10^7$ /kg in young and elderly group, respectively ( $p=0.607$ ). It was found as 1.89 days in elderly group and 1.7 days in young group when we compared their apheresis sessions ( $p=0.786$ ). There was no statistical significance between two groups; despite the mobilization failure rates were 18% and 6% in patients older and younger than 60 years ( $p=0.087$ ). On the other hand, the number of multiple myeloma in the patients with applied autologous stem cell mobilization was higher in elderly patients

than young ones ( $p=0.004$ ) and we also demonstrated that the failure of mobilization were lower in patients with multiple myeloma than lymphoma patients ( $p=0.003$ ). There was no significant difference between the amounts of pre-apheresis WBC, platelets and peripheral CD34+ cells in mobilization failure group and success group.

**Conclusion:** We demonstrated that the amount of pre-apheresis peripheral or collected CD34+ cells and numbers of apheresis sessions are not significantly different in comparison of the young and elderly patients who are planned autologous stem cells transplantation. Mobilization failure rate was higher in lymphoma patients than myeloma patients. It was also found that mobilization failure rates were higher in elderly patients than young patients.

## P56

### MOBILIZATION OF AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS WITH SPECTRA OPTIA V5.0: A SINGLE CENTER EXPERIENCE WITH AN AUTOMATIC INTERFACE-CONTROLLED APHERESIS SYSTEM

Evangelos ELEFTHERAKIS-PAPAIKOVOU,

Ioannis PANAGIOTIDIS, Magdalini MIGKOU,

Dimitrios ZIOGAS, Despoina FOTIOU,

Christine LIACOS, Despoina KALAPANIDA,

Efstathios KASTRITIS, Evangelos TERPOS,

Meletios A. DIMOPOULOS

*Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece*

**Objective:** Available manual apheresis systems generally produce stem cell yields of consistently high quality that can be safely used for autologous transplantation. However, manual apheresis needs continuous interface monitoring/adjustment, suffers from interface instability in poor mobilizers, high collection variability, high platelet loss and failure to electronically document parameters. A new advanced apheresis system, Spectra Optia v5.0, featuring optical sensors, which provide real time automatic interface and product line control, was designed to override these disadvantages.

**Methods:** In our study, we evaluated data of 10 stem cell leukaphereses performed in 8 patients with various malignancies using Spectra Optia after 2011 to test its feasibility and effectiveness. We compared our data with those obtained from 225 patients that had undergone a stem cell collection for autologous transplantation in our Department between 2004 and 2011, using the COBE Spectra machine.

**Results:** The use and function of automatic interface control of Spectra were satisfactory. Due to the application of lower inlet volumes/min, as compared to corresponding volumes with the COBE Spectra machine, our apheresis with Spectra Optia usually took a longer time (median 447 min versus 317 min,  $p<0.005$ ). Regarding other collection parameters, such as the percentage

of CD34+ cells in the final leukapheresis product, total yield of CD34+ cells, and product volume data were comparable for both devices (0.74% versus 0.97% CD34+,  $p=0.103$ ; 6.85 versus 7.1 x 106 CD34+/kg,  $p=0.752$ ; and 403.5 versus 353 ml graft volume,  $p=0.094$ , respectively). Time to engraftment was also comparable for both apheresis devices. More specifically, time interval to neutrophil counts  $>500/\mu\text{l}$ , neutrophil counts  $>1500/\mu\text{l}$  did not significantly differ (10 days versus 9 days,  $p=0.386$  and 11 days versus 10 days,  $p=0.229$ , respectively). However a delay in platelet recovery with Optia device need to be confirmed with additional data from apheresis procedures (median time to platelet counts  $>25000/\mu\text{l}$  was 12 days versus 11 days for COBE Spectra, respectively;  $p=0.037$ ). Platelet loss with Optia was less than with COBE Spectra (1278 versus 2415x103/ $\mu\text{l}$ ,  $p=0.014$ ). No significant differences were observed for product hematocrit between Optia and COBE Spectra (5.7% versus 6.6%,  $p=0.392$ ).

**Conclusion:** The automatic Spectra Optia aphereses were associated with similar and equally variable stem cell collections as aphereses with COBE Spectra. Further data are needed to clarify the potential benefit of lower platelet loss using Optia. We continue to use this procedure in our center and updated results will be presented in the meeting.

## P57

### TECAM (THIOTEPA, ETOPOSIDE, ARA-C, CYCLOPHOSPHAMIDE AND MELPHALAN) AS CONDITIONING REGIMEN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN LYMPHOMA: RETROSPECTIVE SINGLE CENTER EXPERIENCE

Pusem PATIR<sup>1</sup>, Melda CÖMERT ÖZKAN<sup>2</sup>,

Damla GUNENC<sup>3</sup>, Ayşe Uysal ORUC<sup>1</sup>, Mustafa DURAN<sup>1</sup>, Elvina ALMURADOVA<sup>3</sup>, Fahri ŞAHİN<sup>1</sup>, Güray SAYDAM<sup>1</sup>

<sup>1</sup>Ege University Faculty of Medicine, Department of Hematology, Izmir, Turkey, <sup>2</sup>Inonu University Faculty of Medicine, Department of Hematology, Malatya, Turkey, <sup>3</sup>Ege University Faculty of Medicine, Department of Internal Medicine, Izmir, Turkey

**Objective:** High-dose chemotherapy regimens for conditioning followed by autologous stem cell transplantation (ASCT) generally provide favorable results in non-Hodgkin lymphoma (NHL). We have evaluated the efficacy and tolerability of a high-dose conditioning regimen comprising TECAM [thiotepa (40 mg/m<sup>2</sup> x four days), etoposide (200 mg/m<sup>2</sup> x four days), cytosar (200 mg/m<sup>2</sup> x four days), cyclophosphamide (60 mg/kg x one day), and melphalan (60 mg/m<sup>2</sup> x two days)] in patients with NHL.

**Methods:** Seven patients (4 F, 3 M) with NHL at various stages who underwent ASCT were included in this retrospective study. The median age at transplantation was 59 (range, 47–68). The diagnoses were as follows: 2 diffuse large B-cell NHL, 1 angioimmunoblastic T-cell lymphoma, 1 marginal zone lymphoma, 1 follicular lymphoma, 1 T-cell lymphoblastic lymphoma and 1

mantle cell lymphoma.

**Results:** All patients completed the therapy protocol. The median of collected CD34+ cells was  $7.95 \times 10^6/\text{kg}$  (range from  $3.6$  to  $13.8 \times 10^6/\text{kg}$ ). Engraftment for neutrophils and platelets was always achieved except one patient. The median time to recovery of absolute neutrophil ( $500/\mu\text{L}$ ) and platelet ( $20,000/\mu\text{L}$ ) counts independent of transfusion was from  $10$  to  $19$  days (median,  $12$  days) and  $11$ – $41$  days (median,  $25$  days), respectively. The median stay in hospital was  $45$  days (range,  $25$ – $108$ ). Infections were well controlled with antibiotics and resolved after engraftment. Non-infective complications resolved after neutrophil recovery. One patient died due to transplant-related complications, as septic shock with acute distress respiratory syndrome. The overall response rate was  $71\%$  (4 CR,  $57\%$ ; 1 PR,  $14\%$ ), whereas 1 patient ( $14\%$ ) was refractory to TECAM.

**Conclusion:** Treatment of primary progressive and refractory NHL remains particularly difficult. ASCT with variety of conditioning regimen has been still the best option. TECAM treatment regimen provided favorable outcomes as CR in 4 out of 7 patients, with no significant increase in infective and noninfective complications and only 1 transplant-related deaths. Randomized trials on large numbers of patients may be useful to confirm the high anti-NHL activity and low toxicity of this treatment schedule in poor-prognosis NHL patients.

## P58

### EVALUATION OF FEBRILE NEUTROOPENIC EPISODES IN AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NON-HODGKIN LYMPHOMAS

Cansu ATMACA MUTLU<sup>1</sup>, Melda CÖMERT ÖZKAN<sup>2</sup>,

Fahri ŞAHİN<sup>2</sup>, Filiz VURAL<sup>2</sup>, Mahmut TÖBÜ<sup>2</sup>,

Murat TOMBULOĞLU<sup>2</sup>, Güray SAYDAM<sup>2</sup>

<sup>1</sup>Ege University, School of Medicine, Department of Internal Medicine, Izmir, Turkey, <sup>2</sup>Ege University, School of Medicine, Department of Hematology, Izmir, Turkey

**Objective:** The most important cause of mortality in febrile neutropenic episodes (FNEs) that mature after autologous hematopoietic stem cell transplantsations (aHSCT) is infections. Broad-spectrum empiric antibioticotherapy must be started immediately as a standard approach in FNEs. Identification of infectious agents in Non-Hodgkin Lymphoma (NHL) group was aimed.

**Methods:** One hundred and eight aHSCT data from 108 relapsed/refractory NHL patients who was underwent transplantation at the Hospital of Ege University, Adult Hematology Department, Transplant Center between 2008 and 2014 were analyzed retrospectively.

**Results:** Sixty-six patients were male and 42 female. The mean age was  $53.1$  years (19–76). Central venous catheter was used in  $88$  (81.5%) HSCTs. FNEs was detected in  $106$  (98.1%) HSCT. All the patients received antiviral and antifungal prophylaxis and antibacterial prophylaxis was used in  $53$  (49.1%) HSCT. In FNEs,  $14.8\%$  efficient pathogen microorganism was isolated from blood

cultures.  $72.8\%$  of pathogens were gram-positive,  $27.2\%$  were gram-negative bacterias.  $3.7\%$  efficient pathogen microorganism was isolated from urine cultures, all of them were gram-negative bacterias.  $19.4\%$  efficient pathogen microorganism was isolated from catheter cultures.  $57.1\%$  of pathogens were gram-positive,  $42.9\%$  were gram-negative bacterias.  $1.8\%$  efficient pathogen microorganism was isolated from sputum, all of them were gram-negative bacterias. A pathogen was isolated in  $8.3\%$  of stem cell products. Serum galactomannan antigen (SGA) was detected positive in  $12$  (11.1%) episodes and false positivity of SGA was  $8.8\%$  in all HSCTs. CMV-DNA was positive in  $10.2\%$  episodes. Fifty-nine HRCT was performed in FNEs. Pneumonia was detected  $15.7\%$  in all episodes.  $29.4\%$  of pneumonia that detected in HRCTs was fungal and no viral pneumonia was detected.

**Conclusion:** It can supply useful additive for a better FEN management process if the medical centers follow their infection agents closely, perform CMV and SGA assays and modify their empiric antibiotic treatment policies in especially HSCT groups.

## P59

### AUTOLOGOUS HEMATOPOIETIC STEM CELL MOBILIZATION AND HARVEST BY AGE GROUPS IN NON-HODGKIN LYMPHOMA: A SINGLE CENTER EXPERIENCE

Melda CÖMERT ÖZKAN<sup>1</sup>, Cansu ATMACA MUTLU<sup>2</sup>,

Fahri ŞAHİN<sup>1</sup>, Filiz VURAL<sup>1</sup>, Mahmut TÖBÜ<sup>1</sup>,

Murat TOMBULOĞLU<sup>1</sup>, Güray SAYDAM<sup>1</sup>

<sup>1</sup>Ege University, School of Medicine, Department of Hematology, Izmir, Turkey, <sup>2</sup>Ege University, Chool of Medicine, Department of Internal Medicine, Izmir, Turkey

**Objective:** Autologous hemopoietic stem cell transplantation (aHSCT) can offer potential long-term remission or cure in patients with relapsed or refractory non-Hodgkin lymphoma (NHL). The mobilization of HSCs can be a limiting factor for transplantation. HSCs mobilization, harvest and engraftment periods were evaluated by age groups.

**Methods:** Fifty-four relapsed/refractory NHL cases treated with aHSCT in Ege University between 2008–2014 were evaluated retrospectively. Patients were divided into 3 groups according to age range; first group was 18–59 years, second group 60–64 years and third group was >65 years old.

**Results:** Group 1 was consisted of  $18$  patients, group 2 of  $17$  and group 3 of  $19$  patients. All the patients were mobilised after a salvage chemotherapy regimen (ICE or ESHAP) combined with  $10\mu\text{g}/\text{kg}/\text{day}$  dose of filgrastim. Mean collection day after filgrastim administration was  $6.2$  days for group 1,  $5.2$  for group 2 and  $6.8$  days for group 3. Mean apheresis cycle was  $2.4$  for group 1,  $2.7$  for group 2 and  $2.9$  for group 3. Mean total CD34+ HSCs number was  $8.5 \times 10^6$  for group 1,  $5.9 \times 10^6$  for group 2 and  $7.4 \times 10^6$  for group 3. There was no statistically significant difference between groups in terms of HSCs collection day and total apheresis cycle, but CD34+ HSCs number was statistically higher in group 1 compared to group 2, but interestingly there was no

statistical difference between groups 1 and 3. OS after aHSCT was 22.7 months in group 1, 20.4 in group 2 and 19.6 months in group 3. Transplantation related mortality (TRM) was 8% in group 1, 11.7% in group 2 and 20.1% in group 3 ( $p<0.05$ ).

**Conclusion:** High-dose chemotherapy, followed by aHSCT, is an effective treatment option for patients with relapsed/refractory NHL, but TRM is significantly higher in >65 years old patients. Therefore, patients must be carefully selected. There is no reason to explain the HSC quantity difference between the groups,because there is no statistically difference between group 1 and 3 but HSC quantity is lower in group 2. Larger study groups and different parameters are needed to demonstrate this difference.

## P60

### AUTOLOGOUS HEMAPOIETIC STEM CELL MOBILIZATION AND HARVEST IN HODGKIN LYMPHOMA: A SINGLE CENTER EXPERIENCE

Cansu ATMACA MUTLU<sup>1</sup>, Melda CÖMERT ÖZKAN<sup>2</sup>, Fahri ŞAHİN<sup>2</sup>, Filiz VURAL<sup>2</sup>, Mahmut TÖBÜ<sup>2</sup>, Murat TOMBULOĞLU<sup>2</sup>, Güray SAYDAM<sup>2</sup>

<sup>1</sup>Ege University, School of Medicine, Department of Internal Medicine, Izmir, Turkey, <sup>2</sup>Ege University, School of Medicine, Department of Hematology, Izmir, Turkey

**Objective:** Hodgkin lymphoma (HL) is one of the most common malignancies in young adults and has become curable for the majority of patients with autologous hematopoietic stem cell transplantation (aHSCT), even in advanced stage. The mobilization of hematopoietic stem cells (HSCs)can be a limiting factor for transplantation.HSCs mobilization, harvest and engraftment periods were evaluated.

**Methods:** Patients who was underwent aHSCT at the Hospital of Ege University, Adult Hematology Department, Transplant Center between 2008 and 2014 were analyzed retrospectively. Fifty-six relapsed/refractory HL patients who was underwent aHSCT were included to study.

**Results:** The median age of the patients was 43 years (27-75 years), and of 36 (64.2%) males and 20 (35.8%) females.Thirty-five (61.4%) of the patients were nodular sclerosis HL,14 were (24.6%) mixed cellular HL,4 (7.0%) were lymphocyte predominant HL, and 3 (5.3%) were lymphocyte-rich HL. All the patients were mobilised after a salvage chemotherapy regimen (ICE or ESHAP) combined with 10 $\mu$ g/kg/day dose of filgrastim. Mean collection day after filgrastim administration was 5.6 days for female and 6.1 for male. Mean apheresis cycle was 2.5 for female and 2.4 for male. Mean total CD34+ HSCs number was  $8.7 \times 10^6$  for female and  $7.5 \times 10^6$  for male. Poor mobilization was not observed in any patient. There was no statistically difference between sex, mobilisation regimen and type of Hodgkin lymphoma in terms

of HSCs collection day, total apheresis cycle and total CD34+ HSCs number. Mean neutrophil and platelet engraftment time was 12.4 and 14.4 days, respectively. There was no statistically difference in neutrophil and platelet engraftment time in terms of sex, type of HL and radiotherapy history.Transplantation related mortality was 1.7%, complete and partial remission after aHSCT was obtained in 37 (67%) and 9 (16%) of patients, respectively. Overall survival was significantly better in patients with complete remission ( $p<0.05$ ).

**Conclusion:** High-dose chemotherapy, followed by aHSCT,is an effective treatment option for patients with relapsed/refractory Hodgkin lymphoma, allowing further consolidation of response.

## P61

### COMPARISON OF AUTOLOGOUS HEMATOPOETIC STEM CELL MOBILIZATION AND HARVEST DATA IN HL AND NHL PATIENTS

Melda CÖMERT ÖZKAN<sup>1</sup>, Cansu ATMACA MUTLU<sup>2</sup>, Fahri ŞAHİN<sup>1</sup>, Filiz VURAL<sup>1</sup>, Mahmut TÖBÜ<sup>1</sup>, Murat TOMBULOĞLU<sup>1</sup>, Güray SAYDAM<sup>1</sup>

<sup>1</sup>Ege University, School of Medicine, Department of Hematology, Izmir, Turkey, <sup>2</sup>Ege University, School of Medicine, Department of Internal Medicine, Izmir, Turkey

**Objective:** Autologous Hematopoietic Stem Cell Transplantation (aHSCT) provides cure option for relapsed/refractory lypmhoma patients. Poor mobilization of hematopoietic stem cells (HSCs) can be a limiting factor for aHSCT. Non Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) was compared in terms of HSCs mobilization, harvest and engraftment periods.

**Methods:** Sex and age matched 55 relapsed/refractory NHL and 55 relapsed/refractory HL cases treated with aHSCT in Ege University Hospital between 2008-2014 were evaluated retrospectively.

**Results:** All the patients were mobilised after a salvage chemotherapy regimen (ICE or ESHAP) combined with 10 $\mu$ g/kg/day dose of filgrastim. Poor mobilization was not observed. Mean collection day after filgrastim administration was 6.1 days for NHL group and 5.9 for HL group. Mean apheresis cycle was 2.3 for NHL group, 2.4 for HL group. Mean total CD34+ HSCs number was  $8.4 \times 10^6$  for NHL group and  $7.9 \times 10^6$  for HL group. There was no statistically difference between groups in terms of HSCs collection day, total apheresis cycle, and CD34+ HSCs number between groups. Mean neutrophil and platelet engraftment time was 11.7 and 15.7 days in NHL group, and 12.4 and 14.4 in HL group, respectively. There was no statistically significant difference between the groups.

**Conclusion:** Lymphoma type is not a predictor factor for HSC mobilization, harvest and engraftment. Larger study groups and different parameters are needed to demonstrate predictor factors for mobilization and engraftment.

**P62**

**"REAL WORLD DATA" ON CLINICAL FEATURES, PROGNOSIS AND OVERALL SURVIVAL POST AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA IN THE ERA OF NOVEL AGENTS: A REPORT OF THE GREEK SOCIETY OF HEMATOLOGY IN 489 PATIENTS**

**Eirini KATODRITOU<sup>1</sup>, Anastasia POULI<sup>2</sup>, Evangelos TERPOS<sup>3</sup>, Maria KOTSOPOULOU<sup>4</sup>, Sossana DELIMPASI<sup>5</sup>, Argiris S. SYMEONIDIS<sup>6</sup>, Dimitrios CHRISTOULAS<sup>7</sup>, Pavlina KONSTANTINIDOU<sup>1</sup>, Meletios A. DIMOPOULOS<sup>3</sup>, Ioanna SAKELLARI<sup>8</sup>**

<sup>1</sup>Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece, <sup>2</sup>Department of Hematology, St. Savvas Oncology Hospital, Athens, Greece, <sup>3</sup>Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, <sup>4</sup>Department of Hematology, Metaxa Cancer Hospital, Piraeus, Greece, <sup>5</sup>Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos Hospital, Athens, Greece, <sup>6</sup>Hematology Division, Department of Internal Medicine, University of Patras Medical School, Patras, Greece, <sup>7</sup>Department of Hematology, 251 General Air Force Hospital, Athens, Greece, <sup>8</sup>Department of Hematology and Bone Marrow Transplantation Unit, G. Papanikolaou General Hospital, Thessaloniki, Greece

**Objective:** Autologous stem cell transplantation (ASCT) and novel agent-based therapies have improved multiple myeloma (MM) outcome. In the era of novel agents, prognostic factors for post-ASCT survival are not clearly defined and data regarding the role of post-ASCT consolidation/maintenance (C/M) therapy are inconclusive. Our aim was to describe "real world data" on clinical features, prognosis and post-ASCT survival of MM patients treated with ASCT in Greece, in the era of novel agents.

**Methods:** We reviewed the medical files of 489 consecutive MM patients (M/F: 278/211, median age: 56 years, range: 31-79 years; ISS-1: 189, ISS-2: 141, ISS-3: 90, missing data: 69) treated with ASCT between 2000 and 2013 in seven Greek Hematology Centers.

**Results:** High risk cytogenetics, i.e. del17p and/or t(4;14), were found in 24/104 (23%) patients with available data; 220 (45%) patients received conventional treatment and 269 (55%) received novel agent-based therapies. The median number of induction cycles was 4 (range: 1-9). The median number of pre-ASCT treatment lines was 1 (range: 1-3); 470 patients underwent single and 19 tandem ASCT; 378 patients were mobilized with cyclophosphamide + G-CSF, 79 patients with G-CSF alone and 32 patients with multi-agent chemotherapy. The median number of CD34+ cells infused was 5.9x10<sup>6</sup>/kg (range: 2.6-7.43x10<sup>6</sup>/kg); 176 patients had ≥very good partial response (vgPR) pre-ASCT and 203 had ≥vgPR post-ASCT. Post-ASCT, 266 patients received consolidation and/or maintenance therapy (consolidation: 80, maintenance: 186); consolidation and maintenance treatment included interferon A or dexamethasone (36 patients), thalidomide (99 patients),

bortezomib ± dexamethasone (26 patients), lenalidomide (78 patients) and bortezomib + immunomodulator (thalidomide or lenalidomide) + dexamethasone (27 patients). During evaluation, 337 patients were alive (68.9%) and 149 patients (30.5%) died (due to MM progression: 88%, ASCT-related: 2%, secondary malignancy: 2%); 3 patients did not have survival data. After a median post-ASCT follow-up of 56 months (95% CI: 51.2-60.7), the median post-ASCT time to progression and post-ASCT survival were 46 months (95% CI: 38-54) and 101 months (95% CI: 79-122), respectively. In the multivariate analysis, pre-ASCT treatment with novel agents and post-ASCT consolidation and/or maintenance therapy predicted for longer survival, whereas the presence of del17p and/or t(4;14) predicted for shorter post-ASCT survival ( $p<0.05$ ).

**Conclusion:** In the era of novel agents, patients treated with ASCT enjoy prolonged survival outcomes. Pre-ASCT treatment with novel agents and any type of consolidation or maintenance therapy predict positively for post-ASCT survival, indicating the importance of continuous treatment in MM. High risk features remain a strong negative predictor for post-ASCT survival.

## OTHER HEMATOLOGICAL MALIGNANCIES AND TREATMENT COMPLICATIONS

**P63**

**HEMATOLOGIC MALIGNANCIES IN AN AEGEAN ISLAND POPULATION: THE CASE OF CHIOS**

**Ioulia CHALIORI, Electra DIMITRAKOPOULOU, Ioannis STAMOULIS, Maria PAPADOPOULOU, Christos POZIOPoulos**

*HematologyLab and Blood Bank Department, Chios General Hospital, Chios, Greece*

**Objective:** This study aims at recording the frequency of the various sub-types of Hematologic Malignancies (HMs) in an island population so as to draw a first round of comparisons regarding their occurrence. The case of reference is the North Aegean island of Chios, the fifth largest Greek island in terms of size and the sixth in terms of population (51,390 habitants, year 2011). The study is designed so as to offer the basis for researches that may relate the prevalence of different HMs to special genetic, social and environmental conditions (e.g. poor quality of water). It is also expected that the study will inform health-related policies regarding, for example, the allocation of resources between central and remote (e.g. island) public health care facilities.

**Methods:** Prevalence of HMs patients between 1-1-2011 and 30-6-2015. Sources: Chios state hospital archives, all private practice archives by hematologists (total of 2). Classification: WHO 2008.

**Results:** Total HMs: 308. Lymphoid Malignancies (LMS): 171 (55%). Myeloid Malignancies (MMs): 138 (45%). LMs: 52 CLL/SLL,

37 PCN (27 MM, 10 MGUS), 15 HL, 13 FL (1 grade 3B), 12MZL, 10 DLBCL-NOS, 10 T-LGL, 8LL/ALL, 4 LPL-MW, 3 MALT, 3 HCL, 1MF, 1 Angioimmunoblastic T-cell, 1HDCN, MMs: 53 MDS (23 RA, 2 RAS, 5 RN, 14 RCMD, 9 RAEB2), MPN=72 (46 ET, 17 PV, 6 CML, 3 PM), 13 AML.

**Conclusion:** The 4.5 year period prevalence seems to be too high in comparison to all available international standards and therefore further study is needed.

## P64

### INVESTIGATION OF SEASONAL FREQUENCY AND PATHOGENS IN FEBRILE NEUTROPENIA

Seray KARAGOZ<sup>1</sup>, Ozan SALIM<sup>1</sup>, Orhan Kemal YUCEL<sup>1</sup>, Utku ILTAR<sup>1</sup>, Ramazan ERDEM<sup>1</sup>, Ozge TURHAN<sup>2</sup>, Levent UNDAR<sup>1</sup>

<sup>1</sup>Department of Hematology, Akdeniz University, Antalya, Turkey, <sup>2</sup>Department of Infectious Diseases and Clinical Microbiology, Akdeniz University, Antalya, Turkey

**Objective:** Febrile neutropenia is the most frequent complication in patients with hematological malignancies. The most common cause of mortality of patients with febrile neutropenia is infections. Fever during neutropenia may be the only sign of a severe underlying infection. Infections can rapidly progress, leading to life - threatening complication. Therefore fever in neutropenic patients must be accepted as an infection and empiric wide - spectrum antibiotic therapy must be initiated in order to avoid progression and possibly death. The aim of this study was to examine demographical and clinical characteristics of patients, difference in frequencies of episodes between months and seasons, distribution and frequency variance of isolated pathogens.

**Methods:** In this study 194 febrile neutropenic episodes of 105 patients with hematological malignancies who have been hospitalized between 1 June 2013 and 31 May 2014 in Akdeniz University Faculty of Medicine, Hematology Department were evaluated retrospectively.

**Results:** There was no difference in frequency of febrile neutropenic episodes between months ( $p = 0.564$ ) and seasons ( $p = 0.345$ ). There was no pathogen microorganism isolated in 54.6% of febrile neutropenic episodes. In 45.4% of 194 febrile neutropenic episodes pathogens were observed. 50.4% of all agents was gram negative bacteria, 29.2% was gram positive, 13.3% was viral agents, 5.3% was fungi and 1.8% was parasites. The most frequent gram negative bacteria was E. Coli and the most frequent gram positive bacteria was KNS.

**Conclusion:** This is the first study that examines FEN episodes according to months and seasons as far as we know.

## P65

### WHAT IS YOUR TREATMENT? DISSEMINATED HISTIOCYTIC SARCOMA

Veysi ASOGLU<sup>1</sup>, Muhammet MADEN<sup>2</sup>, Ali GOKYER<sup>1</sup>, Mehmet Sevki UYANIK<sup>2</sup>, Gulsum Emel PAMUK<sup>2</sup>

<sup>1</sup>Department of Internal Medicine, Edirne State Hospital, Edirne, Turkey, <sup>2</sup>Department of Hematology, Trakya University, Edirne, Turkey

**Introduction:** Histiocytic sarcoma (HS) is a rare, but aggressive and resistant hematopoietic malignancy. HS reflects the morphological and immunophenotypic characteristics of mature tissue histiocytes. Average presentation age is 44-55. Clinical presentation often involves gastrointestinal tract, skin and soft tissue, but has also wide range of extranodal areas such as bone, lymph nodes, liver, spleen, lungs and CNS.

**Case:** A 73-year-old female patient was admitted to our clinic with complaint of swelling in the left axilla. The physical examination revealed left axillary lymphadenopathie. In the blood count leukocyte 71300/uL, hemoglobin 10.1 g/dL, platelets 216000/uL, in the biochemical analysis, LDH 279 U/L were detected. PET/CT revealed increased FDG uptake in lymphadenopathies in the neck, left ear, nodular lesions on right hemithorax, the lower and upper limb bone, and bone marrow of left tibia (SUVmax between 0.5 and 4.9). It was determined CD23 positive, LCA weak positive, CD68 strong positive, Ki67 70-80%, CD1a and CD21 negative in the lymph node biopsy. According to present findings the patient was diagnosed as Histiocytic Sarcoma (WHO-2008). It was initially started CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) regime. After second course of CHOP was observed progression in lesions. Additionally 4 courses of ICE (ifosfamide, carboplatin, etoposide) regime were applied. First 15 days of ICE regime a significant regression was observed in skin lesions, however reprogression was observed after 15 days. A month after the forth course of ICE the patient died because of febrile neutropenia and pneumonia.

**Conclusion:** There is no standard treatment protocol for HS, because it is rarely seen. CHOP and ICE are the most preferred treatment regimens. It was demonstrated progression to CHOP and ICE regime in the our case. HS is very rare subtype of NHL and should be detailed pathological examination, and further studies with case series are required to determine effective treatment protocols.

**P66****MILIARY TUBERCULOSIS MIMICKING LYMPHOMA:  
A CASE REPORT****Pelin AYTAN<sup>1</sup>, Özkan HATEM<sup>2</sup>**

<sup>1</sup>*Mersin State Hospital, Department of Hematology, Mersin, Turkey, <sup>2</sup>Mersin State Hospital, Department of Radiology, Mersin, Turkey*

**Introduction:** Miliary tuberculosis (MT) still remains a perplexing disease that continues to elude the most experienced clinicians and is a diagnostic and therapeutic challenge. We present two cases of miliary tuberculosis that mimic lymphoma. Mortality from this disease has remained high despite effective therapy being available.

**Cases:** The first case is a 27-year-old male who presented with fever with evening rise of temperature of several weeks of duration, anorexia, weight loss and weakness. He was a farmer. The second case is a 42-year-old female who presented with night sweats, coughing but no hemoptysis. She was a tailor. They both

had no history of immunosuppressive agent intake or HIV. They both had sputum smear negativity and normal chest radiography. They both had elevated transaminases and C-reactive protein. They both had anemia but the LDH levels were in normal limits. The first case had massive splenomegaly and the second case had bilateral cervical, supraclavicular lymph nodes greater than 2 cm. In PET CT there were multiple lesions in the spleens and thoracal regions of both patients with increased FDG intensity. While splenectomy was performed to the first case, cervical lymphadenectomy was done to the second case. Both biopsy results were caseified granulomatous inflammation. Anti-tuberculosis treatment was administered for six months to both patients. They have been still following up at hematology clinic and there are regressions in the lesions.

**Conclusion:** MT is a disease that may mimic malignancies and is not uncommon in developing countries. It should be considered in the differential diagnosis in patients with night sweats, anorexia, weight loss and fever even in the patients with a positive PET scan. Biopsy is the method of diagnosis.

# INDEX

ARCHIVES OF HELLENIC MEDICINE 2015, 32(Suppl 1):50-52  
ΑΡΧΕΙΑ ΕΛΛΗΝΙΚΗΣ ΙΑΤΡΙΚΗΣ 2015, 32(Συμπλ 1):50-52

## A

- AKAD SOYER Nur ..... P45, P47  
AKDAĞ Damla ..... P48  
AKKAYA Bahar ..... P12  
AKYOL Gülsah ..... P54  
ALIYEVA Alide ..... P04  
ALMURADOVA Elvina ..... P57  
ALP Gülay ..... P07  
ANARGYROU Konstantinos ..... P16  
ANGELOPOULOU Maria K. ..... P13, P14, P16, P17, P23  
APOSTOLAKOU Filia ..... P39  
AR Cem ..... P15  
ASOGLU Veysi ..... P27, P65  
ASSIMAKOPOULOS Ioannis ..... P14  
ATMACA MUTLU Cansu ..... P58, P59, P60, P61  
AVŞAR Emin ..... P15  
AYCICEK Merve ..... P09  
AYTAN Pelin ..... P08, P66

## B

- BAGRATUNİ Tina ..... P34  
BARBAROUSI Despoina ..... P20, P22  
BAŞLAR Zafer ..... P15  
BİLGİR Ferda ..... P35  
BİLGİR Oktay ..... P35, P47  
BİREKUL Ayşe ..... P52, P54, P55  
BOUTSIKAS Georgios ..... P13, P14, P16, P17, P23  
BRIASOULIS Evangelos ..... P06

## C

- CEKDEMİR Demet ..... P47  
CERAN Funda ..... P10  
ÇETİN Mustafa ..... P54, P55  
ÇETİNTEPE Tugba ..... P35  
CHALIORI Ioulia ..... P63  
CHATZIOANNOU Sofia ..... P13, P14  
CHRISTOULAS Dimitrios ..... P16, P25, P26, P28, P29, P37, P38, P49, P50, P62  
CÖMERT ÖZKAN Melda ..... P57, P58, P59, P60, P61

## D

- DADASOVA Elvina ..... P21  
DAĞDAŞ Simten ..... P10  
DASOULA Aggeliki ..... P06  
DELIMPASI Sossana ..... P31, P62  
DIAMANTOPOULOS Panagiotis ..... P11  
DIMITRAKOPOULOU Aglaia ..... P11  
DIMITRAKOPOULOU Electra ..... P63  
DIMOPOULOS Meletios A. ..... P18, P25, P26, P28, P29, P30, P31, P33, P34, P37, P38, P39, P40, P43, P49, P50, P51, P53, P56, P62  
DİMOUN Maria ..... P16, P36, P41  
DİNÇKAL Çiğdem ..... P45  
DOLGUN Anıl ..... P15  
DONMEZ Ayhan ..... P04, P19  
DUMAN Hatice ..... P09  
DURAN Mustafa ..... P19, P57  
DURMUS Yusuf ..... P24

## E

- ELEUTHERAKIS-PAPAIAKOVOU Evangelos ..... P18, P34, P37, P39, P40, P49, P50, P51, P53, P56  
ERDEM Ramazan ..... P12, P64  
ERDOĞAN Kivilcim ..... P08  
ERMIŞ TURAK Esra ..... P55  
ESER Bülent ..... P54, P55

## F

- FALAY Mesude ..... P10  
FERHANOĞLU Burhan ..... P15  
FOTİOU Despoina ..... P37, P38, P39, P51, P56

## G

- GALANOPoulos Athanasios ..... P11  
GAVRIATOPoulos Maria ..... P18, P25, P26, P28, P29, P34, P37, P38, P40, P49, P50  
GEORGOUSI Zafeiroula ..... P11  
GIANNAKI Eythimia ..... P30  
GIANNAKOPOULOU Nefeli ..... P11  
GIANNOPoulos Andreas ..... P44  
GIANNOPoulos Evlambia ..... P32  
GKOTZAMANIDOU Maria ..... P28, P33, P39, P43, P49

GOKYER Ali .....	P03, P65	LOUKOPOULOS Dimitris .....	P44
GULIAMTZI Stamatia .....	P46	LOUPIS Theodoros .....	P44
GUNDOGAN Erdal .....	P05	<b>M</b>	
GÜNENÇ Damla .....	P48, P57	MADEN Muhammet .....	P02, P24, P27, P65
GÜNEŞ Ahmet Kürşad .....	P10	MANDACI Neslihan .....	P55
GÜRKAN Emel .....	P08	MANDALA Evdokia .....	P30
<b>H</b>		MANIOS Efstatios .....	P51, P53
HADJIAGGELIDOU Christina .....	P30, P32	MANTZOURANI Marina .....	P44
HATEMİ Özkan .....	P66	MARGARITIS Dimitrios .....	P46
HATZIMICHAEL Eleftheria .....	P06	MARKALAKI Dimitra .....	P30, P32
HAZNEDAROGLU Ibrahim C. ....	P47	MATSOUKA Charis .....	P20, P22
<b>I</b>		MAZARAKIS Michail .....	P18
IGGLEZOU Maria .....	P06	MEDENİ Şerife Solmaz .....	P35
ILHAN Osman.....	P47	MELAKOPOULOS Ioannis .....	P34
ILIAKIS Theodoros .....	P36, P41	MELEA Pelagia .....	P34
ILTAR Utku .....	P12, P64	MICHAEL Michael .....	P31
<b>K</b>		MIGKOU Magdalini .....	P18, P25, P26, P28, P29, P38, P40, P49, P50, P51, P53, P56
KAFANTARI Eftychia .....	P26, P29, 37	MOSCHOGIANNIS Maria .....	P23
KALAPANIDA Despoina .....	P26, P29, P50, P56	MUNSHI Nikhil .....	P43
KALPADAKIS Christina .....	P23	<b>N</b>	
KANELLIAS Nikolaos .....	P18, P20, P22, P25, P28, P37, P40	NACARKAHYA Gulper .....	P01
KARAGOZ Isik Didem .....	P01	NAGIYEVA Terane .....	P19
KARAGOZ Seray .....	P64	NAMDAROĞLU Sinem .....	P35
KARAKUŞ Esen .....	P52, P54	NİKOLAOU Eftychia .....	P36, P41
KARPUZ Ozlem .....	P12	<b>O</b>	
KASTRITIS Efstatios .....	P18, P25, P26, P28, P29, P34, P37, P38, P39, P40, P49, P50, P51, P53, P56	OKAN Vahap .....	P05
KATODRITOU Eirini .....	P30, P31, P32, P62	ÖMÜR Özgür .....	P21
KATSENOUS Andreas .....	P06	ÖNGÖREN Şeniz .....	P15
KAYNAR Leylagül .....	P54, P55	ORUC Ayşe Uysal .....	P57
KILIC Ibrahim Halil .....	P01	OYTUN Merve Guner .....	P04
KİPER UNAL Hatice Demet .....	P19, P21, P42	OZASLAN Mehmet .....	P01
KÖKER Yavuz .....	P52	ÖZBALAK Murat .....	P15
KONSTANTINIDOU Pavlina .....	P30, P31, P32, P62	OZDEMIRKIRAN Fusun .....	P47
KONSTANTOPOULOS Konstantinos.....	P13, P14, P16, P17, P23, P44	ÖZET Gülsüm .....	P10
KOSEOGLU Fatos Dilan .....	P42	ÖZKUL Yusuf.....	P52
KOTSANTI Sotiria .....	P36, P41	ÖZLÜ Can .....	P35
KOTSIANIDIS Ioannis .....	P46	OZLUK Anıl .....	P04
KOTSOPOULOU Maria .....	P31, P62	ÖZSAN Nazan .....	P21
KOURTI Georgia .....	P17	ÖZTÜRK Erman .....	P14
KURTOGLU Erdal .....	P09	<b>P</b>	
KYRTSONIS Marie-Christine .....	P11, P31, P36, P41	PALASKA Vassiliki .....	P32
<b>L</b>		PAMBOUCAS Constantinos .....	P40
LIACOS Christine .....	P51, P53, P56	PAMUK Gulsum Emel .....	P02, P03, P24, P27, P65

PAMUK Omer Nuri .....	P27
PANAGIOTIDIS Ioannis .....	P25, P38, P34, P39, P49, P51, P53, P56
PANAYIOTIDIS Panayiotis .....	P13, P14, P16, P17, P23, P36, P41
PANGALIS Gerassimos .....	P13, P14, P17, P23
PAPADAKI Sofia .....	P32
PAPADIMITRIOU Christos .....	P49, P53
PAPADOPOULOU Maria .....	P63
PAPADOPOULOU Vassiliki .....	P11
PAPAGEORGIOU Sotirios .....	P17, P23
PAPAIOANNOU Konstantina .....	P20, P22
PAPAIOANNOU Paraskevi .....	P36, P41
PAPASSOTIRIOU Gerasimos-Petros .....	P39
PAPASSOTIRIOU Ioannis .....	P18, P39
PAPATHEODOROU Athanasios .....	P16, P30
PATIR Püsem .....	P04, P19, P42, P45, P48, P57
PEHLİVAN Mustafa .....	P05
PETSA Panayiota .....	P36, P41
POLITOU Marianna .....	P44
POULI Anastasia .....	P36, P41, P62
POZIOPoulos Christos .....	P63
PRASSOPOULOS Vassilios .....	P13, P14
<b>R</b>	
RIGOUTSOS Isidore .....	P06
RONDOGIANNI Phoebe .....	P13, P14
ROUSSOU Maria .....	P25, P26, P29, P38, P40, P50, P53
ROUSSOU Paraskevi .....	P17, P18
<b>S</b>	
ŞAHİN Fahri .....	P07, P42, P47, P48, P57, P58, P59, P60, P61
SAINIS Ioannis .....	P06
SAKELLARI Ioanna .....	P62
SALİHOĞLU Ayşe .....	P15
SALIM Ozan .....	P09, P12, P64
SARI Ibrahim .....	P05
SAYDAM Güray .....	P07, P42, P45, P47, P48, P57, P58, P59, P60, P61
ŞİVGİN Serdar .....	P54, P55
SOFOTASIOU Maria .....	P11
SOLTEKIN Hediye .....	P09
SOTIROPOULOS Vassilios .....	P13
SOULIOTIS Vassilis L.....	P33, P43
SOYSAL Teoman .....	P15
SPANAKIS Nikolaos .....	P11
SPANOUDAKIS Emmanouil .....	P46
SPYRIDIS Nikos .....	P32
STAMOULIS Ioannis .....	P63

SYMEONIDIS Argiris S. ....	P31, P62
----------------------------	----------

**T**

TEKATAS Demet .....	P02
TEMİZ Ebru .....	P01
TERPOS Evangelos .....	P16, P17, P18, P25, P26, P28, P29, P30, P31, P32, P33, P34, P37, P38, P39, P40, P43, P49, P50, P51, P53, P56, P62
TESSEROMATIS Christina .....	P34
TÖBÜ Mahmut .....	P07, P21, P58, P59, P60, P61
TOMBULOĞLU Murat .....	P04, P07, P19, P58, P59, P60, P61
TOUMANIDIS Savvas Th. ....	P40
TRAIJE Enkeleida .....	P20, P22
TSIRIGOTIS Panagiotis .....	P44
TURHAN Ozge .....	P12, P64
TZENOU Tatiana .....	P36, P41

**U**

ULUBAHSI Melike .....	P09
ÜNAL Ali .....	P47, P52, P54, P55
ÜNAL Mehmet Çağrı .....	P52, P54, P55
UNDAR Levent .....	P09, P12, P64
UYANIK Mehmet Sevki .....	P02, P03, P24, P65

**V**

VADIKOLIA Chrysa .....	P31
VAKALOPOULOU Sofia .....	P30
VARDOUNIOTI Ioanna .....	P20, P22
VASSILAKOPOULOS Theodoros .....	P13, P14, P16, P17, P23
VERROU Eugenia .....	P23, P32
VINIÖU Nora-Athina .....	P11, P44
VURAL Filiz .....	P58, P59, P60, P61

**Y**

YILDIZ Hamit .....	P05
YILDIZHAN Esra .....	P54
YILMAZ Mehmet .....	P01, P05, P47
YUCEL Orhan Kemal .....	P09, P12, P64

**Z**

ZAGORIDIS Costas .....	P46
ZAGOURI Flora .....	P26, P50
ZIOGAS Dimitrios .....	P28, P37, P38, P51, P56
ZOI Christine .....	P44
ZOI Katerina .....	P44